var title_f19_42_20128="Primary teeth identification";
var content_f19_42_20128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Conventional identification of the primary teeth (United States)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    By convention in the United States, general dentists identify the 20 primary teeth by the letters A through T, as depicted above. Different identification systems are used in other countries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Dentistry 2000 - Human Teeth Numbering Charts. file://www.dentistry2000.com/dentalhealthcare/teeth_numbering.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20128=[""].join("\n");
var outline_f19_42_20128=null;
var title_f19_42_20129="Patient information: Social anxiety disorder (The Basics)";
var content_f19_42_20129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/32/32257\">",
"         Patient information: Generalized anxiety disorder (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Social anxiety disorder (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/social-anxiety-disorder-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H17573045\">",
"      <span class=\"h1\">",
"       What is social anxiety disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with social anxiety disorder feel very anxious in social situations. They often fear that they will be embarrassed in front of other people. The anxiety can be so bad that it can keep the person from doing things they want and need to do in their lives.",
"     </p>",
"     <p>",
"      Some people have social anxiety in many different situations (for example, at meetings or parties). This problem is sometimes called &ldquo;social phobia.&rdquo; Other people have social anxiety only at certain times (for example, speaking or performing in front of people). This problem is sometimes called &ldquo;performance anxiety.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17573060\">",
"      <span class=\"h1\">",
"       What are the symptoms of social anxiety disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with this problem often avoid social activities, mostly because they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Worry about being embarrassed in front of other people",
"       </li>",
"       <li>",
"        Fear that others will say bad things about them",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people have physical symptoms if they go to social events. They might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid looking at or talking to other people",
"       </li>",
"       <li>",
"        Blush",
"       </li>",
"       <li>",
"        Sweat",
"       </li>",
"       <li>",
"        Tremble",
"       </li>",
"       <li>",
"        Have a very fast heartbeat",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17573075\">",
"      <span class=\"h1\">",
"       How is social anxiety disorder treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cognitive behavioral therapy (CBT) - In this type of therapy, you talk with a psychologist or counselor about the things you think and do. Then he or she helps you change how you see your situation and how you react to it. This teaches you how to cope better with your anxiety.",
"       </li>",
"       <li>",
"        Medicines &ndash; Some medicines used to treat depression can relieve anxiety, too, even in people who are not depressed. Your doctor or nurse will decide which medicines are best for your situation.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people have CBT and take medicines at the same time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17573090\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you take medicines to treat social anxiety disorder, speak to your doctor before you start trying to get pregnant. Some of the medicines used to treat anxiety might cause problems for babies, so you might need to switch medicines before you get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17573107\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with social anxiety disorder often have to deal with some anxiety for the rest of their life. For some, anxiety comes and goes, but gets bad during times of stress. The good news is, many people find good treatments or ways to deal with their anxiety.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17573122\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=see_link\">",
"       Patient information: Generalized anxiety disorder (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/42/20129?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83069 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20129=[""].join("\n");
var outline_f19_42_20129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17573045\">",
"      What is social anxiety disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17573060\">",
"      What are the symptoms of social anxiety disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17573075\">",
"      How is social anxiety disorder treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17573090\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17573107\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17573122\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=related_link\">",
"      Patient information: Generalized anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_42_20130="Ultrasound images of vasa previa";
var content_f19_42_20130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Ultrasound images of vasa previa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound images showing a posterior&nbsp;placenta with an anterior succinturiate lobe complicated by vasa previa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of The Division of Maternal Fetal Medicine at The Valley Hospital, Ridgewood New Jersey.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20130=[""].join("\n");
var outline_f19_42_20130=null;
var title_f19_42_20131="Ofloxacin (otic): Pediatric drug information";
var content_f19_42_20131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ofloxacin (otic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=see_link\">",
"    see \"Ofloxacin (otic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16484?source=see_link\">",
"    see \"Ofloxacin (otic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Otic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=see_link\">",
"      see \"Ofloxacin (otic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acute otitis media with tympanostomy tubes: Children &gt;1 year to 12 years: Instill 5 drops (0.25 mL) into the affected ear(s) twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic suppurative otitis media with perforated tympanic membranes: Adolescents &ge;12 years and Adults: Instill 10 drops (0.5 mL) into the affected ear(s) twice daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otitis externa:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6 months to 13 years: Instill 5 drops into the affected ear(s) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &ge;13 years and Adults: Instill 10 drops into the affected ear(s) once daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9497976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic [drops]: 0.3% (5 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9496349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for ophthalmic use or injection. Gently clean any discharge that can be easily removed from the outer ear. Warm otic solution by holding bottle in hand for 1-2 minutes prior to instillation. The tip of the bottle should not touch the fingers, ear, or any surface. Patient should lie on side with affected ear upward. For middle ear infections, gently press the tragus 4 times in a pumping motion to allow the drops to pass through the hole or tube in the eardrum and into the middle ear. For otitis externa infection, pull the outer ear upward and backward to allow the ear drops to flow down into the ear canal. Patient should remain on his/her side for at least 5 minutes. If necessary, repeat procedure for the other ear.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10512869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic suppurative otitis media with or without perforation of the tympanic membrane; instillation into the ear canal of patients with tympanostomy tubes for treatment of acute otitis media caused by susceptible",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     ; otitis externa caused by susceptible",
"     <i>",
"      S. aureus",
"     </i>",
"     or",
"     <i>",
"      P. aeruginosa",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9496297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Floxin may be confused with Flexeril&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Floxin: Brand name for ofloxacin [U.S., Canada], but also the brand name for flunarizine [Thailand], norfloxacin [South Africa], and perfloxacin [Philippines]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Floxin [U.S., Canada] may be confused with Flexin brand name for diclofenac [Argentina], cyclobenzaprine [Chile], and orphenadrine [Israel]; Flogen brand name for naproxen [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9497566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Diarrhea, fever, headache, hearing loss transient, hypertension, nausea, otorrhagia, tinnitus, transient neuropsychiatric disturbances, tremor, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ofloxacin, any component, or other quinolones; patients with viral infections of the external ear canal",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy (primarily with systemic use). Prolonged use may result in fungal or bacterial superinfection. There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotics.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9497665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9497666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9496359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9775942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies ofloxacin otic as pregnancy category C. When administered orally, ofloxacin crosses the placenta. Refer to the Ofloxacin (Systemic) monograph for details. The amount of ofloxacin available systemically following topical application of the otic drops is significantly less in comparison to oral doses.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10512876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Presence of otorrhea, cultures",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10512870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ofloxacin inhibits DNA gyrase (bacterial topoisomerase II) thereby inhibiting relaxation of supercoiled DNA and promoting breakage of DNA strands. DNA gyrase maintains the superhelical structure of DNA and is required for DNA replication, transcription, repair, recombination, and transposition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10512871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Minimal absorption unless tympanic membrane is perforated",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10512877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16484?source=see_link\">",
"      see \"Ofloxacin (otic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contaminating otic solution container. Notify physician if tendon pain, swelling, burning, tingling, numbness, or weakness develops.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16030 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-B40BC8A1ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20131=[""].join("\n");
var outline_f19_42_20131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512847\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512872\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497976\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496349\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512875\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512869\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512849\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496297\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497566\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512866\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512867\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497665\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497666\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496359\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775942\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512876\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512870\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512871\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512877\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=related_link\">",
"      Ofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30020?source=related_link\">",
"      Ofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21363?source=related_link\">",
"      Ofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=related_link\">",
"      Ofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16484?source=related_link\">",
"      Ofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=related_link\">",
"      Ofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=related_link\">",
"      Ofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/28/34246?source=related_link\">",
"      Ofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_42_20132="Gastric cancer UGI";
var content_f19_42_20132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A double contrast upper GI study demonstrates a gastric cancer infiltrating the wall of the gastric antrum producing an apple core lesion (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonthan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAR4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwLoaWkA5pe9BQveiiigLhRRRQIKXFABzU4t38kOFOCcUDIMU4DNOETEgBT+VaVjpryNuZQB70BcpxxjaCcA46etPdVJUBQfwrbi0oFcZBPTpUX2BFJMjE88ADFAirbWCTAYh259yf606/0w2zKyu2CBj61t2H7qIBYhyeuM03V23xKeB3oFc5WYnneOagbrWhfR7HYY/SqRQnJA6UDIxSmlIpMUDE7UU4D6UtACYoxSgUoFADcUEU8ClVGeURopeRuAqjJP0AoAiIpCK6vSvAHirVJNttoN+q4z5k8LRL+bAZrstL+BPiK5Tdd3ljagnAA3SH8elArnkWKMV7sv7Ps20bvEgDdwLHI/8ARlZWpfAnXLe8jSz1G0ubRvvytG0bJz/cyc/nQFzx3FJXofin4UeIdDiaaNFv4FGT9nRt+M4+7ivP2UjIwQe4NAxhFJTsUh5oAKSlNFACUUtFADB1pwpo606gAooooEFFFLQBNbBfNAcZXvXQw6fvtTFnByfmHrXPouGzhvbg12+lxgworMTuGOR+FAM5j7MyO27txzWnaCVTGGUYJ596t3VsBOw4x9Ku29qNq8E4piJraI43BRmqlxatvYAc5zmtyCEMuFB6dahltiWAGRx1oEYtpbs1yAOTVnV7Jo4kYjKkYHHfFatjbIJNxwCOO1aV5aCbTWXGWQ5HT0oA84vYWOcr2q54W8OXXiC5u4LVNxjgaRunGCMd/erepwBS/QNXd/BoQabbX17MfMec+WVBGAooGec6x4RvrGFT5e6VSd6gjkeo5/SuXI7d6+lvEsOkX9sTFP5b8n5CCRz0I9K8G120Wy1ObzkilgLsAyOA2M9eO/1oaBMwRRinOF3tsztycZ64oFIoAOat6dY3Oo3sNpZQPPczNtjjTqxxmoFXmvqL4AeB7bTPDcGtahYgardkyI8qjfHERhQvcZHP40CbOQ8D/Ameb7PeeLLjy1zlrCEAk8cbpA35gDt1r23SfCGi6Vg6dpGn2zf3orZFbH1AzXRpEoUYFP2Dk0CKYt8dsY54oEB5zj2xVxlxjCk59McfnS7R6UAUDBlsio2gBFaLKPSmFFA5/pQBkXFosiFWUEEc15D8SvhRZ6vF9q0aOKz1FRn5ECpL7MBjn3r3CRRis67RSvIFMD4Sv7O4sLqS1vYWguYjh426g4qvXv8A8fPDEU+mJq1nB/pdu4EpUD5o8HOfpxXgJpFJjaTFKaSkAUUUGmAwdadSLS0CCiigUDFqSLG4bhxTBUiDPWgDotNtTPErPn5TjrXV2ETNFEvbtzjHNZ3hq2Etom8gg+hrqIYTkEYAHc8UyWZDWLF92D1z7CrYhAUZz9BV9l2kdz+lDKzc8LTERwqqADaeatLb4UNzg+hpot1Lj58+tXGWOGMKWPzCgBkVuvBUHH1rVtYFCEEg7ucAg1kDnG1jitKxUqOGxxQBzmt6YPOYYI5J69qy7O+bSlkhkLiI5YbMZU+tdNrE7JMd33RXEeIblELYIzzgbuppAQa54guIZsW04dWzu456+orl727e5kDln3nO7JzmkupDKxYkZPNVjkmkUkHU1ZsbOe8uYre2jaWaVlSNF6sxOAB+PFSWNlJcXEUKRtJNK4REXqzE4AHvmvqr4O/DeLwnafb70+Zq1zGu8HG2Addq8deeT7fmA2c38K/gythJZ6x4nZ/7QiYSxWkbjZGccbzjLMM9iAMd692jTgAUsa4AxUqggdc0CGgUuKcOmKXFADCPTikI5NSY5pMduBQBERxTCv61M3HemsPpQBXZB681RlRWBIYEZI4ORkda02Bx15qpcDPfnFAHIeIrGO7tZYZV3K64P5V8cavp02mXstrOOYnKZ+nb619q6zhYWz2r5M+KqLH431ArIGaUIzgfwnaBj8gDTBHHHrRTnGGI4z7U2kUJR9KWkoAavWnU1OtPoAQdqUCgCn7eKAECntWnYWolOSuRVFIyQD26VtaQgUkAAnrigTOt0hyqqo6AZ4rpLY+Yh3AhR+dZnhe2EhJYAHHbrXSRwCNslPlJqiSjOEGNobdjqRUKAs2TurVurdH+6SNoFMSCMKep/wAKAK0aBGyBnPr60+VfMC4Qgjg89auJDGcghuMHNaFvaRttxGTxxnpQBz6K2Pu/pWnbRkxknJzTnh2XW0wsq4Jzjj6VdhXci7hhQOn4UAYOrIdzH5lVVJPPtXl/ieYSTDHTnH5V6r4sO20cx5ORjPtXkWuqfMBbOTSY0YjZzVm0h3/vD0HQepqAIWkAFaUC+WI9wIXpSGe0fs76dZ3Gr39zcxI11bpF5G7OVyX3EfkBX0ZCowBivkX4e+KJfDGsx3kcZlhPySxbsblz/MV9PeEvFWleJrZn0y43SIqmWJgQ8ZPY56/UcUxHRDqPpTgM4oHTpxThSEHbpSY9qdRtx04pgNPJoxS0GgBhBHpSYODn1p9NbjrSGREZqtcjjvVpuneqN5JtXjNAHP604SMnNfJHxRaF/G2oGDPITzDnjdtHT8MV7d8cvE11pGh7dPm8m4mlWINk5AIJOPfjvXzRK7O7PIzO7HLMxJJPqTTBDGOVAxyM856j0/n+dNNKaSpKCkoooQCJTgKSPqam2UwGoOKlVARycU2FflB6irMYwMEAigAVflwCc9a09NQ+ZwT07CqiplOcD8K0NPjIkbj8MfSgR23hicx7uDkZ4ruQVuLZc8Nz0HvXA6KTC3zcEnHIrqrOUhyM5BXiqJLUqnzTknbgY469KRVBJ2/yqOZ8QnJGcenvRaTIq4agC5FEN3RiMAEgVrWK7GUDkDByRWcZWkjxjA46DmtWwwqFm5wMdKAKrbS7s/LEn8aiJxkAEDsKszqodioweMD2qruI5x2x0oAyvEEPnabJgZKfMRXkevxgP3yK9ouF8yKVCOGUjpXmXiPT3WdwYztH8QXjpQwRyVpbE73YECtAxnykBB9sVfhgwgVRgfSnvECOcY7UrDM+3Bi6kjJr0L4X+IJ9F8QWrRGAJcyxQSvKD8kZcbsHPH/1q8/kXAI9KksZ2ik56buRQB9yRnKjBqReleH/AA2+KUdvaRaf4idEtoY1jguI4ySABjD469ByB9a9c03XtK1CBZbPULWVCMgrIM/l1oEatBqGC4guAfJljlxwdjBv5VMcetAAKTHPWilPBxQA00xsc0srKqlnYADnJ4Arkdb8feG9GaYX2r24ZMAogLkHnuM0gOnkdVHJxXnvxY8Yt4T8P/b4YPtDGVY9hJHXPeuE8efG2GK3CaDCJhLGGjeQFSffHp/hXi2qeM9S1h1XVfIlgLKXVYsnA7DJP+elMZT8WeJL7xLqbXd/IwX/AJZwhiVQf4+9YZqe8EAmP2V2aM9Ny4I4qvSKEooopAFIKXvSUwHW65Yirnl8AjHaq1mMs/pgVoKo2Z56cUCIoE/drgdRVlYz1OMfSp7OLdEhwMlRxVtYkXPAP1oAqQxNjG0kVradFmbJA9enWoEdehwMjjFWbVxuYZxkUCNqNssAeSetdTpyMxR+oIODXI2cyKVG8nnHSu5sWX7HGOMjnjFUhDZ4HMcbKuc5FNtoGMmX7HBFaFnhyYyCTnIpJMLIzEY56DFAGlZquPug8D8604I2JORhTxisGO4LACJCo4yevFa0MTsMu+FxnOQcUAWDbqfvAkj2qnsWNdrLzipLiUPF5YcjnqB1FUGRQSwkPtxQBZkQMWwu0j071yOvWY8xsqSQPTOK6cFcncxxjjisjVwGGc9R6UAcbd2gXaVA9CKzpUYZBFb15GzbRtHGenesydRuyfxpAYs0XOKrJFtkYHj0rUnTBPHGeKzywEm70oGWbZznaDgnnirqyMqhhwazYflOc81ZifPO4Z6UAatneywyJJGxR1III4I+le6+GfElz4s0qVLScWuv2qtJFtPySYA4IJ6Gvn2N1JGOv1ra0PV5NL1GG6hcpJEwYEdaBH0IviTVodK86/tLeC6XIkBVgqt/30eK8y0b4r+I7vx5Ppmo/Y4bNA6qsMRXkMNpJZjn0/GvSPG7xzaf50MqxuzFMNjB6dfXHp714P4/itbexuNZ0twuphgjgbTtIYZI/L8qAKnxp8VeIdR1GOC5vJY7Ek4t4ztRyCMEgHmuW1vN74et7yJPKLJmRR3IYqR9OM1s63c23iLwtbT2wX7Uqt5inBZHyM/mAfzri7PVGtILi1mQyQSHG0n7vY4/z1FA0ZbMdoGBxTSc/WjHyn2pvakUJ2o7UUUgCikJo9aACjtSd6KYE9kMl/wrUhJEWSQOOtZ+nvtWX0IH9aubv3Tcgcd6BFy3ZljiwcjaOfwp6yFVOSarQPiFVyOACalUlvu9aBFqPnnBFXEIBx1NV7dG/iI5q7sCcgDP1pgXbJQGGegrqtPuwsMeGII6/nXGrOw/OtvTn8xEAZQevJoEdrYuZeUbbgMfrxTWuIhGwOXb17VUtJ/KtSCSTs7HHcVVLbnYBiAT36daYGgl4VddpwvGQK2Irzfb9wBgCuaRlDAFsgelatpIgUgk/hQBaaXH/wCuoGmYD6VMXiII5Ue9Z9zIidie/WgCd52x1qtNIGX5j271C9wpPc/jUcjCQH5gB35oAz9QYQRMVzg9x61zlxIVKndnPY1t604EMSg/eyT71iTRB1U5BHJ69KAKcsofOSST+tZUx3MwY9eBith4QARWc1vls+vORSGQRzAjbn5gOasJKOCM+n1qsYyrc/8A1qsRjco7H07g0AWonJ5OeferNoTLcqmSSxCgDvVPO04B/CtDSSFv4JOm2RSfzFAHt3jm8NroVlHI2J3aRz6EnGf6V5LrYyZLdXDRXSMVGRyykH/GvTPiTvn06xeJeDDIwY9FO1R/SvG9WaSPUtNcybgsoSQE8Jnjj60xGF4PcR69NZuxEcqsm3I5YH/DNS+I9KisobkbTuXDK341Bolvv8cpFuAC3Ehye4Ga63xBGLsXcLYx5ZHB9qQzzODltmAS3AzTFXMm08UkTFXRl6gg1I2ZJXkOBk54pFEJpDQeaTtQAp9s0etHeigAo60lLQBZscbZM/7P9asOD5bHH4ZqtYnG/j0/rVmbmB+eo9aBFm2wFUY6VbiKg8KSR0H4VQgbGOvQEVfgY5DY/I96ALkDTGQErEseOcMS2fyxV9mARsdetUoh8uSa0Ybd5FyVIB6YzTEVmDSPjaSfatazjkVo1CkYPPNW7PT1AQhgfU5q3CgWfGMc9fTmgRs2iZsUzy/RiTzVO5Pk/wCsIHH9at2b4cxgnDcVm66WXy0AO7HQDrzTAfBKGcDOc9OtalqTnAz1ziuf0pZWcBQcZ6nNbsJ8uVSz8dcigC7JnIUH71JcRAxKf4xnOOmKcWUyBgSMf4UjsQoORuAz6cYoAyJFKMeevegjcc+o6VburYSrvj+VumM1XCMhy4x9M0AZGtx4SE+mR+orMQ4j+b+db+qRb4QMEsvIGfzrm7ncpwfwpANldScY6+tRSoMdM+lUzKSx+vFToxKnPNAyDgNu5B9c8iq5k2429BRdOVA2g1VXcerEY7UAWHu93yg8+ma2tAOb+1jZC5aVRgd+RXLyYXBBP1rpfAVxHJ4r0rzRuUTqe/YGgD2XxvORp9haQkyMEb5txGfmAORXhvie+cXUdpGhDJMuAD1IavUPGF39l06yu0T5jcNk57ZB/wAa8v1uO2/4Se1kRt3mSiQpk4BLUMEUvDYRfFN3Lc5LQrK45/i3Bf8A2atu31CL7fJBK25pPlAOawdHlRPF96Zx8rvMCM4/jz/SrFzbTRay1wvKA5UelAHK2cTS3UMI+V2cIM9jnvV3VkNrdSw5B78VDqTsmqzyABG8zf8ALxg9c0B/tUybULyuOSSTk0hlMj5c+9JTpcb2C5wD3ptAxKKKKBBRRRQBNaHG7Pt/WrMhzAc5PFU4D96pnbERH0oGWFfaB64q3DKAi9Tzms4HGKt2aF2BONufzoEb2n/PhjnGeldDGQsXfNc7aPtCjj2rYik+Q8DimSa9pL8rDtj9asLvEo2jIzzWVBeLGSCOvp0q/HcAgDkg/pTA1bEySTxhEJcsAMZ65q7q9opdT950PPHfNJouIJFlPzd/pUt1cLLchVAwefpQBkRiQHhSpOCBjFTRg8EscioZ7wIxyBgHrUZvN2NinJ/CgDTEuGxnj2+lSo+8cEk49Ko26PIAQvrzVq1BQjLEn0oAmuEaOIZ4Oe/Gf85qpluep55qzcSyuAoRcAHFZ7GTOSx6dCKAEu+g3DNc5rSAKrKCOvAHSti7diG+U/hWPfNuTlTg98dKAOfc4fjPWrBfC9f/AK1VrjIlzjJBx0pQ+eCBkAfhSGV7gnbyT7ZqJSNwyR9adKQcjIzmoFdQwzg0gG3A+Y4JOe9bPgZgnirTCeQJxj64rAnYnpyPepdNmkhuopoh+8icOo6cg5oGer/EWYR+F7Nhk/6XIDj6LXEeL4YrXxBpawoiqsmDtByTuHJr0L4u6aY/CkVzAwFvHqCN0xhZFBH+FcN4ygWTWdLIUkmXnA68g0xI5DWY2i8T3aoxUtOSGB/vH/69dPao8tlJNMWKt8o47Dis/wCIFiLPxPA4GEmVH/HPNdjpVusujZCjaGPGOOtAM8u1qHydQZQxYEBsmrth5VlppvSN0/IQEdM8Va8ewLDq8OxQFNupOPXc1UNPt5JrEoI926QY/I0hmT9fxpSOO+atalb+RePEONoGc+4zVZ0KgFuM8igY3FAGTWlY6TNdWklyuFhjBZmPQAdTWa+3cdmSvYkYNACd+OlFFFAhY+M1Ix+Wok707oKBko5/Crlu+1AFxVJT2qRGx0oA3rWUDbnHPNafn4QAcjtXLpN3BOauR3DFfmb8KCTaNwM/QZ4q5aXqhkJPGefeuq+GXhO21S7uY9at5i4iLImQAOnJ/Ouyu/hPolvaz3LLfbB8yosy5Jz7r0pgcDpWpNcSbY0MhB4UDNb/ANluY1WWWF0DcglcZ5rqPB3hGxtYrmeK3mO7ICysD39gDipbvTryzfzYZmSEP8ycFQPcUxHl81tKXy/yr69c1YtXhXAwW+tbHjDV7YSDesLKR0MKZI9N3WsG2s4Ztstg7EbQWRyMg9ePUUAb0dxttmKKMgcDIqpHdvjldufWqBlYZBkA/EVVjALuAVO31IoA3mvOCNwyM96RLhSG34OOoIrFuY3RlZD9eRTPOkDYIOO5FFwNaZ4TglF9iKyL9QwPAAyRmnu524BwD0yao3cvygAg4BoAwdTbYzEEEf8A16pifIyAPWn6y4GB/EazUkGOT2qSiaSUmqrydulOY+/NV5D83HSgB5bI4NIrHJGaizSg896Bn0auzxB8I4Ipo1lE8DR5C5IlRQY+/quM15xNK91eaGkK75TLh8jturovhJqgk+HPiixuWCpaIbmNjgbD8vf8ay7K3WPx+00EYEboJETjC7vmHtx0pknOfEf/AEjxZaxAgE7E47ZIrs/DFqE0eWNSCQ2R6HmuA8SlpvHUcZGX+0oD+LA16FYyR6Rpkl1fN5cMal2Przxj68DHqaEDPMfGcp/4SCXfhtqgAdgOcVr+CLEiwkuJgG3viNT6Ac/n/SuPnln1K/aRhuuLiThRxyTwBXoUdrcWVnY6fCqI3lB5T1JfGCPpQhs891Cc3F7NKTuy5wfUU+ysZbt2JzHbxjdLKRwgxn8T6Cu5sfCum2FmL7WJcRxYLg7cfTB7k9q4nV9Ra/nYhRHb7iyRKoUDjHQd8UguWNd1gX6pbWcIt9Pi5SMDBY4HLc4PfFY9LSUDsFFFFAgTvTjTV706gYoPNOzxTKM0ASB61NBUS3rM5ASKJpWJ6DaP8cVkZp6O6I6qxAcbWweo64/z6UAeo+BPF+qpqyPDcQQWbSeXh9pJUYO3p+tfVdqEu7YDAKMAfpXwjolwbfUYX3hQrZGema+qvhf43XVrYpdLHChwYnMvL5OCCMcY/WmS9DvLuBbWM7AMHsPwrjfGuoCx8N3SEgzzAEAemf8AIqx8TfF8GheHLm4hnQzKQo2MCRlgCP1r5u1T4halq10ZLpsJkKq5HC5+lArCahJPfXDSyuI41weSBmpNMv5rZleNtpToQM1zGqahPLKYidsa/LtHfB4p+kzus53NmLGG568cc0Dsdot2t3LwVSc8nJADH29KlgixMFb7zBsjvwK5WK923I8vgg8NnPauzhzdW9veEjfjYeeuB/higQ4QNcwOqsFcLkZ/CsZ3lifbu5rat5fKDBTgkYqjcoJ2k2k7hzyaAK5nd/vHt69KgkYng9/SrMMYYY7/AFoe35AzkHPegDi9VlMl1IeODj8KoKxrSv7cpM/ORms5uvXpSKHAk8VG2ehpVODwaDlu9AEdb3h3wrq+vDfp9tmLn9452rxjP+elP0bTbaC0j1PVeYi37mAnHmY/iPt6D2r0TxN4vuNI0b7DYtG1zcg72VhhOBz05+lMGyGHT4/CmiXOhpewXeo6jk3MltIDHFGNpCg45JPf2rV8LRW8ut3E3/PK3wSTx8rYH86xPDVv5NncX9/MZpZEyd5Azx/9auw0S0ji8LXWpjhpRgDpxkGgk820OxXWvipcZ4WGR5ceu0gf1rb+NlwLC1ttNiOGuVWRx6qpOP1H6UvwUga48X61qBGYyDGG92fcf0FYXxlvhqvjqSOPPlWgFoO43Akn9T+lA+pH8ONDheFtZucF438uBCeN394jFddGu/U4mgcvcOMbsjoM9P1qS0hWysrWzhKJHbxCM7j96TuR9a5HTPEU4tNVvPkgktI/IgfPDMdw49+/40C3KvxE1XeE0qMhlSQTO4OecHA/XNcIamuJ5Z5Wlmcs7HLE1EeR0pFoZSmj60UAFFFFACDpS0i9KUUALRRRSAXFL2puKWmBJGdhVwRuB6Ht713ek+NV0zRYxBEwukXbGNx5YEfMTj3z+lcGEJBYA46E46UnpQK1y/qGr6hqLyteXk8okYuyGQlc5z0zVEUUDrQM1ZLJjLEGIaSRA/Xp9asrAbVAZkwSOAKboqTXl/GZJPlJAO4ngV0V1DbtCh8t32k4eRiox7Cgk5/TzvucyYIHv7V3djdBdKQE4QTfKP8AgIrmrC3U3AIjGByABxXQWsVzd7I7O3eVQM/u0J570wY6biYqTkD360iW8nmSNjCMp45rUGmTgkzmCJsZwzgn9K1oYLJLaRJAJGAOCWxnI9qYjk0R88UPCWweQTXSROC7RiIIg4A9KkUFW2mAXCn+6Mn8aLAebavasJXKqSG+YVzEqYcivXNW0+2vJ3W1kSGYf8snDKQfTkYrgNa0K8tZGdkQjPY8/rSY0c6F54q3pqW5vYBeE/ZjIokx1255pyWj7cnap64ZsVPp2mXN7exW0MLs8jYGAaQzqNUjmvvGwj+zuttbY29dmFXjHtWbeQPf61PHyULBQwHHQZru9Us3spLiSWRGcW8VuNuSTII1Vsn/AHgao+HdFea6BjKMcYJJPLH0pklHXpZLY6bYRLkztg4J6cV6v4ptP7N8DGAZUxxhcdyWIJrm7bwjdXnxMNreLELfTYgXk3NsYttOFOOTXs00Nnqlx/ZwsGmtww82VgdvHvj+VAHnHwn8M/2X4U/tGVCj3BklYHPQEgf+g15dp1ql943upXXeqXPm5992RmvruOxt4rMWqQotuE2CPHGPSuXk+Hvh+Nrmazsfs1zMQzSRyP1Bz0JxQB5ja2EEm6+uIQLWwT7RIvOWYdB+JrwTxDrkmpJFbxwJa2sJysKNkZ9T619IeMNNvvDfgDXndQzOEYNGCcIrA88fWvlaQ7mJIGSc8UMaIyaCeKDSUigIpKU0nSgA70nNLRQAg6GnU1adSAKWk/CrmmWMt/dLBBsVjzuc4AHqaYFSul8LeD9U8RTzR2tvLEkcTSmaSJtmBjjOOuD+Nep+HfA0MSxaTcW0EitGkkVw8YPmTFcncD/Dk49sV6v4O8M3emQSi8igDvwdgByMf54p2JufL2vaBdWNhmzt5ntLdf38hQ8k4+Y1ymME+or7M1rwdG1nNb20MaW85LzcDPSvA/HXhS00rRdSXy4UntHV7eQEb5QXwVJ9NpJx7UAmeXU5RntzRtPJqSNCThTk+o6CkUd54T0oJGJpHRnZQcICQvfk5/lViTSpppY0HzNkK0kz7VXNHw60q/1yWSzs4cWsSI0zBgjMuepJNesf8K8M2rfaJwkWmtZpEoXadkoPUDv9e9Mg4vUvCX9hXFpFNPHeSzp5ixICEUbc/Mc5PrVOee+giM0k5jt/uJEpKoxx2ArptY027NnchnB+xyLCHdAXk+XoMHpXPapbwRxAWwln1edT+7lTgAjBxzgkY4+lMCixZrl0nu4VYDlEYsV6enFaraeuCzSSbe7dB+XXvXMpozrbmWE3QullwxwuGY46c9sGvStKifTtWnbUUF7DdJtitygYgjGWyT+H4UAclqFvd6dc4kO5WG5WXP3fU1YttR+zgFgd3XODmul1ya1W9nZIlB3Yw4zsx/D+FY0kUZkVirIhJ2snQ/rxQBB/alldyf6XCSwxywNa7QaDLpyvGWkY7dy7GIDH69ayysVu0rSvlQNwwBn0rTsdXtJx9kidPNjUfe4yfY59qAMS6iSOaOOPw7FcROMiSXeFP4girkd9DplrkJp+mheskSO7Lx0BZjzTNJTW9cnks306W0g4YXDMMJjOT15zXPa7pMIvImjna980hfKxgBsdznvjNAHW/C23fxPqKaneKq6dBI6RxknMhAHOO/3uvSvXV8I6bB5lzZwiMkEjZnhsdetcx8PvCrwWGnTzIkDrlkWMAKoK4IIB4716lY2ggQoPmX3pAYWgaNENOAlle5mZi8sr8Mzdv0rpbeBIQBGuAKSKNY0YIgUHsO1ToMKBQAhHFIFxz3p2PpQaAKV/Zw3lrLb3MSywSqVdGHDA18efFn4cXfhTXJDpVlez6M0YlEyxs6wnJyhbnpgHJ9a+zJgxibZjdivK/jVoeu+IfDzWemKsasFZ/nC/MCcgnPTFIaPj4+3SkrR1vTjpWovZtPDOyAZaLoD6VnEUFCUGg0fhSASgUtHamAi9KWkXpS0AKOmTXtvgX4ewf2bpN7IS0l5EJXc8FM/MABn6CvExXuHwo1LVJrSB9QvZ2tFfYkSKo4xxTQmfQek2FmlvbEW6b41AVioJHFbIU9aoWaxm2jaNSMgHHer6sCOeopCI7lS0EgQDdtOARxnFfMPxr8PvpkEl7dPJNcXkvlxxomVQ7gxbOfQEfjX1H1Jz0rzz4s+G7nW9LhSyuBBsYtIAqksPQE9KYHx4YZPPWEqVlLBcNxgnpXWeEvDv9s3UUPmAQCRVYonzOCTnJz/jgViXOl3UetS2McbvOjsibsZb5toP6/hXe+Atbm0R7vTfsix6orGLc4HqRgA96Q2epeIPCx0jSxdaTHHA626RGGOPAlAGCWOfStbR549X0C20+OY213bxIzKOQ3Xg8966vwjcS3vh+0OqqDO6BSJAATxXBa7o8/hfU9RudL0ie/tb8ZmaAgy5yeB7UyTTitW0EvcRBprWRQsg27ij44IH9fauA1cWBvH+yyXsd0+5N08YzyvJB3ZFa/h2S6vtLENybm2tIpFa3uPMVeAvKNz2rk/FFjY2Wp3sVrc+bJGRIgkk4HAJwQaYGzpcNrL5Hm3Rl81HUhflBbGBk9//AK9ZNxaXqSyppplQBGiV5yAsecbsc9cd64uTUpntxbCXaiuzAk9jjj9Kkvb1Zdq3U5kbGFYt93gUrgdRbzST3KwSS7liG0ZUfMc/ePNSXEJsJT5k6RMf4QevNebyy3cBkbfhF5G3B7006vOYh+9dmHQNjAouOx6dbW9vcwM8khmPUAnkc9jT1s0jWSaG1UbCB5mBwa4bQrwvBOZpwrBc8MASPauz8KahDHpMttIZHjbDqCBt5zyTTES/2zfajFDHD/qYCCUI5x0z9K6Cy8FTJ9lvNMjLGXY0pzyuByMk+9cFp5uItdmXSBsVlPm5+6WIOME+g5r3bwYJdM8PWmnO++5VQ3zsO/PJoA1vC1h/ZWkW2nwsz3MbiVpCoAJZc4611encSyruJJw2CeF4GcUWduqQo2AGI7dKtxxqjMyjBbrUgPc4U8E0oORmo5Cei8moYpX/AHisOQTg5HI9aYFvOO1Jn14qs8yoEQthmOOlVZNSjiuCjf6vgK2fvMewoA0icVheJbC51O0NvBci1QkFpNoYsMHjrxUr6zauoCzxFw+xgGBw3p9ao63eC4t4jby7ZUJcAdGxkYP+e1AzyvU/h/o2k2bHVLe3uLcy/KRAokdiPb6V4J450W10bWpYtNm82yPKhj80Z7qe5+tfSvxMtNTudFtbvRLvy9QWSN2hKowKgHcAD7183eNrO6j1B7m+eGS5uCZD5QwcY6kDgcCgEcwaVR1opR0pFDKKU9aSkAgp4KbPukvnOS3GPTGM/rTQTtK5O0kEj6Z/xNLTAUcV7n8HLpbax0+znlRXlcyEseikfKK8i8L29nc6zAupzRQ2YOXLvtzxwPzr6M0fw3pF9a2l3ZBhhR5bI4KsMfSmiWeu2zKI1AYY9QfarauCSOK57Q45BbRpKDlfl5PXFdFEgUHk/nSAeBXP+MmMelSMkixyAHaxPHUV0DEAnJ/WuM8eSSSWvlqhePd8xB5Ugjt3oQHgni+2j0u6tb+4PmsrufkIB5xyOOuR+lXbUafcXOn6na35nQL5iuGAYODyG9O34Ve1hrPUo1kiljW5gfZ5ZIyhLDDfQYqGXwmsdrff2c6xmTbJNMGDAkkklBj6iqEemX+uxXnh3S9Ttg/2yErIFRvl3cZDVgaj4g1nUb6BxvtbeUYCk/KcAk849q57RZGgNtcR3MkQt2XMbn/WYxx07+lbXjvxpa3vhK0j0kiS7kbmIHBTA5/WgDltavbvSrC50e3uBCyyb0LpnC4+n+c1h6hFDc6TbXck8Ut+AEIVgRwPvEelc/rPi671HEFwx8tMEgsM7gMelULfWFQbVOO31OKVx2Ibuyudzyhw2SScfX0qhNFcZGQcmultbuLaN7oFHOeParDzxupClSvqMZBoA5620+5ngcFwDtyoz3yOv61Yj0KVRy6Fs88cCrv2tIS2WwuQCM9KJtQlltsWo2gn7x7+tAEa2tvY3EO9l80DeST9eK0Jtdjkiit1zEoGMIc7uw4rGvraaW5Dzy4DKMkcYp1jaq8qFeQuBnPWgDt/DOtw291bK7P5aKzKuARwDx078V6to3jGa8toJJ7BIFYhWkLbiBjjsOvWvH7GFFjDKuNvGT3qRb+WLUQJJznggZ644oEfSGj+IkvLqW3WVP3AGR2bI4APrXQSalBbW7TXskVvGoyXkcAfrXgfhzx1FpHn3AhaVeu0kdvQ4rpbO41bx8j3BiS20y5OxYi2SuNuWzt5FAHVp4/0q81F47KTzVRW2kNgSEY46Vyfxe+I9zoVnY/2NLEk827eQQ44xgdKk1DwzF4ekEixtPYc7mVdpTj19+lVtT8GWPim9tJIZkWOIkrGHyCMjg8cDigDibb4n+L7rQ5JHughGSNsCjK57Hbk/nXNR/E/XINFNhLeNJHJJv4OHTnoGxmvZ4NBuNJvFspXzaMwSIIehJwR0rJ1P4brb3Cy7kuRMShgmwS0ec7c465PWgDJ+Hnika/qYga0aO5MiOZHlBHmYHOMdTt/WvTTDeS6o91bxhYYIFiMWeGYsxZhx7gf/qrye10iP4c6w91M2+LCzpufB3gkKhOOOePxr1iHxAmq+GIbvw9c25vJ0WQwPKFZDjkHPoeKAPOvHNw8umia51FUErnbLGcEx44IH4GvAtW1ee5MtvFcO1oTySMGT3bv+FfROl6bc2PhmYa1qSLM0g2Tyog3hk5RRjjv0weDXz1q2mC109rlpEL/AGx4sKeq7cg/p+tDGjEo980uQehBpppFAeTSH3oooABS0gpaANbw3pseraolrLOsAKkgk43H0r638D6bHpegWEAYNHDEqrjoeOo9q+Q/DwVtas1d9gaTG7GccV9LWHiQWljFYj7yKiIMnJGO9NEs9Mh1FCQqpj/a/CrqzuSGDAg1hPbMumxzA7T5eWyO2MmuX1HxLdWemyzpEwC52Bs8t2z7UCPTPnOWY4A9K8R+L3iG5XWbePTNQj+0RNt+z+aVxn+9irlt48upbW6hu9Yjt7hEMm1YWOAB0zXh/ifxlNq2uz3ckNvgzHbKseH2bu3PUj1oHua3iJJvszTxxzrq982wbJDtBBBZl9u2ffNbvgvxjdNpAs57cmRY/LLNn5+vFUJprq3gGqWOnyalaOkYiZoXLQg/e245B61iPe65I622naelqiIQDEjfOWJI+Ynqc9KAL2svPfxubKdkmjAZowxGwk9iK4M3l0rEi4nXd1AcjpXU6tb3dmGjmP2OSfYXGSMY/wDr1izLZFlFxOrEKMlAck/UcUAjHCk+tW7WxeZgAcD+96VpC10pwphvgHPVJEZT+eMVoW9jJGqrBCkwPeNif60h3MW4jjtwVWXew4IzRb3GWfOckdcnk1tv4deSYmS3nQdSAD+fSpZNAhjfMazqRyc80CuZj3PmxlCv7xcN7+n4daagu5HBXdtX17HNbtvosalysnzYwWYEd6uR6NcuoEEfmZz93OOtMDEeFp7U+YkjFTznr/n/AApIC0Bj2AhSB8o711KeH5Ex9umWAE5Ksdv/AOutTT/C9nMqzWlxHckKAY1JyOfzNAHOWt3PJG3VcdNp6UtvGbqYsQcqcHA5zWhrtk1jaO9tCd/+yCa57wjBq11rsNskUpjlkIZmU4U4J/p0oEeleFtCF00SNCCpOCDnPv0r3mzktLKzghjiEMeNkaDsB6fnWLpGi2mkWFt5SAXRjVWZs+nJx2yc07UtQtLOZZNQl2W6cJwWJY9wByaANnWZ4oYF8xWxLlD3znsfauF13xJZ2Nvc26TLZrGnysgO4NnqMetU/iN4tSzs8R3GEceYjEEYXAzkda8H1vXZNc1KGDSWmaESCSWWQthjn7vrt9vegD6L8MeN9PuLW3guZHuZ2UgSMDmQg8Z967Sza31WGC5EX3Gyo9OtfP8A8MvDNxPdSvcTzIUUvHHECwznouTxXs+i3Mtk/wBisbaSdwR57tnbH7E0AQeP/Cdtr8EatAjMMAlmI2jOQcex5/CuV+H+hR6RqAjuUmM06HaJh8oK53YPocg16zGvmhZGXbxgqe1cv4i+3Lcw2mj2ERKsrmWbITac7gCDkHgfnQBpT6PbX8MQniQtDIHXPQMO/wCprhPiJ4Ls59N2WUKWhzlp41PyDHLE/gK9Rty32ePzAofaNwUkjOOaranYQahb+RdIXjyGwCRkj6UDPjj4i6U8dxEtojzw26yFplViAuFI3HseGrgWGCc19peMfCmmjT9SbTtNX7ffW/kFkBOBgAHHTjFfN/xe8NroOo2ccETybYcS3CoQrEBevYYyaATPOqKU0nakUA6UUgpaAJI3MciujYdSGB9CK9r8CeKrPV77T0ufLSRFxOGU53YP5jNeI1e0i/bTr+G6UZ2Nkgdx3oQmrn2tPqFvPDb2Ucy+dKBhOc7cVzHxP0Oa9XT0t/MW0Rm88oeg+XBP61zHgrXv7V8U2ksEQGIFAJ6Y2fXrXr1yn2uycIAzEco3f2pkng8vhG7udP1Gc2ztc7TAFwRiIj5nx3rzo6RPpGvskQSGGMj9665dh3IBPHI7V9CarpOo6h420XUNIRYLe2ikju4ycZBxg9ee9c74m+HN/qfieHUTNEoRw2wDO9cglev60AUp/FQ8MeErBZ5IrlZ0cmby2DA56FR9QOfeuI0jX4WWXVzFKCjASgMQucnbkD+Vex+IPAKav4aWxjuFtyCXdUTJzySAc9zivBZ7C5sZrnT7ZSkUMhE0UYBLOMgbmPJ/KgDC8UXk+p6zJcXLFnfHXOAPQViH71bWo2V1HM0k5CljuPJOKxsZPAzSKEDEdDWvo0bxyrMVYEcjBwKXT9HkdUmlU7W5ArYgtT8oUYHpgUA2WG1K884GGSQfLnhjVk+JNQjUKyxSDkHzFzx9af8AYmVenO3HT3qhd2LGB+oIHNMRZGuktzaW249xu65+tXrPxVdwuqxNHHj+6v8AjXLCOUAbhn3FAk8uZSo6deKANzUdWa6uWmmw8xOdzEnvWFPqE6yCRHaNl6bCRg+1PnZZGBUemRjpVG6wOD+dAGxZeMNRiTy7zbexYx+9yG/Bh/XNer/DG5tbvVbaxm0+e2vQY7yBy+4SI8YPHGDgV4t4ctlvPEGn28gBR5RuBGQRjPTv0r62+FmjyQeFdOl1SygivowyxEKN6xEnaCevQ0AzavNRhVJvtUbRQJ0eRSFcgdj3rz3W/E+j+VPdNfRKdrYkeCVvLAA+6MV61cWNvcxeXcwxzRZ3bHXIz9K8z8aeDoZLjyNPgSK0nBWVAnCjjp9aEI8S8TavoOqZjGr3LAZzJ9nkw3tg1m6Xq2g6ZA/lSylx02wsS35nAro/iD4STS3eKaFo5ViPlIiKEjXj5ie5J/ICvKryE211LCxBKNjPrQNHofhjXb3VNQlt7G6fS0l+SOVHfzJSWHy5BwOB2+le2fDK31i2vGglEs1vC22WV9wycnoe9fLmjqJPOLGYCBRKGiGWjO4Ddj6kD8a+s/grq11qHhOJLl3maNiBLIuCwJP8v8KAPSVIIH04rL1WVLdopHICgksx7DBOf0rVUcDNZmu6Wmr6Vc2UjeWJ42jZgMkAjHFIDnfh/wCNR4tjmkSxuLeFSfLkeNlDL+PeuwGCM9c15XZwa94c1e10SHVrGO0AUQyzQks6qvTAOAccde2a9PWVREGLAg9+1MBtyqhXY44Wvmf4hyX3inXvEtnCEgTTowUbb98MgyrfXNfS7OJR6Y6ivA/jft0JdWuraJDPqZVMouGyIwpJPoBQB86SoUdlYYZSQR6EGo8U40nekUNHSlpBS0gFpRTe9LTA2/D3iK/0K7hns5D+7yQpxzX0hoPxBsLnwxFcmYrczZwDjIbAyP1r5WFKODkcH1FArH3F4Pnie3eGZt10MsxI5x/k1tXNhHOM5ZWHQqcYNfGtr471tZYWjvzauuN8igfMAfp+lezz/FpNNvreea4S406dAcxlW2557dxTEdj4s8Qz+FGgkvIZLuweQI7xAb0BIAyOM9f0ryj4hG0iv7jUdKmkW3ul855QgAT2Pf8A/XUXi74xWmsb0trOURAgYliRt4zzwentXl2v64dYvIyYzDax8RxKenJJJ9+aAsO1q7V7ZI9zMxO/J/WqFrZyELK6kIeQa1rK1F6kYZAYwABn0z610CacLtorW2Vd2AACQo49STigDG027myY9xKjp+Vdn4Z0PUNVv4rWKBVdhuJkUAAYzW58JPD9jPqs93fwCaG34QOgIL47g9cZr2rTtNtLdhPHGoMp83dgZ5FAjyy+8N29nrttp7B2ViolkAHQjt/k1J4r0G0t53ggshHEPlLHGSMcmvT9TtrZ5Vdo1WbO4NgZ7Vz3iu7t4ZokkCGV853DOBxTA8c1DSIbXzJI428tTgEqDnmsm8gsEWNjbkueWwAMV6H4pNq1mDtZGVucYG45HNc9f2NtPp8E0flqcYySMtzQByD2lrOf3Ucy/lxWTrOmvZIu5t27BxjHHNdjpNorXYMjsFQ7ivHOOn4VZ121t75RtiEjoMYwAf8APNKwHnuipJBqEF0jPHJEwdCvXI7/AEr7J0PxNYy+HbPUJZkVZlUMPRyOR+ea+ULREbUYDBDvg8wBgMZIGSefw6V7R4ZlSycBpLVbCOPcFZUO0kcBs/h+NFhnrKa9YGeKCSdY7iQbliY4YjGc4qfUbq1gtWnuGURoN25ug968c18rqt7Hcm4s0KxCSTBVSMKQACOSCeMA96861m81jRbmaNJVVXXMkQkXJzgjrwcjFFhG58ZdYvZb+7lsYpBA42DzCMY2gM20/SvDpWZpCXOT3Ndx4h8Va5PNLZS3UVwVzb7ZLWIsoI4KttyOPftXFT20tuI/NQqHB2nIOccUmUiXTbt7K6SeL/ddSMhlPUEf56V9g/BjV9L1HwhZrpaFEjypVwNwbc2c/jmvjVa+g/2efFmk2ulHRpyIb8PuBfaPMJYkYPfqBQDPosds0Gs7T9RW7Ljyni2kKN+Pn+lX88DAFAjD8S+GbDxDCkd9G+5G3LJGcMDj1rB8K6BJoF1fWNzdTXNo8oeBpTlgu0YBI9MV3B5FZt5avcXA+ZkUHO4UAXH+VeFHT0rwj4wRy3+najcXSM0lv5sEMKAY+ZB8/wBfr6GvaJmQW7wPMQcY3ZGRnpXlvxFsdORYbWeKOKJpDOG3AZlA+U/zpoR8qmkq1qSBNQulByFlcAjuNxqrSLGjpS0gpaQBS9qSlFMBR2p1NFOoAcKBxnHSgUtADo03uqlgoPc1etdMkuLjy43Vh6iqcUbSSKqjJJr2X4S+CZNWdbh8i2jI3HHLdeF4x25oE2c3p1k1jpu3qxAxmu68E+FW17RL145BHKkiEkclhzkY+p/SvS/Bfgy1tbR2v4vPuDITukQDgdAAansbP+xfEjxxQrDb3IypQnaWGeCMUyR/h7SLfRbC3toycknLyHksRya6WRQLRQMfKvFZOvmLZDPLOqQBvmOQMHHXNSRX8FxCyLMCcblKt1GM5B/woAS4RpmyDnC8VwHixPtV0yysUZASp6YOABVvxT4ke3cm0uZ4GI3MISm4YYdmVhg59PyrnPEetx3lp9tiMyhyylcj5GAHtz6/jTApPcC7s9soBZTjY2ATg1j3ChY5YpptoUn5eDnniqsl3iJizN5wbruBDVmTzSXM+5pW27u2OPfpQBVfVfst48ZVGjhZQzh8Ec9qnuvEv2iFktT5SyAfMMMd3+1XHyzf6beI7MVkkJ6A4O447VBas0TqyyHqCR60rjsddots73yiRoztPAJ7kYH612cGooLGW2NurwF13Mh2knHPP4V5zBrcnnxhPk2nKc9DzjmvYPBHirTL3TU02/skBhXLOCqiU/XHH/1qBF6zhtokhtZrN1t2WNRN1VsgELnr1P51BqfhOGa8lvZZSYsBDEBnAAABHHXivQ3eC4MTTtFHZyhdkbcEHAI5qa6W3JuLzz9iRjYiSOoRgAORxTA8V8S+Frmwmnk8rz4tjSSuvIPtnsf8K4V9NtLu4nW4nEVnG/zIuAV9ME/zr6H1y7trbQ5pkmSS2cux8phgqV5Gcdf614Tq99bXEcVlb2zJBI7Py2WYf7Rx0+lICbRfh1pesX9jFZawGWTLzRMfm2+isBgmsnxv4Jv/AAj4lhgtJHMM6mS0uN2CMZ+UtgfNx+tejfCbw6ia1bXPnu1tNH5Maj/noGDMw46KvH4ivfL2xiuLRrZ4klQjHzqD+PSgZ4D8L/iVfILaHVm+1MFWLzp32sOele96Lq1tqtus1rPHJwMqrAkfXFfLPjLwZrFteyTLbSadGJ9satnYSScENXq3wP0TVdPWefWSUdcBOg3gg5PAGR6UAexBvXrUU8mxCetJI6xplmAX1PSq91+8QqpG6kB5F4t1bU7qXWryyYWDWj/ZnDtu2qOfMxj/AB6V5N47+IEuvafEkrec6zMYQTsZAFUbmA9TyB9a+i9Q0ON5NQN2ymK5Ksw4ycDucc18qfFKytdP8d6pb2QIhUo2OMBiik4/OmCOVldpJHdzlmJYn3NR0rUgpFDR0paQdKWgBaBSUtACjrThSCtzwvop1m4mUbz5Sg7EGS2TQBjjkgAZPtWxa+HdVuADHYXG0jOfLP8AhXtHhP4eWI1JA9lugVSVLg/e45JzXtuk6TZ2sCxxxoSvcCmTc+VNE8MzxE+ZbsCo3NuBDdeuOuK9o+GEsEFtHbvqcsbBtsVtztGSfw5J/Wut8dadajSJrlIVFxCMhlHzEZGR78Vy3hOxjEsN2sBEYIYF8jBycDigR6sWEafMDwBz1zXO65qUUivHZyA3EbDjkEe4/wDrVqeZLLYSPCxdyvy9+a8g8WtqmkavDeuZZoGQBsA8Pg8frQgL+uarc6haS24XEMhHyEHI/vAj61k22p3Fpp9sn70SRblAJOQMcY9gaSwvV1KHz0mMdyD+8UNg5xjdVO81i5achwPlXBJFMDMu9QkednmLliXVj1JBxUusBYdIMU7xrMuXUZ+8uBj8ajv7+1ucM1tEjBcHywQD+tZWpRwzNtSYhscKfpQBjJdq0eNjBwevaqlxI24NGxB9jzUkkDo5+Z8HtVfA385JpDMW8/d3L/LjJzVSNsP6D1rS1mPDJInIxg/nWNvywB6UhlzIVgcnPY+lbk3iAXMNpHI0iKn+tKdTgdvb2rAO5yoUHOKlSzAVSzs3qqr/AFoA9H1fxpZy6Fp0dtqDERIsTxZbIAXBBGPbr71van8QvDV/pyRGaZWtFHk5Z/3ucZDYHTjvXi1zHEjEJGR05Jqrkc+uKdxWO48ReNreSCa00aC4ihfglpyV9eFIH5VzcOrKmowzNE7W6vl4y2S6ZyVz1GQMVk5BJB5q9Z2ksib0gkdevyqSMDrSGfWfwp0uGx0uG/WfzormMfZVXcRHG3O3n36/SvRQeOc18/fB3Wdcgh0e1lgZ9MR5IkzuOwHnpn1PH1r32J/MTdtZTkjBpsRV1O1hu7Z4rhFaJlwQ3TFfOWu/FHW08TSafoUVtZWNqxiVp5CSwUkZ6ZAPoAa+lLqETxNGSQGGDj0rx3xH8II77xbDewXBgs5Im85osiQOSTxzjnj8ulAHoHhnUbjUdFt7mQxSs4BLQklDx7gH9K1obmOSENGSfcCud8N+Fk8PW8arqF7dKH4adySq7QAvXGAR6d66DIiOAyHPGCMUAVtRiM6NwSu0/jxXyz8Z7BNN8WahJKsb/a4VWPa/IIC8kfgK+qNQcLExkYqCO1fM/wAcotEju4xbzStqO5ncbtw5A7mgDyI0hpTSUihopaQUtIApR0pBThTAcK9L+C0c9p4pLTWkpjli25ZCB161wvh6NJtasI5UWSNp0DKwyCM9CK+xoLK1idzFbQIQcArGBxxTQmy7bReQGVIsuOeK0LYkpHJKHjcn7pzViFR85wM56/gKgviQEwSPp9aCTkvFJN3dRrJcPAqyEOgJ+Zfce/8AWqOkW+q2EqxWdobnTZXHzsSSBnqD+fWr3jLh8jgmPn3ro/Bv/Iu2v+6f/QjQBowp5NqhgHT7wP615n8Xbh5ltYoZlWJcO/BJDc/416nIBtbj1rxn4zAJNZlAFJXkjjuaAPPbGSRXOxzuHBArRkbMBdnfc3H1qhpvMi/57VNqjHy1GTjH9KYFaZgMAMCe/UVVeQ+b15qT/lmPwqvcAbQcDPrSAjKsoPPyjsagaJXGclPwNJN3qkPvD60AM1OINbtGgJbtxXPrancpdguf0rp7sAR8DHy9q5s/cNIpF2EqkQwv6daUvjAXAGeT+FVZCdsYzwO1Oh6fjQIpzMWZiSTURyTmlk6U6LlufSgZp6PpYuQZZt3lgOVQA5cqASB+dex/Drw7dFBbyWCKs0LS4ZThBvUhG9CevrgVh/C+NH1/QVdFYee3BGf4BX05bQRRhmjiRWb7xVQCfrTEY3hnwvY6KskttD5dxM3mS/MSM+wPA/CukHTrxTV7/WlXp+NIAPWmMB1yBTz1FM70ARkZ4JFV54VIyeCDkMexqyoyxz6VG/3TTAw9cR4tJn3mWbKnPlg7h9Mc18wfFjQDY3MF0iylnQmQOxLLz3/xr6w1Ti3fHHFfOXxT/wCQdq57qEA9sjmgDxQ9aQe1OamHpSKP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20132=[""].join("\n");
var outline_f19_42_20132=null;
var title_f19_42_20133="MRI retracted hamstring complete avulsion";
var content_f19_42_20133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of retracted hamstring following complete avulsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is a 57-year-old male who was involved in a water skiing injury. The MRI of the thigh using a fast STIR sequence in the coronal plane (A, B) and proton density with fat saturation in the sagittal plane (C, D) demonstrate a completely detached and retracted hamstring injury. The retracted hamstring tendon is seen as redundant low signal structures distally (blue arrowhead). The retracted tendon is remote and detached from its insertion site at the ischial tuberosity (white arrow). A seroma (red thin arrow) is seen as a large high intensity homogeneous signal. Clot within the seroma (yellow thick arrow) is seen as intermediate signal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20133=[""].join("\n");
var outline_f19_42_20133=null;
var title_f19_42_20134="Superior pole vessels";
var content_f19_42_20134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior pole vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 431px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGvAb4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorF8Y+Ibfwr4cu9ZvYLm4gtygaK2CmRi7qgxuZR1YdSKANqisDT/E0UtxFbaxZzaDdz7/s1vqVzbeZchF3OYxFK+Qo5bpgHPSs2z+JXhW58QahpH9s2EU1nbxXfnS3cIinieNpN0Z35YKi7mJAwCp6HNAHY0Vz6eNvCr2aXieJtDa0d3jWcX8RQsihnUNuxlVIJHYHJp9v4x8M3E95Bb+ItGlms43luY0vomaBE++zgNlQvcnGO9AG7RXKzeONJml0T+wruw1i31HUv7Neazu0kWBvIlmySu4E4jA28fezn16qgAooooAKKKKACiiigAooooAKKKKACiivNYkkm/aQuJRuMNr4VSM8jCvJdsenU5EY59vpQB6VRRRQAVwvjrxTreheNfBGmaVpsV7p+s3U1veuQfMhCorKyncAMDzGOQchMDBruq+ZbfUJr79sVYzdTNb29xKkcTTMUXbp2GCqTgEsSeB2NAH01RRRQAVz/wAQdbm8N+B9d1q1ELXFhZy3ESz52M6qSoOCDgnA4IroK8L8Y63qviDwj8ara4uI5tO0wfZrOMIoMQSANKCw+9zzg5IOR6AAHV/Anx1q3j7w3qWo63bWNvLbXxtUFoGCkCKN+dzE5y/tXpNeHfsjkf8ACBa4AeRrLnGf+ne3r3GgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis6113SbvVJtNtdUsJtRgBMtrHcI0sY4+8gOR1HUd6ANGiiigAooooAKKK8K1rxtP4O1XxULK5tIJ7vxBLg3VvG8bBLGzJG+S5t0U5YcbmY84Xg0Ae60V414f8AHfjTxVp+pS6BHoS3lpolhqcdtJaSSGea4hkcwg+coUFkABOcA8561Z034ga94mfSbrw2+lW+ka5qj2emz3llLKxhitZJJZGUSoSTLE6AfLgLk5yDQB65XOfEPw0fF/g/UNCW6jtTdeX+9kh85RtkV8FNy7gduOo614zd/HLVv+EQ/tb7V4a027i0mO9W2uY5JjqMzTzQssAEqFVUw5P3yN3PTJ3bj4s6tB4o1mzuo9MsrOxa+V4pRC1zDHBHIyT+X9qEswby1bYIUG18hyBuIBqat8Izq2iJpE1x4b02wNwbqZdG8OpbNI6xssf35ZAMFiW4yy5TgFs2PEXwx1DXH1fzvEFvFHq9nZQ3gjsHUiW1ZnjeIiYeWhcgsnzHAIDqTuHBQ+P7vxn4g8OWmotp0yaf4k06SK4tREA/m2958rCO4nUEGP8Av5+b7o4z33xN8Z+INC128stAfSEjs/Dt3rsv221kmZzCyjyxtlTaG3dSDjHegCXQPhk+m61pOp3OqQT3FnfzX8xWK5Y3LPbGBdzT3MzAqMHOeQqjAxmoNS+FdzPDpf2HxCbG8sG1eRLqK0/eB75nYMp8wFTHuHPJbH8PbBg+LOu3Hj+TSUtdIjskvUtzbzTQx3Bha3VxMpe5V3+ZwQqwEFM4bcMVevfiP4k0jwh4Y1/UbLTrtPEFkBbQWcMgaO+lgR7aIkuco7CRScDbuQZIBYgF3wv8KbvSPEB1W98Qi9lbUoNRK+RMSTHazW+3fNPK5yJQ2SxxtwBgjb6TqupWOkWEt9qt7bWNlFjzLi5lWKNMkAZZiAMkgfUivH9P+J3iY/EkeHL630ULBqMdhcQl4raaRDCpNxEJLrzGBdgyoIWynG8sK9luraC8t3gu4Yp4HGGjlQMrD3B4NAEenajZanbrcabeW13AwBElvKsikH3BxVquH1L4TeBNQkSSTwxp1vKjiRZbFTaOrDoQ0RU/rVcfDVrSfztC8Y+LtNwm1YTqH2uEe+y4V/0IoA9Aorzz+xviVp0T/YfFuh6w2couq6S0JxzwXgkA9Odn4U9tf+IWnmJb/wAE6fqa/wDLSXSdYUEfRJ0T/wBCoA9Aorz/AP4WbDazvHrfhTxfpYQZaaTSzcRf99wGQVY074s+A78uE8U6Zbuh2tHeyfZHU+hWXaR+VAHcUVXsb20v4FmsbqC5hYAiSGQOpB7gjirFABRRRQAV5x4XlW6+OXjlgGLWenabbkt/Du86TA9jkH616PXmnw+Rn+MHxTudpMbTabCrnplLXJX8C/60Ael0UUUAFfIXw9LT/tPpetuZZ/EOsxK5br5cEmBjHGFdOcnOegxz9e18w/C3w+kvxl07VbeRpUfUvEGoEleFXzEtwAc8/eBz/tYx3oA+nqKKhvbqKytZbm4LiKJdzbEZzj2VQSfwFAE1fPuhxvcfCr45XBP+u1bWWQnHKJEMcDoeCOa9i0XxPa6zqMkOmGC9slJQ3dpcLKInABMcycNG5ycDBGByVJAPmnwotBrXwN8TvGpB1ufVZMsm92MjSJllzyeAMZ5x1oAx/wBj+9WTRvFVjn54b6KcjHZ4go5+sR/KvoOvlH9jzWILfxLrOmzyqk9/YW8sSsceY0ZkyB6nDk464BPY4+rqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4T4u6jfpo2n6Doc7wat4hvF02KeNsPbxFWeaYcg5WNXxg5BK1j+Kvh74B0jw/p9k+gppkXnRW0GsafEsdxZTEhYpWmHz5L7BuO4biN3GTWhfquq/HfSYntw8ehaJPdibg+XNcyrGo9jshk/A1s/E+50+LwNrNpqkyRpf2N1boHOA5FtLIwz2wkbtk/3aAKXwz17U7sat4e8TSRzeIdBmSC4uI02Ldwuu6G4C9FLLkEAnDK3TgV29ee6G0kvxm1WTklfDlgs/bEhnuCMj1xmvQqACiiigAooooAiu4EurWa3lMgjlQxsY5GjYAjBwykMp9CCCO1QaPptpo2k2em6bCILGzhSCCIEnYigBRkkk8DqST61cooAwfEPhLSfEVxHJrEd5cIgQG2F9OlvJtbcN8CuI3567lOcAHIAFb1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFVdR06y1O3aDUbO2u4GGDHcRLIpHuCMVaooA4XUfhH4Cv5IpH8L6fbSxOJEksFNm6sOhDQlTUP8AwrOK2nSXRvFvjDTNgwsSaobiL8UnEgr0CigDz6Lw58QLCaV7Px5aahCQPLh1XRkJXA7vC8ecn2/+uJf/ABPsIHa80LwrrDLnaLHUZrVmHb5ZI2AP/Aq9BooA88k8f67p1p5ut/DnxNGwA3LpzW98Ow42SBj1/u5x29OQ+HvxH8K2XjHx2+uaquj3l5qkbx2+pxtav5S28aqSrgYOVbOT6HAyM+5V5v8ADe2gvPEfxGN3DHPnXth81Q3AtoMDn0oA7DRvFGga5n+xdb0zUCMAi1uo5SPrtJxWxXF6n8K/AepRMl14R0UBurQWqwt/30gB/WuK8R/DvQdEtorLwrr+s+Hr8k/Z7MeI57OKRU+dyC6y8BAx4UjCnOMEgA9fvLt7ea1jSzubjz5PLZogu2EYJ3vuYfLxjjJyRxXzZ+zRrJuvEfhyzdJGlfRNTvnld9xPnagi4J6kg25Oe+6tPwlpviq98Qtf6P8AEmx1TUFQw29uC+sW8cYALeZcRrFHG7HplAxwo3HmvO/2cLnxDaeL9Ol0XTbPUpf+Ebn8iC4vDbAW/wBv+Y7wjfN5ok4I+6RzxigD7OrlvFV55k620UHiNZICJGuNMjwqgjvu+WTjPygMfbOKwz498R6bbSXHiX4ea1bQxn5pNNure/UL/e2hlfH/AAHNcpe/E7wwZWurj4j+K9Mt7kmWFG0WNYgjHICM9kxKgFRkse3JzQB1Pgy4iuPF0tw19Lqc1vYvFJcajaGx1G3QujBZYtkYljYhijiMbSjgFt7EUf2Y4i3wM8PecrbpvtTPuzls3MvP4jFUrXxhoU+v6Wr+KNI8TB1uIrO6ikjjv7VvId3EqxkLJE6xnoigOsfyscMm1+zlBJb/AAU8LJMmxjA7gZB+VpXZTx6gg/jQB87fs8Lv8Tah4bmdLPVbi3D6ddODut760ZyvHXBV5dwyMoHXoxr668Kayuv6DbX/AJJt52LRXFuW3G3njYpLET32urLkcHGRwRXxzoy3Wm/G/V4tLWJLqHUr9IZZEbbAwnZo3JX5ljLrErkf8spJM8EkfQ2qa1qlkuk+LfB0Nl/Z+vTww6rZamzxeRcEeUhLIGMcu8JA+VYblQYXDNQB6vRXEW/inxYpZL/4fahvXjdZanaSxt7gySRtjp1UUyHxB47vXZbfwPaWK44fUtaRTn/dhjl4/EdDx0yAd1SOyopZ2CqOpJwBXDDRvHmqiP8AtbxRp+jxbiXh0Sw3yEc/L505YfiIwTjt0p1v8LfC7PFNrVtc+IbqMY8/W7l70+5COTGuf9lQKAOtstTsL52WyvbW4ZRkiGVXI/I1brjr74ZeDLqAJF4c02wlUho7nToFtJ4mHIZJYgrKfofrmszw/rureF/EcHhbxncPeQXjldG1xkCi54J+zT4ACzgA7WwBIB2YEEA9EooooAKKp6vqlho2ny3+rXtvZWUWDJPcSCNFycDJPHJIH1NcfH4+v9ThNx4Y8Ga/qtmSPLupfJso5lIzuQTushHuUAoA7yiuGf4kWOmylPFej614bTKgXN/bq9sSTgZnhZ415/vleorsNOv7PU7OO7027t7y0lGUmt5BIjD1DAkGgCzRRRQAU2WRIo3kldUjQFmZjgKB1JPpTq8h+J/ia18Ry3XhLT9SjtNHRhH4h1YH5IIycG0jbo08h+XaMlQTwScAA2Pg8G1n/hIPGsyOh8Q3mbQOGUiygBjg+Vvu7sPJx18wGrXi28g1nxBo+jfZWLwax5MjSojqUNhNIzAHOVIfyzkD7/oRna8H3N3cQyKmjrpGgwxxQ6ZDIpjnZFBBZosfukxsCofmAB3BT8o8w8S6i0th498Y2FreJfFB4e0YAMnmTSeXG0satgMTK0ab+eLcYJGaAOs+D5GsN4m8YfIw17UnFs65+a0t/wBxCefXY7/8Dr0WszwzpEOgeHNM0i1/1FjbR2yH1CKFz9TjNadABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnvws48RfEUd/7fJx7fZoK9Crx/4JarJfeP/ivbzKm+DWgdwPJXDRqCOvAiHfucAUAewV5rceIry2u54oPGFnZokjDy/EGhSrKDk8IwkgV0HADBW4H3j1r0qsnXdKu9SaA2evanpHlhg32JLdvNzjG7zopOmOMY6nOeMAHFWOu63dXsc8FxrGtSQkgwWOj/ANmWLZBAZ5Los7qDz+5dj/snpXln7MthaN4m8N3ltOUaPwi4MDMGaQtqU+9s8YAZemOMgZPU+w2Hh/WZvFEZ1a51TUdKs5A8c2pXsMe+QcqyW9tEiuA2DmY5BXIXoa8M/ZXmK+NPD8Zdtr+ErkBc8ZGqSn/H86APqyeGK4heG4iSWFxtZHUMrD0IPWudm0XxBd+Z5/il7QFjsGnWEMYC9gfO83J6ZPGewFbd7ei1uLKI29zKbqUxBoYi6xYRm3SH+Fflxk92Ud6xtR8XWWm+N9J8M3sFzFc6rbyzWdyVUwytHy8Wc5DhcNyMYI5zxQBwUOgaP4r1Sb+19G0zWre2XzfPvtDl029tztbaXEiqJ0Y7h8oUAgfK3VaPw5+FPh/U/hh4fu7KfWdD1C/062muLrSNRlt2kfYpLFMmMk9zt7+teo+MZ5tM8P61q0U8jC102eQWx2+WzKhYNnGc8Y64welc78Ab37f8G/Cc3zfLZiH5gB/q2Kdv92gD5rv9E/4Rr9oY6Qk1zrEUd6FnN+wmnvIZrTdMjEAB3dZJEGcAkgE9TXuvge4to5Lvw/q8iahoutu9sHY7kmmaHzA2QANtzb4myo2+aJ+dzAV43+0va22nfGuK7uDLHDcW9jdztC+1wqyujMpz8pCx8HjBA+teiTQXNvd31jrJnMyF7W/NsCJnRczLcW4AP72NmW7jAZiBLcoqs0IFAHp/hvV5NJ1aPwnr9y8l+sZbTrybrqMCjnJ6GdB99R1GHAAYqvYVyngrXk12E2uom2m1WwCS+fCAYrmKRT5V3AefkkXcOCdpDrk4yeroAKK4r4geItKjtZ9GHjPw/oGpPgS/brjEqxsp+6FnidGOQQwb8OQRyj2virRIRcf23rbabw0V3YNHq8IUD70sMkX2naeOIpJD1JZfvUAewVneIdE0/wARaRPpmsWyXNnMMMjZBBHIZSOVYHkMMEHkVx9l42u9KtbW78TnT73QrpgsHiLSCWtQDnBnjJYwrnjeGdM/eKcCvQQQQCDkHuKAPM7y78Y+ANJbzDD4t0iAKkMsxmTUFGSAJPKilExxtG/ah4y2Sc1i6d8WfE2tS2yaD4JW8eZgvltc3UXl5GcySPaLEu0dRvJ7DJxXs1FAHC6P4Lu7/UYdZ8fXkGr6nEyS2tlChWwsHA6xI2S75yfNf5v7oXpXdUVia74s8P6BPHBrOs2FncyjMcEs6iWTt8qZ3Nz6A0AbZAIIIyD2NcXqfw18O3N3Ne6ZDc6Dqc3L3miztZu5znLqnySHOfvq3U+tSr8TPBQuntp/E2l2twgBaO8mFuwyMjiTb1GD+IrpdP1Gx1KFZtOvLa7iYZDwSrIpHqCDQBx7aR4+0xW/szxNpWsRhsrHrGnmOTH90zQMq/j5Rx71YXUvHyDbJ4a8OSt/ej1yZR+Rtc12LsqKWdgqjqScAVzGpeP/AAvYXJtDrFvd34OPsVhm7uc/9cYgz+nOMUAcd408MfEfxxa/2bcazo/hbSnXE402SW7nnz/CzMsW1fZTzkg5HFbfwz+Feg+ALVRZedfXoJYXV3hmiJADCJQAsYOBnaMtgbicDHR+GtV1LVhdTX+hz6RbBlFqLqZGnlXHLPGmRGM8AbiT3C9K26AMTxPNLnSrG1lmgmvL6NfNi6okeZnz/sssRj+sg9a4B9KtdQ8feE/Bmn5m0XwXaxajdNJtcmcIYrRGIIIcDzJT8uOF9a3tb8RWGknX/GGpkHTNEgextdhBM0m5TMEOcEtIsUIBwQ8Ldmqz8K9AvdG8OyXmvHd4j1iY6jqZ5wkrgYiXlsLGoVAASPlyOtAHZ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeM/B21Fn8Z/jBEqqoN1Yy4Bzy6TOT+JYmvZq8w8BRrH8b/ioV/jTSXPTr9nkH9B+tAHp9R3CPJbypFKYZGUhZAAShI4ODwce9SVzfxC1248M+FbjWbeNXSzmgkuQyF8W3nIJmAHOVjLt36dDQAureGJL7QLWwi13WLa9tEAi1BJx5rMBgtKmPLlz3DKRycbTgjwL4F6bLovxst9BuI9t3onh24sLnauFLC9Lq49nSWN8/7eOua+nZC5hYwlN5U7C3K57Z9q8rsr/Rn+Leh+IYFtornWrK80pnSYOZdjQz27HHTfCC/wBHjGT8tAHXeD7y81HW/Fdzc3Ej2kWoCytIDjbEkUSbiMDOWkaTOSeAvpXDfFbXrPVbnwXJpv21ZbHxjZ2zTPbyQowxKJNrsAHTaGyykjpzg1keOvGkngjxPrfhaAzSXeu3Ud5YpaQyXE2J4/LePaskRQ+ZE7B1lDDeuBgEi74I+EMl9YWsvj5Yvsazm+j8OwPI9vHcNkGWZ5JJGlcrjjdsB3fe3EkA9O8QPZ674X1uytLmK6E1lNCwt5VZvmRh2zg81xP7L0nmfAzw0S25l+0qec4/0mXA/LFbOr/CnwleJHJpmlQaBqMJLW+oaKi2c8LEEZDIAG4J4YEH0rP8Aa9c+HtXHgrxhBaWmruZJ7C/tYRDb6upO55FUcLPk5kj9TuGQaAPJf2y7BE1fw5fIpM1zZXdsffY0bKP/IjV65rlt/a+ieHvG+nQ3E8yWlvcXEFsSJbi2O2UFNvLSRksyjkMryx4IlNcn+13ab/BGiXwQsbbVFVmA+6rxSDJ/wCBBB+Ndp8ANQbUvg74XlkAV4bY2hGc/wCpdov12Z/GgDuNNntLrT7a402SGWyljWSGSEgoyEZBUjjBFWawdK0KTR9buZtNuQmkXZaaawdSRHOxyZIjn5QxJLJjBY7htJbfvUAZ+t6kmlWYuJrS9uYS4SQWlu07oCD8xjXLMOg+UMeemMkcHdafo+pWkmrfDqJItQjmP2xtGuUs7hWxkiSB0MUkvbZcKpGScqa9MrC1/wALafrFyl6RLZavEu2HUrNvKuIwDkKWHDpnkxuGQnqpoA8o3w63JeQT2Vt/aF07xXdksb2kWqOYyGAV8PaX3lsSMkiSM/fdPmiPgNrFx4e1K88Hapqkl7pIKtoNzcjbKE+YNbSAnckilHUIwBzDMBwmBt+ItKuNbvRp2uwWlr4sjQ/YLyF2httZhjO8xnBLxupO4DJaJwJYywDCsHwu1nrvjIWGvWZlOu2ElveGaIRSXMlq6mKYsnC3EeZopdrZV4Y2UKpSgD3eivL/AAvf+Jgr2ehapYasbTCT6Z4hL22o2WRwJZow4kGQcP5eHHId+p1mstf1jVbS18Ta3p+lxEG4XSdHmfzrkIy5LTttcxgldyoi/eALEHBAMXxZ4m1LUhi3kurHRnkkS2TTLiF73V0QYeRJQ2y2txkZkLB+VAMbFQ/GeDhLr081vpFja+H9OvJ2gtJI72S1F7IiZlkaT93eXkqvvBBMSlVYsxbpF8TZZr74p6qkt7FJY6ZawWdvbvEsdtZPKFd7i4djgpEGSYKMb2VMD9yzLp2Edvo8elaRo5u9B0nUbd7dL648ybWr61giHzW6sGaJQzRhYghba8jKkW3JAPWfBWmWNh4fFvZTWN2jSymea0hWOOSXeRJwCeQwKncWbI+Yk5NR3fgPwheTtPeeFNAuJ3+9JLp0LsfqSuaXRdW0zT0sNGktV0L5Rb6fZXc0CPOiDA8pFkYkAAcEAgEZHWujoA5Nfhv4HXOPB3hzk550yE/+y10WnafZ6ZapbabaW9pbIMLFBGsaKPYAACrVFABRRXHfFHxFeaF4fjttDQS+ItWmXT9MjIJAmfrI2AcJGoZySMYXBxmgDnEgh8bfEWOwtIol8JeD590ixbfLudTxlUwAeIQxJ5HzsMg4pulfFS6/siG61HRZJU01I4/EdzASg06csyOFiOTIEKlnwflRlYbwadfeH7bwvomgaFZ3WpXNhpyvc6nBYXc0V9OHJzd5iYSSASFy0YznfkAlFUt8L6ToHi7W74Xl3F4lTTDbSQavb3JUTrvZ0gufJKxzSRPHuwy8LImRksWAPVqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvENA8RQaH8ePizJfM5t4rPT7lwrDKxxwKGYAkcL5uTzx7k17fXgPiLTvs/xn+IOo28MV1A3hyCS/tnXJni3KJYgOOWhhYA54Yr2yKAPfqgvrS3v7K4s72FJ7W4jaKWKQZV0YYZSO4IJFZPgu6S40GCNdV/tSW2/cyTPF5UwI5VZozysoUruBC5OTtXOBu0AeY+HfEUPw9QeFvGuoCC2tUxpOsXzrHFeW4+7G78ATRghSDgsAGGcnHh9gPE3xb8TRReD44rXSdM1KK7/t2VZHEckQJXDOcy7d5YBwXZmLMY1YRp2Pxs160l+I8uk/EWz1N/BWnWQ1CytLCFi1/Nt2M7yKQVVPMdcbkH3STg81T4w8beMIzoHgTRJvBmi28eAsVoXvGjKnaFXCxwZG0je6E5yrnBoA9In/AOED+GF99v1i7W48U6gdxurgfadSvGchQEVRuCkqFCoqoMYwK83+Mnjf4jNp63lmkvhDSJ7d3toJGjF7dEAk72PEThcMI1O8843EELzfwl0S+0z9oXSdO1O3uU1Gxju7m7uruRTNdh4sKz7XkU7S+0YkblTkgggfQfxnhYfD7U9Qjv5LKTTIpL5QrDbcbYnBhcHgh1YgejbWAJUCgDxb4d/HmHT9Yt7XXdS1O+0i5G2aW/jiafT5fl+YvFgSQsS3VQy7emOv0H4p8O6R400FbPUV8+2cpc21zbybZIZByk0Ug5Vh1DDsccgkH5k+G2l+DfFnhXR/DmrvYW2o/Z1giaDUVlkDSbnL+Xcqpibcwb/R2bc3DDChasfCL4lXnw51O48P+Jjcy+EU1K506C9lTmzlif5l4J+XDKxUfdySuRkUAdH8V7rX7fwJeeB/FEE2o6m81u2iasiAJqQSVW8pyeFudiv8ufnIwuSQG6X9k68ln+Gl5aTZDWGq3EARlKsoISQggnggyMOg6YxxXqWvaPpHi3w/Lp+qwQahpV5GCRnKsDyrKw6HoQwPuK878OX83w012TR/GB87TtRkQWPiYpzcEYRIb1gMCYLgCU4DqOSCCKAPW6KKKACiiigDmvEiaJ4gtrzS768W2urGaGRZc+VNaTMf3E0ZYd2O1SMqxDoc/MtebWV5cx/EfQYtQgSK4fW8XwhRvLS+TTrpHcHkKk0TWkiLnP38/MrY9A+INjZXNtbyTxKl3iSCG5liMlvhxhoLnAP7iQDDbhtyFOQ4Q157qUpabw3qQivFuLTW7GwkaZ2ZprZ5njWKZ+VaWCfzFzlmwud3745APXNb8PaNrrQNrOlWN+9uSYXuYFkaInGShIyvQdPSjRfD2jaG876PpVjYyT486S3gVGlxnG5gMtjJxnpmtSqes3g07R769ZkVbaCSYl2CqAqk5JPAHHWgD5o8EeIbbW7v+0Dam91O6v31QWEgP+mX800sNpHuZctDbRQu7MuQp+YcoRXoHg+PWdVttU1681X7BDcNL9q8SP5aGS1ikfylson3xw2+35/Mk3FsscHcsi+W+BZzqXw/1Kbw5Kba9g0NLA36wnzoYlh3skZILh5r24lTcoO5bd9vzhTX0DpWiSa39jk1XT107QbDaunaIVXHyYCSzqPl4wNkXIThmy+0RgGp4O0rQLOwF94diR0vlDtfMzSzXY/hZ5nJeQehJIxjHGK6CiigAooooAK8W8I67beKfGHir4i6k6nwz4Zim0/SmUbwFRd91cqBnJYBQrKeVyMZ6938XNafw98MfE2pxStFPDYyiGRRysrDYh/BmWuD8BO3hH4QeBPD9hpNrq95rtq8jWt9dLbo4kieeRSSjbj8wQJt5B5IAJoA9lhnimaRY5EZ4mCyIGBKMQGww7HBBx6EVLXnPwpHh6UyX3gzUoV0+/tYL260dpFmktJHjTyuQxMQEa7PKOVAVdmwA7vRqACiiigAooooAKKKKACiiubvvFtlpviTUtP1WS2sLKxsLa+kv7m4WOMedLLEFO7AHMQ5zyWAx6gHSV5/8Y9QWx0rRlk1q20pJtQVXFzfzafHdKI5CYmuogWh6BgeASm3vV3U/iN4esNT0NJNW0gaRqsF1LHqjahGsAaBol2K33WJMh6NxsPB7bv/AAkuhHVodKGtaZ/akyh4rP7VH5zqV3AqmdxGBnIHTmgDxbRfigfD3h2V5byKOwez1ieyuNVv2vhPdW86LHHBcHY08JDnaCN5Axu4qzpfxZ1681WOF7zwyrmXR400xYZDd3YuooHneP8AfcKnmsQdjDC8njJ9ou9Y02zmuIbvUbOCW3t/tcySzqrRQZI81gTwmVb5jxwfSsOw1PwhY+J9US01jSk13USk93b/ANoK0r7IRtbyi3y4iUHIAyBk+tAHkEPxr8UyWN5efYdCjeJVLWM8saTWjteQwhJFW5eUgLI4Zmhj2sF+XB211WueMNc8O+I7uxvr3R45iunR3OrTxTpZWglN4d7QtOQo/cxxgh0yzgsx+VR3X/CfeDjam5Hizw/9mDiMy/2lDsDEZC53YzgE49qnbxf4ea9+wW+uaTPqbRebHZJexmaRfL8wEIDuIKfNnHTnpQBw/g7x5r3iTxFounRto8cFxY3N7NcLbSsJ0hvFgDwgyDakqHcpbdjIPzAYPq1cn4e8eaFqmm6C93qmmWGq6tZ291Hpst7H5wMyBlQKcM3XAOOfStvX21ZNMkbw/FYy6iCuxL6R44iMjdlkViDjOODzQBo0V4n4h+K/jzwzO41n4W3L24LEXFjftcRlQeWykLbc9Rv2/wA8UdK/ac8LXDxx6hpOsWkjHDbBFME9chX3/wDjtAHvVFcLpXxc8A6nCJIfFWlwHoUvZfsrg+6y7TXWaZrGmarEsul6jZ3sTdHt51kB+hUn0P5UAXqKKKACiiigAooooAK8Z11GPx58Rwpp66lLP4JLJp7PsF3/AKQy+WWPA3Z25Pr6V7NXkGuW6zftGPG/nsl14LlgdYHMcuPtWfkcEFW54ORjrmgDs/BEaXCLqFlqkOpaeYjbxyXFqRfRlW/1U0xbJKHcpVkDgj5iWBJ6yvPPAx+16ja6lLo1tqE80bQ/8JHbJFDMyoMbLuNtsiSgrsKqHAYE4j+6vodAHnnx28PafrPw28Q3l1bBr6w0y6ltp0Yo8eIyzKGBBKttGVPBxyDXU+Eb21vfCWk6lbrFFb3lnDcgqoQYaNSOO3GB+FYHjT4i+G9Eun0OV31jXZwY00Wwj+0XEpK5Kso4QbTklyPlyea8g8L/AAgvDpdpdfF7xA1n4YsMm10GXUiYIFySiyylgvyhivGTjHzADbQBFPPqMvx3u/EHwltB4iS4iktrmcoY9MtSwjJUTA4dvMDTPtJ3eZgDduNes2Pw1tr26Gq/EO+/4SjUlyViuowthagk8RW/K9CBufcx2g5FcJ41+P3h7w5CmhfDuzstUuYlEELKywWNv2UAjG8A7eF2rg/fGKh8ZfDPxd4rl02fxzqmo6oZ2Il07RDHFZWQC4VisrDeQW3FsMxwVC4waAPbNZ0HQvE2htpmp2Flf6Wy7BEVBVRjA2EfdIHQrgjtivH/ABR4dsvDNre+GPG/m3vgHWbgPba27f6TpV0cKgnlPJXhQkzZ2gBHynTy34AeL7jwbJHfPbSweHrmAvqC5fy5mQ8zW6mPHmRKCZEWQ7kOQuUwPrx103xBopVhbajpV9D7SRTxMPyIINAHz14C8Raz8FPEo8HePpJJvCty/wDxK9YCnyI8k8Z/hU/xJn5DyMod1fRGq6dY61pdxYanbQ3lhcpslikG5XU/5zmvILnR7Tw0B4F8b2r6r4D1OYQ6NfTkyGxduEtZG+8uCT5cmcgHbnjiTwnfXPwm1i38I+INYTU/C8uF0/UJWAn03cSIoLkdBG21gknAyjDAGAoBetLu9+El1FYaxPNe/D+ZxFZ6hIS8mjsxwsM5PLQcgJIfu8K3G016tBNFcQRzW8iSwyKHSRGDKykZBBHUEd6J4Y7iGSG4jSWGRSro6hlYHqCD1FeUXFrf/CKdrzTVutR+HrnddWQ3SzaN6yw9S0Hdk5K/eHG4UAetUVW06+tdSsYL3T7iK5tJ0EkU0TBldT0II61ZoAiuoIrq1mt7iKOWGVDHJHKgZHUjBDA8EEdRXhaXFxDY6tY3ZCT6frehTTW7StLLk3sce5nYAt8sSIpPLrEsp5lr3mvD/HU13ZeJtTs7/Msl7caXJHN8oBih1S3aNioHBP2p4ueSLUt34APcK5f4pzeR8MvF0vGU0i7I3dCfJbArqK5D4tbX+H2qW7523hhsio6t50yRbc9s78Z7ZzxQB5f4SeDQtC0zQIw7aXoOrSARmMSPfztqV1HbxAnAJXyt/bDNExKqrA+82TzvZwPeRRw3LRqZYo5DIqPjlQxA3AHIzgZ9B0ryc2QvNE8OpYXk1jqT+KtSWKURq580yXyztg8ZWPzyhOQGCZBGQfVtPs7fTrC2srGJYbW3jWKKNeiIowAPwFAFiiiigAooprsqIzOwVVGSScAD1oA8m/aqmEfwP11SwHmyWyYPf9/G2B/3zn8K2fG91ZaP4b0W11fw1LrPh5lht5poNjy2speKOErFwzEs/Bj+ZSBgc8cz8eNT8OeN/hJ4istD8R6TfXlnCL8RWl7FM22JgzZVWzjaD+OPpW9NpOveJ9J8Na9o2uxNZmC11D+x9QtY2t53CK6fvUG+M5w27MgDBSAQMEA6L4b2tjZeFLa20e81G502EmG3XULfyJYETCCLaY0bC7eC4LHuTxXUVBYvcSWcD3sMcF0yAyxRSGRUfHIDELuAPfAz6Cp6ACiiigAooooAKKKKACuD8Z+AJPEOuvq1vqiWl2gsGt1ktfOjSS1nllBdd671YTFduVIIDA5rvKKAPLYfhlqtpLHe2PiHT01R31GS5ll0kvCxvGiLeXEJl8vaIVHLPuJYnJJqvpXwcTSdWspbTVzNpttNZT/ZbtbkkvbRxRqw8q5ji3YhUgtE2D6gAV61RQBxPj/wBb+MNS0q6lvZLRbYmG8iSJWF9amSORrdyeQpeKM5HbcMfMawH+EYGvajef2lbXVjdXd1fJaX8N1Kscs6OGyi3SQsuZGBHlAlCVLZO6vVaKAPIZPhPrTWRiXxcFnRn+zT+Vel7FWjVNsEn23zVB27mV3dCQmEG07p4PhE8PieXU31w3cEl8upeXdLc+YtwIljLjy7hIcnDHJhPDFeVwK9XooA8x0H4ZX2japoVxZ+IVtrfToLWC4W0t5onvxBAIsTAztC27HUxFwoVQwKhq9OoooAKy9a8O6LrqbNb0jT9RQdBd2yS4/76BrUooA88vPg/wCFD5zaNFfaBLKwZ20m7eBGI9YsmI+mChGOK4/VPglPEtx9gXwlrKSHIi1fREt5AO4+0Wuw5OTzsJBr3OigD57fwzeaBbSQXPg7xlpVvGBtufCXiSW7U+pEMjqwxxxsPSrMGvWYJ07TPjHrOiX8armHxPp8AcemfPijLdD0Y/4+91V1HT7PU7V7XUrS3u7aQbXiuI1kRh6EEEGgDhFj+JcccEul6z4N1u2Yglp7We1Lrz91o5JB6fwn/GV/Evj2ynjS88AwXsPO+bTNajcjj+5MsZP5/wD11u/hH4SaWa40izuvD95Ku03GiXclkw64O2NghIyeqmmf8It430p92heOft0CptW117T0nyfUywmNvzBoAcvxMSC4MOreD/GWnbRkytpZuIv++oGkqWy+LvgO6neA+JbO0mQ4aO/V7Nh+EyrUCeJPHulNCmueCbfUowhMt1oOpK+GGOBDOI2556MaYvxW8ITiK28SC90GaYZFtr+nyWw+m518s/gxoA7PSdf0fWU36Pq2n36ZxutblJR/46TXnWuTPaftHeH5pLSWKO50O6tY5mZStyUZZSqKDkFc85Aznit2PwP8OPE9obq00DwxqEEvP2m0t4W3e+9Bz09a808XfDvRtH+LHw/0fw9ea3oMF/BqK+bY6jKZFKRq+EMpcKCM5AAzx3AoA7rw75NzqtnqWrNdeGtfv2iuCtvKot9RR1DrA24GKSRRmIkATERblKqwr0uvJtN8I+Mba+1HS7DxzrlvBaNFLaz6lZ29/HcRMDwWKI29XVwVDcDyz/EANiaD4pWcsQtb3wdqsAB3m4t7izkJwMcq0i+ueP58AHC+OPDvifwx8VdX8UeFkd4dds0h8+HSjfy20yhEKqoddgYIrb2+TIw2AAa8N1hWvfilaxfEq+v7y2t9Tgtb0ak6wzRxsqszbEZo44txBOxvun1Oa+j28efE7T3Meo/Cw3WGKiax1eMq/XBC7SQDgdcY/SvnX4kX8fif4u39zrul6vo0F9JBDNaNCBdRgwLGrbMHdl9pwASVGBzQB7r8TPhPdX/g+90uyuLm/t7awmezV2RPLkjEbRKEHyBiRKgMaxqEk244yfVPh/qsmu+BfD2qzsrz3mnwTylem9o1LfrmvMvgx8WtEb4e6daeNNdstO1/Ts2N1DfS+VKSjbFZg5yTt27j/eDZxU/wI8VaLBd+JvBtpd2S2+lahLNpjRTRmOa0mdpF8sqx3bSxBI6Bkzg5AAOD0/wvo2l2njXwnrkMC6da6tKIyy3ESW8EsaSQyG6G6GNkVztEiAbh94bjWN8IPHt78LPGN14Q8TXLP4f88RlpV2GykcBllAyQsbBgXALKD8ysRkt6P4u1efwt+0BA8ep2GiaV4j0dA93eQLJb3NzAz7fMO9CCI2ABDDO5Bzmub03wZoPjD4j+OfCt7pVnpanT7O606XTm3xx7Q2ZoPlACMZhuQfKTuzk80AfQuvaPpviTRLrS9YtYr3TbyPZJE/KsOoII5BBwQRyCAQQRXy38XtB8V+Gtb0yOSYap5NvLZWF1dp5g1ezJ3/YbnHWdcHb080HKlZFAbsfgr4wv/A/iOT4YePpWiuIZNmj3cp/dzRn7kaseqtj5M9DmM4IVa9x8T6Dp3ifQ7vSNatluLK5Ta6nqD2ZT2YHkEdCKAPNPh/4lufCY0TQ/ENw1z4d1WONvD2ts24MrruS0nbtIAcI3R1HGCCK9H8YeILTwr4Y1HW9QjuJbWyiMjx28ZkduQAAB6kjk4A6kgAmvPdLdZDN8MPid5Woi4t8abfz7gNUgX1Y9LiPCk4O7kMPU3PDWt6l4I12z8I+M7t7yxu28rQ9dmPNx6W1wegnA+63SQf7WQQDzjwD4tn0+5l1Twhos9jbzRrqN/wCDNyuZLV1BW909gFBOMbohwSGXAO019B+HNd03xJotrq2iXcd3YXKb45UPX1BHUEHgg8ggg14n8RPA1r4RmF/DDcr4OExuRJYrm68NXDMCbm2wM/Z2IBkiHA+8Bjis7SLnxD4U8WSCxFs3iG9H2p7KN1h07xRCBzc2xxiG7wVLoOG4bBBoA+j6wr/TBc+KLaWWygnsZbRhctIqsDLFNE9vwepUtMwPY88HFHgzxRpvi/RE1PSXfZuMU0Ey7JraZfvxSp1V1PUfQjIIJ2DDC90s7QobiNGRJSo3KrEFgD1AJVcjvtHoKAJa5L4op5vhe3jJwH1fSlz6Z1C3FdbXJ/EtZX0PTUhRn3a3pZYKuSFF7CxP0G3OaALEXhpLXxNpt5YrHHptvHfyyQs7MxuriWJ/MUHIH/LxnkY8zgcnHSUVxHxD+INt4TaOxsrGbWNfnTfDYQOqbQTtVpXY4jVnIRc5LMQqgmgDt6KwdH1O7iez0rWXt7nWltRc30lkuyCDJIXhmLAMQwX12MeMYqs/jvw1Hfmym1ixiuzOII4pLiNWlJVW3IC2WXDdR3BFAHT14h8YfEdvq/jSy8GyPNNplsi3Oo20CSP9snfLQWjmPLAbEkmZcEuqAKCTXq914l0e20jVNUfULd7HTFZ7uWJvM8ragkIIXPO1lOBycj1ryn4fWN/qulaBrhuDFqHiW+u9WuFIEj26OAsciMcEBLdfIGAQGuQ3OMEA39b+CPgzXNEitb3R9Ps9QRQRfaTbCzKv/eCAkEez7vrnmofg7c6j4cu5/AHiG/i1GbT4BNpV9DEES4s0IiZCBwJInG1gST8w64zXqcaCONUXcQoAG5ix/Enk/U15F4/utI8OfFvwPdy3s8dxPeXTzxKCyxQzwJACwVflRp1g5Y/fZj64APX6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmSxpNG0cqK8bDBVhkH8KfRQBw+pfCnwVe3Md1HoNvp97GSyXOmM1lKpPU7oSpP45rzzxp4O1fw78QPh7d6L4pvr6cXl5b2w8QH7WkBkt2LDeuyRgQm0BmJ6YPBz73XnHxenS11j4dTzcR/8JLDDkf3nhmVf1NAD01b4m6ZbqdR8MeH9bfdgnSdTe3bbnqEnTGQO2/8AGlf4raVpzSL4q0jxD4bCOqGbULBmtyTjpNFvTHPUkV6HRQBlaF4j0TxBE0mhavp+oopwxtLhJdp64O0nB9jXzL8WrRbD9qLRLpn3LdXWlzsDj5P3vlenbYGr6C8Q/Dfwd4hkeXVfDunyXLsHNzFH5M5YdD5se188DvXzJ+0N4bj8EfEDR7vRb6+HnwRXETXUzXT28kMyhSrSkll5UhSSMg9jwAeu3Om6P4e+Ncvh6/0i1udA8bWn2pkuYxLG2oQM7OSrZHzKQxOPvEY71y3x0+H3hTw14j8I+IJNBsovCslz/Z2sW0AMCKJAfLm+QDG3LktkE7UFavxz0zxzaaNpfiG5k0XVY/DeoRaoJrK2ltp1RSd6lC8gZD8hYhhgKeD27+zjk+Knw1v7LxZoE2iLfqYhCbhJ/lwrxzxyKMHkqRkdVPUdQDmfjB4PXQPhbpk/g+K4j/4RK4GowxJeSK5t13ecnmltwGxmPBzgYHYVg/DDUNMvf2gDdaR9hW3u/Cm8vaXZuFuHF0o3s5VWaTauG3jdlTnPWvU/hnqJ1zwNb2upqjahYh9K1OEneBPD+7fOezABxnqrg968c8D+DJPhv8f9NsL+5/4kl1aXkWhSEE5DOJDbMeSGXdIck4bII5YigD134q/DrTPiHoi2t672mo2xL2N/EP3lu/H5qSBlcjoCCCART+GHiTVhc3Hg/wAbtCPFmmRLL50TfJqFseFuEyAc5BVhjhhnvgaOtfErwxpeqtpSXs2pauoJax0q3kvZkAIB3LEG24yPvY61zOv3+gfEmSOy0i+utD8c6Tm80031rJa3UDcjOyRQXicLh1GQR1HSgDu/GnhfTvF+hvpuqLIoDrNBcQtsmtZl5SWJ+qup6H6g5BIrhtNvBri3fw3+KtvBcanLE32W6KbItXgXpNFj7ky8FkHKn5l46dV8O/F6+KdOnhvrc6f4i05hb6rpr8NbTY6jk7o2+8jAkEd+DWX8Zn8Jt4ft4fF2tw6LOJhcabeb8TwXEeCJIx1O3Iz2wecZBoAoeGNXvfDmtDwL47uRfwXKFNH1W5XP9oRcg28+RtMyjjP8YIOM5zzHjXwrY+C1htNSWe5+Gt1cIxzM3neHLrIEc9vLncsRYgEZ+UnPRirb+jX9t48sL3wN8QYLc65BClyk1s4Ed7Cf9Xe2rDkHPXH3Tx0OKs+FNYura7f4e/EYJdX80EkdlfSrmHWrbGG69JVU4dDk/wAQyDmgDzjxDL4j+F3iM63cyNdzNGqjUY4W8jXoFwBb3SoD5V4oP7ubGH6HuK76/wDFp8VKupeFb26ubWyK+fb2sJ+26VdKZAXntWKtNEys6PEPm+QGPLHcmn8E7sQeEJdEnuXlOiapd6JBLORumSB28sDAAJEYA4/uH0NX/HHgg6xfQa94dvBo3i20XbBfqmVnTjMFwv8Ay0jOB7qcEdwQDI034t6NHdw2PiG60uzuTxJcJqMCxIc8B45XSeNumVaP5c43HGa9Mr5/gPjDxdreo2E2trp/iWxHmvoeoNcWgSNgPnhns5o/Og3cBmVmToxyfm3tI+H3jbMU93rHh3StQjJC39raXGpXaIT8ypPeSsVDDI+6evtQB0nxX8eSeE7S007QrMar4t1V/J03T1OcnnMsgyCI1wSTx06gZYeS6HoGrw6bq+pazrc+p+IdQ1o2enPZo1t9sv1hMDySSx4k8iE/aFAXYAkcjAZZcauhaWukX/ijWNAubu+1vU7uPwzpGpag7TzyTKW+0XO5hjYh3/KoCkWn+1W74fK21tZalocSMCn/AAjvhCGYFl8pRmW8cg/Mr+SZM8Fo4V2ndJggFy58GeENK8P3yT2MXiLU7UxW0k+q3LXQudQkVUjSQMzbGZpIyflAUS5HeubPwf8Ah3BqupRXWlBND8P6b/xMLn7VMpmuGUSEsQ4IMcSByB8p+0Dj5a76ezh8KW8M08VxLougWzXSSblefUb+UurHAxulO5hg8O9yMAFBVRNFnNhpHhe+aKS/1KdtY8QSR5KsocO8YJHKNIY4VVusKOP4aAPn74qeBNI8A+BNLksr7VtK13xBmSfRvtJa3aNQZPJcKMuYyyIpJO5j05JH1J8OLKGLwJ4Sc2yJcQaRbwozJ88amKPcmTyASi5HcqM9K8f063h+Lvxhn1tZIptC0fNpZATvtkiU7ZnZY+CJSzqu50BVeUkAYD1z4Y3M2o+Fk1SRwLW/me4sYFQIlvaZ2wIigcDy0Rj/ALTt2wAAdZXnnxR8KaJc+GvFF7qNrLP/AGpDbQXszXBH2aCOQfvk3ZCiIM8xUABipz1r0Ouf+IdjPqfgDxLp9mqvdXem3NvCrMFDSPEyqMkgDJIHPFAHmHw8+KMnhu4t/BPxVd9O161Xy4NVuHLW2oxD7knnHuR3bqRyQx217cpDKCpBB5BHevn/AFnwdcTWd3ot1oJ1TSpJQRpz3DD7Moe8bNm7ttil8v7OPLQbPkxgKxcU/h9f678Jvilb+A/EN7NeeF9VJGj3NwciM9EVW7Z4RoxwGZCoAbkA+jaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvHv2jDHbD4eai7OGtvFdkOGbbtO9myo6n5BzjI5x1New14t+1qsifCuK8icqbLU7a4O0kE43KMEdDlgc+1AHtNFFFABXy9+2REser+FrkqR/o1zuYdwkkDYHbPJ/OvqGvm39tC2c6X4Zu127EN5Axyc/PGrD2x+6/l70AfRGrWEGqaXeafeIJLa7heCVCOGRlKkfkTXnPwZ8QxWXwjt18Q3lpaXHh15dIvnmmEccMkD+Wqsx4Hy+X+ddnqXiCDSfBFx4huUllt7XTzfOiYLsqx78Dtk/lXgN74c06+tbzxR8VfE8Ph3RNfuYdVj8PaZd7lnCxqAzkAtI5G0t5Q685zjaAUrD4keI4/ip4ufwJYHxCmuW8U9taQtuitpwiRpLKwACDahJDFSQYw2xgwXqrL4Ia74qk0S7+KXiZ737BCsYsLPcd2NuS87HcWYIu8qoJI4buUs/irpnh3wwqfC/4ea1f+HrdTi9S1eC1YLwz79ru5BBDMwzkHJ707xNofjnx98NrTWr/wAUm3s72xW8Ok6HYuu5XiLbGYO0kvULsGAf1AB6PYa/8PPBoGiWOseGtH8ptrWiXUMRVv8AbGc7vduTWl448HaV4z0tLfUVaO5hPm2d/A2ye0l4KyROOVIIB9DgZr5p+C/wtvNd8GXusCHw3eR3DS2smjahpw81GRtrAXIxJbyYBxgMBuBIJ6evfBLxLFbRr4Nu7maRrNZF0x7iMJKYYiEe2mx8vnwNhWxgMhjcZBJoA4W+1vxNa+N7GS6tbSHxzosC2c0jL5MetxM5Cqzj5Qkw2mNsYjmjZGAMiCvQvEWlaf8AFrwrpPiLw9IbbX9JleSxF6jKIJwVEtrcxehKBG646jIPzaPxj8FHxPoy3+m24n1qwRxHblwqX0DY821kzxtcDg8FXCsCMZrz7whLqmgaGvj/AMPtNqumuxh1rT2BF1PDGdouHUgbbyL5kkHKyhN2QSKAOWltbe2057mxjv8ASLDR7km7tIyZr7wfenrNF3mspMZdBlWXLLgggeoabf2XxO0Sfwp4vSGz8UWsSXsFzZSZWQf8sdQspR1QnB4OQSVb31PGWhNr8GneOfAUtvLr0FsWgPAi1W1cZNtLnHDcFSfut6dR5Jf2NnHoVv4l8MSXtl4btrmSQrFGTe+Eb7P73EfVrYk4lgIxg7lGDQBmaF4juPh/qt54H+K9lNPpBu3vIdVUSGeGUkn7XFIPnfJbO5T5iFmBz0H0NofiVrKWxsNevIbmG9C/2XrUZUQagGA2KxX5VnIPQYWT7yfxInK6cNG+M/g+40nxTb20Wv6cQszWcobyXZMx3Nu/OYpFIZc5BHB3YzXlHhyXX/hZ4hvPAfivSx4h8JXKPdLAEDKYVIZprdGOSR954RkqVLrwCxAPofx94Mt/FVvbTw3Mmm6/YMZdN1WAfvbWT3HR0boyHhhn2I5iHxzrt34f8QaBc6ctn8R7GydobONgYrskFUubdmIDRluSCcqQVPIq/oPiq20bTLK4uNVGq+ELrC2Ou+Z5nkZO0RXTex4Erdxtkw4DSbvjrwbp/i/T4kuS9rqVo3m2GpQDE9nLwQyN1xkDK9CBz2IAPL9Z0r7Hd2fhbQpJY4dMtbbw3YyooDJc3S+Zdz5BGJUtI96txzK3XOK7TR5dOtr7Udfk2Wmi6Qv9gaTHHGSECyLHKUQcktOqQhcH/ULt+/XK2V/qdv4tjsPEdraReMdPgvL3T4oI1itvEU5gWKOZJGI2SrGpjdD0D7gdowNi/sr+OLTfDXh6L+0W8NWsEsr3DDy579htgMxyNyp81zIOHB8hlyTigC0tvZ2t4llc3YOg+F9+qavdyqFFzftmYFwBj5d7XDAAYZoCvQgcH8VNf1PT/Dw0+2zb+NPHl1HbrEz4awsS4jijPB2nDgMBnEk0zKeBXYvHptvbC1knll8LaHc/ar66OWk1XVPO3iNQv3yJjuZUGDKUjX7jpXjvjYXN78T9H8QSw399qq6/ZfaTCoa006BZlWOx8wMVadWwX2nAZjjuaAPbvgL4aj8N+B0ihYbGmlRCgKrKqSMgnxkgmTBkz2RkTkICZ/hprel6N8NUi1PUrO2h8PSzaTdSyzKojMErRLvPZmVUYDvvGOorudNsbfTLC3srKPy7aBBHGm4thR0GSST+NeVeDPA2l6r8XPFfjyaCC4gNwtnpweNSBLEiJPMMjqJI2QEf3XPRgaAOw8P6jr/iHVxqDW7aR4biyLeCeL/S7/II8yRWH7mME5VfvnALbRlT1rKrLtYAg9iM0tFAHM3mo2nhe88OaT9gWDRpV+x290H+S1mUKsMJB5G9d6hs/eUL1cV5h+0y2n654Y1O0tJZIvEPhr7NqkE6EArvMm5FYchhHE0hHHSM5Pb2XxBo9lr+jXel6pF5tncpsdc4I5yGU9mBAII5BAI5FeEa7r1z4k8KX1rq1wvm6Wl94avruRQqXF0GHn3KKCCGjtIJpcEBf320E4NAHtHgDxAvirwVouuKEVr61SWRUOQkmMOv4MGH4Vv15P8Asutct8GtKN3GYz9outqkEYHnvng9Pm3CvWKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvL/ANpm1N38EPEyKrs0aQyjapJG2eMk49MA5PYc9q9QrjvjLALn4TeMEYZA0q5k5OOVjZv6UAdgrB1DKcqRkEdxS1leE7z+0fC2jXvz/wCk2UM3zgBvmQHkDjPPatWgArw79ru2874eaVIVJWPVo1fAJwrwyp/Nl617BrupQ6ZYmWeSWMyHy0eO2kn2uQSCVQE4474HbPIryT40q978BNXvrnULy/Zbm3uVkvLL7GYwLiNSqxsisFA3EbtxOfvEEUAdz8NEg1n4P+GYbpFmt7nRbeGZCBhgYVVhx+NeGeOfhENEs0trOCxaLT1We1v5LCyto5WT7sd3LJcAyqRw22IBiQT3Fek/BHVL6H4CaJPaCyluLUTwM99cG3hjjjnkXczBW4CqD057kcmszT9L024upLzSLia91F90huvC/h2CKK5J6n7XdLKrtkkZE3c9OaAPQ/B2p6F428OWmuaMkSCWL7MzxBBLCEb5oCwz8oYdAdpGCMgg1jfB+d9Hi1TwNfsxvPDs2y2dySbiwkJa3kztAJAzGcZwY+TzXJ/CLUpLj4z+MLXSYL2HSBZRSail5dxXDjUN+3dmKR0BZAwYA5zGAQMYrd8VX1hPrHgr4ieGp0urZrtdHupovlW4tLiTyxkkZPlz7GA46t60AM1C0ufhTrmpa9plvLd+CtUuGvNXtYlLzabO2N93GOrxHA3p1XG5eAVGT8atOuBoB8feCrkTrEkd8/2WTALIAI7xCAQxWMskikYkiJBIKLW18Tfi/beAvGmnaPf6Rd3dhPZG8ubq2+ZoE3lQ2zuo2ndyOCMZ6Ggy2vw6mh8T+FQtz8OdVxJqNpbHdHYl8bbuFf8Annzh0HQYIBAwADrPhD4+tPiD4Sh1CMpHqMOIb+3QECKbAJK5J+RvvKcng4zkGsLxbay/DnxHP4y0iGZ/Dl8+fEVhCu4Rkji+RB0YcCTb95fmIyCw8w8Y6PqPwO+IsHi3wypk8HalKI7mzh+6gbkw4zjrlomGMHKHg/N9JaHq2n+ItEtNU0udLrTr2ISRSAcMp7EHoeoIPIOQaAPMLa5tvhjq9vfWE6P8M9ddXR42DQaTcScq6EcLbykj/ZVjkYBwdTxDbp4T+KGkazbmNNK8UuNJ1OFiArXIRmt5QMcsQrxnnkFeCay3tbf4cajN4f1e3jn+G2vytFbllymlzS53W8g6CCRiSrcBSSDx81eZfEv+0/h/4i8B6b4hWW98O6FqYvNM1NHLStaqVzbPHwGkjAGGyMrjAzuAAPQtW+CD6drDa94D8Q32lalbZeyspG/0QDzPNNu2zDeQzZ+TJA3E4PSuhgm0f4teG7rS9YtbjSfEOmTL9ott+270q6HKSxOOo/iSQcMPxA6Lwz4tg1a9NnP5Uc0yG6sJYn3w39qT8ssTdyAVDp1UnurKzUPH/g641S6t/EPhe4TTvGGnoVtrlh+7uo+ptrgD70TH8VPzL3yAeS6c3iPwJ4wutOks4bu+vA0l3pcaLHa+IYQMPdWin5Y7tV/1sHRxyO1egeFPFFhp2gpqvh+Wa/8ABKkpNAqM1zobqMtG0fLGIZ5Tlo+MboyPLtWk+i/Fvwtc6ZrFrcabrenSqLq037LvSrteUljcfiUkHDD/AIEo4KODxFoPjtYzNa23jtk+SZx5Nj4ttExw3URXSD05BPdGyAD2HxT4e0fx34bjt7mQS20my6sr60lAkgkHMc8Mg6MM5BHBHqCRXMeGfE+oaVqy+DviESmqXG5LDWIVMMGqpjAwyn93OBwUz1GVOCKoeFvEq+Tfaj4XsLoC2fdrnhSRNt1ZSsN7SW6HGSxJJUYWTllIfcH7bUrDw98Q/Cghuo49R0m5+ZT8yMjqSMjo0cisCCOGUgggcigDmfibb2nhfwVpcfh+3ih1aCSPSNASWZgkFxcYhWTByGdVLNuYM2A4z8zZq/D3wxYeE/F76VbQI8djZLFb3M6BpwrbSzlvmIEkhk6sgYowSLCtI3M69Hr2k6z4Q8M+KtShktrLXLa90nX7wZW8jTerWlwcELc+W7bHPEhUchsmus+KPxF8PaHcW2kR3uiTeJzOBarfyoItOkKN/pEzH/VhUY8DDNuCjAYkAHpU8SzQyRPuCSKVO1ipwRjgjBB9xzUOm2Ntpmn21jYQJBaW0awwxIMKiKMAD6AVNDnyY9ziRtoy4GAxx1xT6ADIzjPNFcP4Jg83x78QdSZmZje2tgueyRWkUmP++rhz+NduxCgliABySe1AFTWNStdH0m81LUZfJsrOF55pME7UUEk4HJ4HQV4L4r+E2u3Xhu61nw9eNp/iXV1u7jU9HkdWiuBcOJHhTdlUlVQkZkUDfs5Kgk16trLx+J9b8P2NpJHc6IFGsXE8TB45hGym2QMOoaQ+aCD/AMsMchqd8T9J/tDwrfXNpHO2s2drcnTZIGZZI7iWB4VZSvOf3h57deoBABlfAKe3f4W6Rbx3r3V9beZHqAlUpNDdl2eaORTyHDuc55PDc5zXodfOHhLVU8M/tDA2a+XpXjKOQXKBh5f22Mu3mJ3KkFSD0JuDyduB9H0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY3jSy/tHwfrtjyftNhPDwu4/NGw6d+vStmmyIJEZGGVYEEe1AHI/B2cXHwo8HupBA0m2Tj1WJV/pXS6rNd29hLNp9ot7cpgrAZRFvGRuAYgjdjOAcAnAJUHI4H9nGeSf4LeGTMxZ445YDnHHlzyIBx2G3Fd1rWj2Ot2gttSg82NX8xGV2jeN8EB0dSGRsEjcpB5PNAHFa9c6jq0qSpF460O4EZQ2lklm4k5PzF28yMH/gYzx1xxz3ifSrofDbxxBNpWqWsU+j3ExbWNaa8u5JI1LDbErSRonPVXHOAVxgjYu7O9tmnto9C8fTWcZZQY9ct9kgGQHEr3QmAx6kepGRmuUuvFvhXwvp+uz38mhxxywSW1zBZXUmr6jdMVIRLi4P8AqyMMu1y49GAHIBi/AWCXWvhLPEltpV0dL1uW4jk1G3e5W2UxLKJEgTBlcGRgF3Kecg5ABueI/Fmnra3mo6xY3niO0gJiaPVZ5HVpONkRsraJoIyzMgX7QUlBbDDivNvg5H4zXw3faVpOoafomhXg8+7ur2zNzNKiwxq4ggOfNBWSL+H5jIgDHIFdnD4G0Twx48t7rxL4t1LUtN8I2aajqMt1KotoLhnH2aGKFclOFZ/LGf8AlkB1xQB0nh7Sr3wJ8PY9M0jTreL4g+MJZJ2gtwsKWZfLMxznZFAjYAAYbiAAd1ec/EPw7eaF4MZdDXWNKi0nymkthd2UltcNGyCOSRI7gFpN+Du8nLHbuUnBHqmmfCrSfiN5XjL4gQXc2o6mgmisFuXjitbY8ww4XDbguGbkfOzVH8Rfh34L8MaVoE2haFY2OrvrmnQWMyhi/mG4QkEk5YbA5IJ7e1AFL4p3V1o3x28Caxb6TqGq3FvpV41zb2CB5ZI1jcdCQDhnzjucAZJArkfDeqNrsGuaF4S0LUr/AEm+trmdtG0++MUekXTPNblTJMkaiGVW80RMp2kZ8vFej+K/A+nfEH4uaoNQ1HVbN9F0izS3fT7ryXikmluGZwcH5tsaD0wfXGJvCsV58JtV0vwxqFz/AGh4S1W4aLTtRlCrPbXbln8mcjAcSHcVcDO75SMYIAPMbsfELw14Gi8B65ZeFdQ08QiOX+0WurgiKSQiPMiYCkNxGoPmHYNikgVrfAXUtU+Hs8Gg+JriCTSNUvGtoHjuA62V2NwAOcHZMUcDH3ZEZWCtux7Vc+DbbUdYu9Q1eZriV5R5AXIEcG1Q8LBiwZHwQ6YCMAp2hxvL7rwL4eufCl54dk0+M6bdQiCUHLOwVQqMXOSWUKm1iSRsX0FAGzruk2Ou6PeaXq1utzYXcZimibIDKfccg+hHIPIryX+yo7vz/hX8RppL62uIzPoGru4We4jj/hLf8/EWRyB868kdd3UfDHX75Li88G+KZ1fxJoqLtnOR/aNpwI7pQckk/dfBOHB55xXQeOPCth4w0CTTNQ8yNg6zW11CdstrOvKSxt1VlPf0yOhNAHy7aT6n8I/EP/CI+OGuJfDckv2qy1G0BElo/IF3bddpGcSRcjDHhlYh/prwf4he+WKw1Sa2k1Ewi4gubb/UajbnGLiHk8fMu5MkoWHVWRm4M2cHxK0DUPAHxBH2Xxfpa+YJ41CmZeVjvYOxRs4ZR0JKkLxXA6Zd3Pg69vdE12Ge1sdPlN5cQWa/vdIYsQup2A53Wr5Pmxc7CzgqVLIQD2f4g+Ebu8vbbxP4SdLXxdpy7Y2LbY76DOXtpuxVuxP3WwQR1qK2m8P/ABd8IzWl/b3Frd2swFxbM3l3ml3adGVuquDkqw4Iz1BIrZ8JeJDqDR2GpyW39peSLiGa2ObfUIDjFxAcnK8ruXJKEgElSjvj+OvC2pxaynjDwQUXxJbxCK5spH2w6rbg58pz0WQc7JOx4b5fugHA3um6tZeKtP03V9SXTvG1spj0HxMyfuNZgBBNpdqOrdMjrnDLzw2/oOvX11rGonTtOXSfHNqgl1Xw5cShINUXGBPBJyM5wBKPQJIMbGXqLS48OfFrwS6TwO9uzmO4tpQY7mwuUPKsOscqH/JB54DVNMng1TS/CvjjUbqHUIZs+FPGUeBMZP8An3nPQykDaQ3yzL6OASAeo7tD8f8Ahq+sL+1FxZy5tr6wul2ywSDBKOAcq44YMD/dZSQVY8Gs03w8eXQ/HA/tfwVqLLbRa5dKjNDuXYIb7gblOAolIxyA2B0Za6nrD+I00vWTa6J8RIYCLG9+Y6fr8KgnawGDlSxJT78ZO5SVZ1PoOk6naeJ7K+0vV9PEF7Gnlahpd0BIArZAI4xJE+DtccHBBAYMoAM74O6fqekfDbRdO1yOWK8tUkhCTMjOsKyuIQShK58oR9Ca1NZ8Sw2OoDTLG0utV1YqHa0tAuYkJwHldiFjU4ONxy2G2hsGuFhm1D4Qyrb3jT6j8O2dUguWYvPouTjy5O8luCRtbqg4OQAT6dppsZoTfaZ9meK+23BuLfaRcZRQr7h975FUA88AdgKAPMrc/ETwzq+t6jB4W0jV7LVrtLx7Sy1YrNbsIY4m+eWJFcYiUgcckitHSV1H4l6bFe6tt03wrNvQ6RGSbm5KuVZLmTjYoKkNCozkEM5GUr0esHwxo02jXniDc0X2O91Fr21jQn92rxR+YCMAAmYSvxnO/PUmgDbgijt4Y4YI0ihjUIiIoVVUDAAA6AVzPxN+1Q+B9X1DTr2eyv8ATLeW/t5Y5Nil442YLID8rRtyCG45yMMFYdTXI+MZF1m/tfCsI8xbkLc6ngZEdmrcowwf9cR5YU4yvmkfcoA+XLm5guviT4Iks4IoX03VtN0tkaR0lU5iZAY5FWXAXdGXZcMYgwC7iD9o1458VvD+meIE0z4h+FjZanq/hsx3xhjfct7AoWYRsV5DhSHjOD16EMMeraJqlprej2WqadJ5tleQpcQvjGUYAjI7HB6dqALtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlvwh1O10bwJrYmWd4dJ1zULaRba2kmkX/SWP+rRSxwHBO0HA+hrc8QTWfjXR0j0K38L+KdNZiLiC7vMIrD7pV0jkww54Kg89R3zPg5EbPVPiJYs2WXxNcXIGTkLNHFIOD0HJ9jziuv1nwp4e1ydZta0HSdRmUYWS7s45mA9iwNAHlmseHNO00D/AISTTfA2lRs37ubW9cn1KJG6gLBOkS4wTgK64ycDk15h4jkXxN8UItHvtSjvfDGiGykWGKJLax3NcWqyssQ4EflTuBvLkgNhiOK9E17X9O+H9tqJj1vwD4flgDK9noulCa+dvRUEqhWIwPnUqOpOOnF/D74P6p8S9VufF3xCa9tbC8n8+K3mCC6u1GApcqiiNNqqPlVS3JG0YJAG6f8AFi1huhNo0b6nePpa311ctYSXUekPJNNdXQ2jaWAJtY1+YIPKUlhtwbeg+FdS8feKNG8OeJN0lhYj/hIfEroc+ffz5MVuzdBthMa4XgJuAx8prtPj6NE+H/wY/snR9Lht7C7u4Lb7LbsYvNRW82QMwO47kiZS2STu969D+GPh2fw74XRdSKPrV/K9/qUidGuJDlgP9lRtQeyCgDC8RafqvgqC0vdG8Qag2iG5jtbu11A/bDbRyuqCaKR/3mUdlJDuy7CxAG0Cs7xZZzaV4/8AAC6z4mv9Rga+u7owXiWqJH5VnMfMURxI3y7hyScZ9SDW/wDFK9gv7W08HQkSahr8yWzJtJWK3+Z5ndh90mKKYJzlmHHCsV80+OutWuseIJINNH2yTS9MutMiaGVMSajf7LeO3XJ+Z1TzHYD7o5POKANXwZ411PVhZfEODRZ5rDUIf7M1rT7MNNPY+XK7206JjdKvlz5cKM4dWUEAitL4n+N/BHij4W+IILbxTpX2k2b3FtEbwQXC3EQ8yLEZIkDB1XjGc8Y7V0z/AA6t7aSK68O6vqWgaittHbSzWLI0dwI0CoZYpFZGYBQA2A2OM44rH8S+HPFk+mSQa1beHfGVgYmWaL7M2n3p6EGKTe6bxjI/1fIBDDFAHVeCvGekeJ7G2W11C2bVfs0c1zY7ws8DFQSHjPzLgnHSqupS3PhHWX1Ka7nm8MXjk3ouJGlOnTEjEysxJWA9GX7sZ2sAq7yPMPCmq/8ACWaRqWhy3cupazpdjLe6Dqs0W3VLR0Oxobleq3Ecnlq3O2ZWGcgtn3XT2lu9Jtnv4BHNNApnhYZCsVG5SPqSKAOO+KeiXF3Dpmt+Hp4oPFumSO+mK8gUXuULSWjA/eDojehBXdkAE1W1mWb4q/Cid/CWr3mh310pAbLRSwTI2Hglx8y/MCrY7c/MODPa6HY+E/HOk/ZY3/s3UopLO1illeVbG4VWl2wBifKjkiSTKrhR5KADmsrxOD8N/GDeK7ZSvhXWJUh1yFXwtrcMypHehTwAchZMEZ+VsMRQB5FosN1Yafo0FkRpr2OoSW+lXV2wkk0TUxkTWF0yn57af5trjkbxkHivWriKH4q+GvPhSXw/460GZkG8DzdOu9vKMcESQSD6q6HpkYFb4u+H7LTbq48VS2Md74e1CFLLxPZLGzebbA/u7tdvPmQnnIBO3oV2g1xtuNZ8P+KYW069OoeI4LTzNNuJJP3XivSgNwiMi8G6iU/K4GSMEhlOaAKukX39h216s9rc2WjaddltU021y114WvCTi8tMjLWkgJYpgrtZuGUup908JeJDqDR6fqclt/aXki4hmtjm31CA4xcQHJyvK7lyShIBJUo78VNoOn+KPB2geKvhg8dpqum2Kwafv+ZZ7dVwbG5Bb5lyNvJyrDIPUnitOurPS9GfVNMivofBsV4/26xiGb3wjfqSHlhGDmHJbfHgjaxOCrOhAPTfG3hfUtO1w+M/Ascf9uqgTUNOZtkWrwr0Vj0WZRnZJ/wE5XijXPEfhLxl8KLvU9TtLi+0W4XyJbDyCboXG8IIBH1E/mFVGD1IIOMGt3wl4kOoNHYanJbf2n5IuIZrY5t9QgOMXEBycryu5ckoWAJKlHfmfGXh+/8AC+vv4z8HWLXYc7tb0aEc3yDpPEvTz0644LjIzn7wBhXtots9t4E+J8s97ptzMp8PeJGfZOJl5SKSUf6u6X+F+kgyOu4F13Nqej6tp+g+N9Ra21DcYvDvjCCIDzHIGba5U5Xe2BlT8kgAI2ugavQ1Phz4k+CQcQaroGqQ9D3GfzV1I9irDsRXDJK+gSp4F+J23WvDepEW+laxeKCJj1W2uT0EwxlZON+MjDAigDu9B1yW5uX0XxFbw2utpGWManMN5EODLCTyV5G5D8yEgHIKs/FXNhqHwnvJb7Qra41DwHPIZLvS4VMk2kuxy01uvUwknLxj7vLLxuAy9as5vA8Vvo/iy5vL7wOZUGma8HxeaFPgIglkAH7vkhZccbijgq2K7/w/r1zaz2mleI7iCea5GdP1WEBYNRXGQOOEm28lBwwBZONyoAdDo+p2Ws6XbajpVzFdWVygkimjOVZT/np1FXK8u1rw5qPgHVLnxJ4CsmudLnbzNX8OQAAS4GDcWq9FmAHKDiQDH3gM9d8P9T0zVvC1pc6Nqlxqtvl1e5umJmMu4lxICBsYMT8mAFGAoCgCgDo6QKoZmCgM3U45NLRQBwL29jpvxGXTbO1SO21LSfs1xtxtVleV4Rt9CDd5P+yBxmuK/ZB1KW4+Gl1pc77jpd+8Ua/3UdVkIz3+dpK77xRZXS+N/D17aGGMSsbcuULu7j5+ePlVYFulBzjdOOM9fNf2P4t3hvxVdxIqWs2rssShy+0CNTjd3wHXnvQB7/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5p4BeSL4xfE+0Y4iL6bdRrnrvtirHp6xj1H0r0piFBLEADkk9q84sZvsn7Q2rWgVgL/w5b3ZPOCYriSP88SDofw5qz8etabQfhB4nvIyRI9r9lQhsEGZhFuB9t+fwoA828HRv8cfiDeeIdXQHwPoN0Y9Ns1GFvJxgiSXoWwuxtp4G9V5+fd9A3N5bWr26XNxFC9xJ5MKu4UyPgttXPU4VjgdgT2rjvgloSeHfhV4asViaKVrNLmZWGGEsv7xwfoWI9sAV57+0J8Q30Lxh4S0jSLR9Q1G0uDqMltCSJHLRyQxxrhWOWEkhIAzhRgjIIANX4paevjD4s/DjSrebzrDT7u7vr9YWVhG8CwOquOcHLoCOuJR65r2Wvmu08aSHxNc38X2iz1nRcSalbajD5E0qeWqrNMqjOxoyscroGVHitpQvlg16t4H1HxVrVrA80TWOkQygR3epW5S/vogB9+AYWI5yC5zuwSEQMpABi/tBPbeGvhxqGu6e0llqsN4lxBcwEB/PkU27MxYNuxFI4xjgAY24BDPgX8JtH8HeHdK1K/02KTxRLCJpp5l3NbMwP7uMEkIVDbSw5bkk4IA9G8Q+H9N8RQ2cOsW5uIbS6jvI4/MZVMqZKFgCNwBOdpyCQMg1dW9tnvZrRZ4zdQokkkW75kVywQkehKMB/umgCxRWNfa7Fa+KdK0PyJJLi/guLnzFI2xJEYwS3fkyqB+NbNAHk/xJW2tb+88XaLd2uieItAcWskt6ESHU4nSOT7O5GWbOQF/iDA4GCDXRaB8S/D+pTWFlqEtxoms3aIV0/VreS0kLtgbEMiqJDk4+QnPHrR4Y0S11XxLqnizU9KjF8blrXTpLmDE0FtEPL3AEZUu/nMGHLRtHnoAO1ZVbG5QcHIyO9AAVDEbgDg5GR0NQ31pb39lPaXsEdxazxtFLFIoZXQjBUg9QRU9JuXeU3DcBkjPOKAPMPAVzJ4T1x/hzr8izWnktLoFzMP8Aj7tBndbNnhpIhgYHVMHAxXP3fhOKx1b/AIV7qdzOmiXudR8KagMGbTLmIl2gV85OzIdM4+TcuTjjf8Q6fN8RdZ1q30vUmtrTRRANOv4VVhDqqO7OwJzuCKYkYdDvdeoO3ltS8bDxbf8Aw90W7K6b42svECSanYlSpgEEEhnYHkeW6sNhyQwbgnacAFTRNZ1/4b+OLu58T6BewaJfxtJrN/p9u81j56Z23yBMmMyDiRCqnIVsnoO48W6JPJcx+Pvh21vd6jLAv2yzRx9n1u1A4QkZHmgfck/4CcrwPR7S5t720hubSaK4tZ0EkUsTB0kQjIZSOCCOcivL7VR8KfFQtfLZPAWt3AFuVJKaReueUI/gglJBBHyq5IIUHJAONgfTtJ0K31/w+93N8Orib7TJFbD/AE3wtd87pYl5xGCzCSLBADMQGRmVvYPC3iUXssOnanLbHUnh+0W9xbnNvqMHGJ4Dk8cruTJKEjllKO3DXukeKvCF/f8AjGCys7uO7lLa3oOmvJIlxDgAXEIcD/SEGVYYCyqucKxxWFf2dl4e0S31rw9JPqHwxvn+3o1jk3Ph6Y5/0q24yIgS3mREHbl8qVLoQDrfE+k33gDWbzxf4RtXudJuSZte0SI48z1u7cdBMAPmXgSAdmwa6vWLjwv4q8BXF1qs1leeFry1MsssrYjMXXdngqQRnPBUjsRUPg/xM188Om6tLbPqLw/aLa6tj/o+p2/GJ4Tk+q7kyShI5KlWbiPFGgQfD7WG16LSodR8DSXSXt/p5h8xtIuVyPt1unPy/N84UZX7w4yAASeH9evfB4stE8aSvqPhHUgIdL1u9iZJFVh8tvfI4G1sHaHIG7HzAEnEWu+Hpfh/BcRwWNxrnw3uiDd6UN8s+kMCCJ7c5LmIEBioO6MjeuMGvUbq30rxR4faGdbbUtH1CEcZDxzRsMggjqOhBHsRXnWn6xefCu9g0XxTPcXfg+ZxFputyfMbLJwsF03ZRkBZDx64AO0A2PC3iNdMsNP+2at/bHhq82JpuvMwZskhVhuiAAHJ4WTA3H5Xw+DJD4t8I6hpGtTeL/h8kUetMM6hpjNst9XQc4bskw52yepw2QTWb4p8MXXg/UZtX8GaYNS0jVXKaz4ZWMNDcgod08IPypJtUhlOFk4H3tuZ/Bfiew03QY9Q0m+n1DwSpMbmYs1zobqOYpgcsYlyMlstHwSWjO6MA7LwV4s03xho/wBv0tpEZHMNzazpsntZl+9FKh5VgeMflkVkahPc+C9YvtTuZJrnwvfyia5ZmLtpcu0KZBn/AJd22gtj/VsS33WYpU8Y+ELttVPi/wACXKWniURKJoiw+y6tEvKxzD+9jIWQYIzgnGMVL7x//wAJB8OfEM3h7TbyTxNaxCzm0V4c3Ftcy4RQ6HGYwW3b/ulVY9iAAc98evFkGiTs1hqcY1iOwZYIoXLPB5kiKZZtqERQgtC5LH94Y1QADeH9H+G/hCz8C+DNO0GwfzVtkzJPt2maRuXcjJxkngZOBgZ4rwX4g6LoGifDTWNO00QxwaXo501J7ZFQ6jd+dbG6lPB3BGgt1Zs/edkyGUCve/hjJNN8NfCct08j3D6TaNI0hJZmMKZLE85z1oA6WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzfxC0Vh8efB85AEup6Tf2Occt5bRSgf+hHmsX9rISn4LakItxX7Tb78enmDr+OKt/FrStam+Jfwu1jRrOS4t7DULiC7ZBnyo5lQFm9F2JJye+B1IFdF8Z7LSNQ+GHiG28RXy6fpzW+5rognynVg0ZCggsd4TCg5Y8d6AMiy+Ioi8E/2hb6R9ouJb19N0Szs7iOQakVJWNlZSRGuFJfdjYFbI4GTT9Lt/A1v/wkWt2cesePNamjt5ZLRRvnlfAEMO7G2KNFyTx8kRZuRTvhp4TbToofEfiEyQzxWgt9Osrl+NJswB8rE9ZnADSue/yjheeY8SeIrm9SPxFYtH/b2uKdL8GWrqQ8UMu0SXrLg4yMSElcLGkYOC7AgDtG8JW3j743ax4yvkil0XQpl0yxiaL/AI+LmEfPKcjlUd3AIzllBz8vPt9Y3g7w7Z+E/C+m6HpoP2ayiEYYgBpG6s7Y/iZiWPuTXm3x0mk8CaJdeK/DWutoepz3MfnWpiSaHUnxtAMb/dcKATIpB2oc5wpUA6fxfca7ruiXltpOmXdvFIl1bkTbUkmxHcQj5SCFUyeQ6sTypJIABB4n4pauunz6zrOqtc6Vp8lzbWsNziMzTLZM0i+RC4JaVp5nCkrsCxebuxtDcBf/ABY+Ltzo8UsGn29sLjJiktrBTcFQoYuInlZgmGX5zHtBZRnJAPBa5pOq3Ou3dx48vrq71Z3+zLOt8jCHaA0nzyRiAojzJGUWaMB8rzkEAHtXgDXNQj0qy8ey6bZqupl9Ogt4o9w07T7VnC2yNlQNxSRmlZtoKplQuSnX+EfEF82qrAEa7v7pUjjM0rBQN3mzzeWQXjH70tsYgKptEO1nIXz74LaV8QtG0l7C0s9Ri0i6uPli1jToJIYVYLukC/a45FBYuxUBx0IySc9z4f1GLSviHcQeP54NJ1xyF0t7Zja2F/DzkqeDJJ5krkwys+0uGQcliAeuUUDkcdKKACsHxB4P8OeIrqO61zRLC+uo08tZpoQXCZJ2bupXk/L05PHJreooAgsbS2sLOG0sLeG2tYVCRwwoERFHQKo4A9hXi37Rnw+u9SitvGvhVZV8SaPsdxDy8sSMWDqp4MiHJA/iXcvPyiva7y5gsrSa6vJ4re2hQySzSuESNAMlmY8AAckmvM5PiXc6hqOq23h2zinQWtpJpks6Mq3DzRXMxduQVQJABhgp3BgeoNAHK/Bf4j21zpdxfymK305pPM1W2QkpplxIT/pEeelrKcsR/wAsnLE5Usye16/o9h4g0W80nV7ZLmwu4zFNE38QPoRyCOoI5BAI5r4/1/Tb7w3puifE7wf5yWt9HGupxzWTx26XEiKZRsYDdaysxHHyhvunlce5/BzxtZ3GgaXErOmjXL/ZbMySb20+4GP9Blb0/wCeUhxuUqpw20yAGr8PtYvdB1t/Aniu5mnv4VaTR9RuDk6naDsW6GaMcOOpADcjJrP1i1uPhZrd5rumwSXHgbUJPN1axiQs2mSHrdRIOsR/5aIBkfeGRkDsfiB4Tj8WaNHDFcvYarZyrdadfxgF7Wdfutg8Mp6Mp4IJ9iKvw68VN4o0u6stZt0tPEemP9k1awI4jkxw6g9YpB8ynkEHqcGgDz7xHodv4Os11PSGlu/hzdSC/wD+Je2+bQZm5F7ZkZzCdxLxgEAMxAZGZT6F4X8VJdXFrpGszW739zAZ7K8gH+i6rCBnzITkjdggtHklc5G5cMeVRj8I9ZNvcAn4dalMfKkwNujXEjklG4GLdy3DdEbg4Bycrxj4Xh8EW08sMFxc/Dy4mF1Pb2ZP2jw/cZyLy0I5EYJ3Mg+7kkAqWWgDVnil+EOr/arQM/w7v5y1zbhSf7Fmc58yMAf8e7N95OiE5HUg9z4m1C0m0uO0/si68QQanEwW3tYlkiliIGS0jlYlUhgRuYFhnaGwaxvCXiQ3pi8PeJ5bS7urq3MllfxKPsutW23mRByA4UjfH77lyp45+znn+EOoxafqMs0/w8upAlneysXbRpGOBBMx5MBJwkh+6cK3GGoAXT726+Et/BpOtTy3PgG4cRafqUzFm0licLbzsesPZJD93hW4wRZ8UeEfENv40vfFfgg6dbXZt4FktnZlj1fBfzEn7Kyr5flyAZB3K2VI2+kahZWupWE9nfwRXNncIY5YpFDK6kYII7ivLrO6ufhHfQ6bqs0tz8PriQR2N/KxZ9HdjhYJmPJgJ4SQ/c4VuMGgBngTX7e2gvJ/DdjeQWVpKRrHhaVD9q0qViWMtunVozkt5a8MOY8MGjfc8VeG18S/2f4w8C6lbWviOGHNnfL89vfQHnyJwPvRN69VPI5FWvHfg0axcW/iHQL9dG8UWKEQaiBmOWLqYZ16PEevqp+YdweQ8Ja3dprmoix04ab4oj/0nWPDXnDyNRQ/8vlk5+Xc3rkBjlZMHbIADg/ilex+LvCtrpOk6ZLpmu3V5Y+HNS0uZQU0VPN8weWq4wksgh/eDKusaDggY+nLS3itLWG2t0CQwosaKOiqBgD8hXBeIdCtvGcVl4q8GagmneJrLdHb3rRsA4DfPaXUfDFcggqQGRhkYOQb/gPxvH4guLnRtXtv7K8V2C5vdNkP8OcCWJv+WkR4ww6ZAPUZAOzooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAZNLHBDJLNIscUalndzhVA5JJPQV5x4fjPxI1q18TajaSJ4Y06XzdCt51Km7kHH250PIHURBhkAl8fMuF1szfEXXpNDsbgJ4Q06bZrE8Z+a/mUg/Y0btGOPNI5OQgI+aun8Za7/wj2lW8dhbifVL6ZbHTbVVO15mBI3bR8saqrO7dlU98AgHP+Or6HXtRuPD0kwh8P6fEL3xFeeYFRYlw62hP/TQDdJ6RjB/1gNeG+BfHDeJfjFd+IdYlhs5HFtBplpPEUkgtpJ444tuRjBFwrkg/MckfLyPSJ9D/ALY1W3+HNpctdWtuyar4w1JMI15K+WWEgZIMrKGI42xoqg44p3/CNaN8XPiMuvXlhBP4W8PA2VpJ5QC6pOGy+5v47eMjCjG1mL8kZBAHap8SovA00Z8UeJota1aWJY10DSoUmlacx2y/fAG3EiTnBxuE3AyoWvJNetvF3jT4k2l74902Sxt/sLX0OmSKJBa2DSLDKQuQUlVJGlLMN26Jfl4Cj6v0nw9oujIqaRpGnWCKSVFrbJEAT1xtA61w3xbtJ18R+C77SLi1tdYlvJ9PVrxj9muIXt5JGt5QOod4owDyQTkAnggFXwF8P90Gj3WuQ3MDWENtMsK3IeO7uWTzp5ZRkmTMzIQX+YNbqVwMlvSzZ2EMsMjwW6yrI7xO6jcHbJcqTyCRnOOwqr4bv72+sX/tPSJtKuoX8poWkSSN8AfPEyn5ozngsFbjlRWf8QtO+3+HJJBAZ3tCZvLVSztGUaOYIo6uYZJQo/vFaAOmHI46VV1TTbHVrKSz1Wztr2zkxvguYlkjbByMqwINcz8P9bS60xYNQvY21NZUgeMMvlswgVlaDH3opEQzLyT8zAnKkL2FAHByfCLwMzsU0GOGNjl4Le4mhgfnPzRI4RvxB4AHQCus0XRtO0PSotM0eyhsrCIEJBAu1VyST07kknNaFUtZ1O00bTLjUNSmENrAu52wWPXAAA5ZiSAFAJJIAyTQBxuh6tb+DtQ1/Rtf1jGk6dFBf2t7qNzlo4J3kQQvI5yxWSJgpYliroOSMnU8P+OtP1/UobXTdO14wTIZI72fSp4LZlxnPmSKvXt61S0nwjFrOvp4s8XWEcurKAun2c2JF0yEHIAHKmYn5mcZwcKpIXc3cUAZfibTF1nQrvT5IIZ1mABind1jfDA4fbyV45Xowyp4JrkrP4aW8uhf2RrN+x0oxPEdM0lDp9phiSSQrNK33iCrSFDn7legngc9K8j+I/xZsPDGmSX9xA1zp9xj+yvLmERu5omDFwwbcYCWQbtu0rG/LCSMOAefz+Ndd8UeLZfB+meJJZPDktpbSG8utMtnnminNvlXUqIyvl3I52KRt5BwS2BpFva+GruObQ9JOreEvEVqJDZRzb5LmDYJTbnDfJe22WZOcugIDB1Gcfwz8Pn8XeRqevskn21zMwt1+zW1tbwxbWUTOBGMMYYtsavtCMNwIYr2nhTwL4VttU1DSX1nw9Zx6oUCxWHidJZrS4jyYJoo3hEglUk9Jj99hgjgAHs3gXxZBdjT9OutRW+F9bm50jUjhf7St1AzuGBtnQEb1wM/eAHzKkPxG8O6imo2XjHwjDG/iTS42jktmO0alaHl7ZmHRsgMhOQGHTnjx3S7m88K3Wpad4iSeC1tbiOfVltlCSabcMdser2WBhoJD/rI8fKS4KlSUPvfg/xE2pvcabqRhGsWaJI7QZ8m7hcfu7mE5OY2weMkqwZSSAGYA52O3j8deF9P8QeE9UeeC4glU6fqjeda3McmBJbTryVIKhdwyVIPDAkHL8KXt58N9S07wv4nOPDmpYTR7qS4M62Uu0E2DylV3KDu8pmwSo29sCx4kgk+Gnii58W6bbyv4U1Jt2v2sALfZZeMXyRgcjtLt5Iw2Gwcd/relaV4r8Oz6fqUMN/pN/ENy5yrqcFWUjv0IYcggEUAeUeLvDUXgFJp0spr74eSz/arizt8+foM+SftdoV+ZY8kllXlMll4LCuz0PWINVt49A8TPaanb6lATY34VTb6vAVyRgfKJQuSyDhgC6cblTM8Ia1qPhPxDF4J8YXb3ccyk6HrE3W8jGf9HmOMeegxz/GMHg9cLxb4bXwDHd3FtZzXnw7upPPv9Ot8ibRZc7vtdrt+ZYw3zMq8oRuXjIABqeHru5+GOt2vhjWppJvCd/P5OhahNJuNoxXIspSeccHy2JPHy9hj06+tLe/s57S9giuLWdDHLDKoZHUjBUg8EEVwlld2PiTSh4W8Ym11ey1SDNjfgAQ6rDjcCCuAk6gbiFx08xMAMsdLwvrOoeBtbtPB/jG7e6sLpvL0LXJjzcelrcHoJwPutwJAP73BAMr998M4/wCxvEsQ1D4aXxNtDPcHzm0nedot5yfvW5zhXP3c7WONpND406haWl6s+t/ZtLs9MsXvdDv9OYi+E6tGAI2PyeWwLK0RBU5i+YlwE9R8b61pWl6LNHq02kFLn/RxbaldJDFPuGGQ7g2flJ+UKxPpXzp4xt9CaxuPBra+IvC0xT7Nd3MBN/4fTzkPkTxybZfsrsI9rnG393uyNjEA7rw1r+oTa5aSSvDYeLby0W5tXIaHT/FFttUhipGYrlVwOm5OOHT5R2mu6Pp3xF0yG8sJ7nRfE2kysLe6ChbrTbjHMci5IZGBGVyUdGBBIKtW94h8K6J4p8NwaXfwLLYoI5LWWB9jwMo/dyROvKsOxHbjkEg+XXcuv+F9fstP1/Uo4tZZRbaL4nkjxb6mo5FjfqM4fO4q4IPJKkHergHqfgm81+80XHizTYbDV4JWgk+zyiSG4C4xNFySEbOQrYYcgjud+qWlXkt3bn7VbNa3cW1J4vmKK5RWIRyoEijdjcBjII4IIF2gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuB8b61d6vrK+CfDMs0WpXEQk1PUITj+y7VsjcG7TPghFHI5c4AGdTx74kuNFtraw0SKG78Tamxh061lYhNwHzSyY5EUY+ZiOvCjlhVvwV4bTw1pHkSXLX2pXDm4v76Rdr3U7AbnI7DgAKOFUADpQBZ0nTtH8IeGorOxjt9N0bToCeWCpEiglnZj+LMxPJySa811HXrm0trjx1cWTz6xqX/Ep8K6YXPzRyEFHdDtCvKVEj5wVjRFyCGz0fidx4s8Rnw2GK6Dpuy61uUgeXOcbo7Mk9iMSSf7GxTxIccrYa7Z31xq3xY8R5j8O6TBJbeH4ZIwrNEcB7hQxzvmYBE+6duB/FmgBl3p134e0Sw+Hvh+/83xj4iaW91fVRxJBG5zcXZCjgkny4xxzjnKmvW9C0my0HRrLStKgEFjZxLDDGDnaoGBknkn1J5J5rlfhboGoWltf+IvEykeJdecXF1Hu3C0iGfJtl4HCKcH1YsST1ruaACvFf2pDqWm+GvD3iTRmkS50bVUmLKxUBWRlG4gg7WbYhAIyHNe1VleKtBsvE/hzUdE1RN9nfQtDJgAlc9GXII3KcEHsQDQB5L8M/GN5pek2jPa3N74fe3WRbe2ghN1YIXIWT7NDDE7QsOcrGxBBIaRSSvbS6jd+N52stBnurHw8nF3qiK0Mtwf+eNuWAKjpulHT7qfNlk8p+Dmp6x4CfxF4T1exh/4kc65vmkk2tBIZZRII8+UgYA/OzxKNyhiSgB96s9dsrm60613NHeX9m19FCcORGpjDZZCycGVBwxBzwSBmgDirv4aWunNE2gWGn6jaRwrbrpusyyMqIAyhY7gh5ETbJIDGyupDEAJlt3pESCONEXOFAUZYsePc8mnVkLq5TxYdFnhKCSy+2W02c+btkKTLjHGzfBznnzf9k0Aa9c7qOkXOr+KbWXUFT+xdOVZ7eEnPn3ZJxIw9IwBtB6s5bAKIa6KigAqjr0t5Dot/JpZtF1BYHNubxiIRJg7fMI525xnHOKk1XT7TVtMutP1GBbizuomhmibo6MMEcexrxPxVrOpeGdM1HwjrF1qN9d2pjvdI1GJjuktPn+W6GcTbShiKtxKZYVJRpN6gHJfFLxz40k0uJZv7KfzL3+zBaLYSJJvkjPEkLzyQufMilQBg6/IHBKsCej+DngGy8QJfeI/Eeo3Gs+Jj9naHVJVD/Y/NtobgLFHKrRgoZcqduACMBeRXHR/bPiB4+0fTvDdgssXhuRdZ1CVLlHSWb9z5MHmruQvHHGkIYtlvLcnGCa9o8Ja3aeE9Bs9KufCfiXT5IIYoZHj0s3PntHFHGHLWxlBO1FGSc4XHagDnvhXptrqPik3OrxHULhtIjuI5b798TK17dea67vlUkrCSEAA+XAAwK7q1a+8TaTdJaHR4dNF7d2Mttd6e1ys0cUzRMCBKgGSj5yCORx3Pmvg3xDLomq6HPP4a8XiOHTbyzutuhXJ+c3MckJHy9Npl/PntjrNO8eWOkW979n8N+ObrzriS6Ef/AAj84ILtuKqSoGMknk9+tAHJ3WgaoPA/ha7VYbbxdatLp2kQ/Z3jju4Fikc2VykrnKPHAwBZuDtIIyScjwxqUVhFpA0+7mt9Ca5e20a9u8tP4dviMPpl2rHc0DEBRnn7vOQki9r4j8S634q0/TZNB8AeJ0u7LULe9ifURbWeBHJiQfPLuG6PzU6fx+9c/wCJvDuuaVZ634q8UabY3mj6nIyeINCt3Mv+hDGy4VwqZnh+bJAGUVeQy7qAPXvDmsQeJdMuoL20EF7A7Wmo6fL8/lSY5U5A3IykMrYG5WBwM4HE+G5pPhn4ntvCeo3Dv4T1N9ug3U5JNrN1Ni7nqD1iLc4BXLYGOc0e91XQdc0+xivRql3Ja+Z4f1dnGzXbNQW+w3DcL56gkxy++7gM6v6feW+i/EjwPcWtzG8um6hE0UscihZbeQHBVgc7JY3HQ9GWgDI83Rvij4e1HQ9Xt7jTtWspVF1ZGVVu9NuB80cqOpI9GSRcqw4/vLVDw3rF/NqCeBvHdzNBr9u8dzZahasYY9ZgidX3L6P8oEsXoSRlTxS8O21vrmpt4P8AiTZwXXinR4hLY6qhMMt7ak4E8UikSRuCAJFVuvOSDxF8TfAWr/2EJdE1DUdUSyf7RBBcP519ZuBxLaTkh2cdTHKzCQDaGTg0AV/FfhxPAC3VzbWUt78O7qX7Rf6bBuEujSht32u12/MsYb5mVcFCNy8ZA6Rn07xRog8L+LZINU0/VoT/AGfqiBfL1BNu4EEDalwoG7AADbd6YAZIz4S/ESHxjZCx1Iww6/DAs7pGCIryBjhbmDdyY26EH5kbKsARzxVzptz4e0691LSNB1CX4d3dxJJe6HPE0F1p5R/+PyzXIeNCw8wR/KykBlC5+UAy/E0uv+F7y6tp7mc+NrGx/wCJXqVuqqdfsFYGWFt6Ov2mNAWGAWyQcEEgyfst+FbTVNN8T+K9UtI5xrVxNaRxzkzq1uW3SAs+WcMzbSW5bygT1rt2Gm+NdBtNA8R3gvYL0C50PX7UiNp2QFldGA/dXSYJKgAMAxAx5iJL8NNYl8Pak3gXxPBa2etIZLiyureLyrfV4ySzyxr0WUEkyRjoSWXK5wAUgLj4P3mP3118OriT3kk0R2P4lrck/VSfz9I1XTtL8S6JJZ6jb22o6VeRgsjgPHIpwVYH8iCPYir88MdxBJDPGksMilHR1DKykYIIPUGuL8E+E9S8H6zd2Om3kM3gyVDLbWkzMZ7GYtzHGcEGE8nBOVPTPNAHP2uoal8KLqDT/EF1PqXgWVlhs9VlG6bS2OFWG5IHzRE4Cy/wk7W4Kker0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWL4v8AEdl4V0GfVNRErohVIoIELy3ErHakUajlnZiAB+JwATWpe3VvY2c93ezR29rAjSyyyMFWNFGSxJ6AAZzXn/hC2uPG2vQeNdUaRNGhDf8ACP2DKVARhg3kgPJkcZ2DoqN6sSADS8A+HLqG5ufE/ieJP+Eq1SMLKocSCxgBylrGem1erEfefJ5G3Gj451+bRNMhh0yOOfXdSl+x6ZBICVecqTufHIjRVZ2P91SByQDu3lzBZWk91eTRwW0CNLLLIwVY0UZLEngAAEk15kNcj07TtT+JXiGC4zJD9l0XTxlpPs7OPKCpjImuH2MeMhRGp+4TQBn67pHmf2f8L9Fnmdr0HUfEupBSHaB3JkLMCAJLiQMuAThN3G0CrtpbQeNvHcFlZQxx+DPBcyxJHFtEdzqKKAqAAH5IFPT5fnI6hayZItX8J+GorSF4X+J/jm6LSzgAi2O3LtyxPlW0WQoy3OOPmIr1Twf4dsfCnhrT9E0pStpZxCNWbG6Q9WdscFmJLE+pNAGxRRRQAUUUUAeZ/F7wtqVxPp/i3wpGW1/SVdJYI5Whe/tCMvBvXncCNyZyA2eDmsfwf4rj1nxr4F1DKy2upaNfWltcC4SWSSRTbSsJQiKqSYjbKgYyDjpXsleS/EzwJDpN2nj7wRpcUXijS5jeXEEClRqUOGE0ZUZHmMrsQ+0sTxySCAD1qvNNa8ZaU/ibQNWhhuzo9tczafPrnlAWiGRSvl7yQShljiHmKpj3BV3ZyK7fwxrun+JtAsdZ0edZ7G8jEkbg9PVT6MDkEdiCKuTWVrNYPYzW0EllJGYXt3jBjZCMFSp4K44x0oAW+vLawsZ7y9njgtIIzLLNIwVUQDJYnsAKz/Cl5f6josV9qkH2aW5d5YoDGUeKEsTEsgPIk2bSw7MSO1cnrfw2iFhGPC+pXthLaTR3VrY3Nw9zp5eMkojQOTtjz0CbdhCsuCorqPB2vf8ACRaJHdy2rWV7G7W95ZO4ZrWdDh4yRwcHkN/EpVhwRQBt18+ftHaLB4p8eeD9FTUY7Rmt5vtrbTKYopJ7eOAmMEFg85VB2B+bopNe6a9rFhoGkXWqavcx2tjbJvllc8DnAA9SSQABySQBya+YPh7qep+MPjvrWqajpdz9quLeKWKyuD5fk2P2mBcFWOOEZZDg/eR8Ak4oA9g+BHh2z8NeHTZWBml229s1xdpj7JeTOhmaaBsAuMTKm4j7saL1U16dVWRGstNMem2sbGGPbDbhhGvAwFzg7R+FZF7r2p23lCPwnrN2WBLG2ms8JhiADvnQ8gBuAeGGcHIAB0NFcr/wk+r/APQi+JP+/wDp/wD8lVI+q+JpkzZeGbeNvTUNTWL/ANFJL/8Ar/OgDpqRgGBDAEHgg965aRvGc8Jd38N6PtOSW87UBj65t8dvXr7c4Fz4g0zT7mG51/4pWMLROPMtLZ7OCGUrgsu1xJLggjIEmcHqMigDz7UYPDum+KNa8B3bS/8ACJy3sL28kW6OTw7qMq74jGxHyxuSSjL8qsWVhtbJ3tC1rXvD/ia7s9VhFx4itFWTUY7eMqmu2IAVb2BAOLmMYDoPvhdoziPZg+MPE3g3xR8TvDtxbl9S0DW4JvDmr3DWs627liHtlVyoUuJQ2GU5A5yMZGwdInur6HwN4m1O4tvFGllrzwn4kYAy3EQHILdHdQAssZ++oDY/ioA7zxv4dtvHPh6w1PQL6ODWbUC90XVoTny3K5HPO6NxgMpBBB6HAq38PPF6+KtMnS7tm0/X9PcW+qadJ9+2mx29Y2HKsMhh3yDjg/Bfiu70fUL9dWtI7H7NMV8Q2EZPl2MrZK6hBkf8e0uCX/uE7z/y0Zuj+IehajZalD448Gp5ut2UPl3diPuaraA7jEcdJF5KMM88EEHAAMHxV4NM/jqSz0q4/s7UpUfX9DvR/wAut0jol1EQMEwy+ZCzJzlnlJ6gV2nw78YDxRY3FvqFsdO8R6awg1TTZOGt5ccMOTujb7ysCQR3rOtNWtfF/iPwRrugB7nS3tL24N0F+WMERJ5THs+5vun/AJ5t/dqb4h+EbrULi38S+FJUs/GGmxsLaUj93eR9TazjI3RsehzlT8wIoA5Xxn4aHgqW81DS7J77wdqMvmaposLFZLWXO4Xdnggq6ldxVSCCu5cEcW7uKw8b+H7PQ9b1ETtc4uvD/iS2wrSunzK6kY2XKYO5BjeAxXHzrHz3ivULv4q6v8OrbR7W6tbWz1eW71qN1Ik06e02funYfdY73CnvkEd62PGXhhvBr3+paVYy3/gy+fz9X0aAkSWcgIb7ZaYwVZSAxVSCCAy4I4AOn8A+K7651K68LeL0gt/FdhGspMZAjv4CSFuIh1xkYZf4T9cDuq8ju7O18aaZpVrdauBqyZuvDHim1ABmIXJBxgeZgESQnCyKpZQNrLF6B4MuddudAhPiuwhstYjZophBKJIpipwJYyOQrD5grYYZwelAG5RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVwXjrV7zVtXTwT4bkuIb+7iEupahB8v9m2jEjcG/wCe0mGVAORy/AXkAqakJfiL4mm0ryUbwTpUwF9IxyNTu0IIgUd4o2wXJ+842YwGr0gcDjpWf4f0ew8P6NZ6To9sltYWkYihiTooHqepJOSSeSSSeaz/ABrr0mhaQpsoPtWrXkq2mn23/PWd843Y6IoBdz2RGPagDF8ShvF/iZPDEYc6LYbLrWpAAUnJ5isj/vcSOP7gRTkS1gC6tvGHje88Q6o6xeDPBrSLbPKCI7i+Qfvbg5OCsIBVTg/MWIPFSeJY7jwV4K0/wx4dnjl8X+I7loBebQjS3Mg33V665zhV3Nxnb8ijgAVQvtDstS1DRvhXoEYXw1ocUN1rzKVG9clobdsDl5XXzH+7lQTn5qANz4WWdxr1/e/EHWIXiu9YiWHTLeQLutNOBLRjj+KQnzG5PVRxivSKRQFUBQABwAO1LQAUUUUAFFFFABRRRQB5Je2d98J9avdW0ezn1DwNqMxuNQsLdC82lzN96eJRy0R6sg+71HAIrrLD4m+Br+zjurfxdoQikUOBLexxOoIz8yOQyn2IBrr68l8IaLoNhr0/g7xRoenT3dnJJc6Jd3lrHJ9qtGfeFjdgTvhyEZeuFRuh4APSdC1vTPEFh9t0S/t7+z3tGJrdw6FlOCAR1rM0TSLqw8beJb3G3TdRjtJkG8HNwqvHK2Oo+RLcenH1rT1DUbDRbeITkQxGWGBFSM4DSyrEg4Hd3Ue2c9K5PXfiFHa6XeXVhYvKsWlatqKGZtm42UiRgYGcpIXLK2fugHHPAA/W/GscrQ2GnRyq181xapc7wjRSRXsNlIQCDyHnDA8529Oa8R0Xw9oXjf4j2upaxGkunNptrJd2RLqfMvXaYHcjgqfNuEODkEN6gGvR/EFzNdfEC4NxMwi07U1toQqKAkTHR52U8c5fccnn5iM9MeNfCDU7m31vWPEGk6Ve3oXSbTS4pobJ5ljmi08EsAEO5hNbwKOg/fA9xQB6bF4EEFtbrb+J/FumvBrs2mzfZNYlKpbu7/Z1Cybhwj244B757kdFrvgbxJoXhvVLvw5498WXV7b2s01vb3bQXRlkCFlTLRZ5YAfQ4FZur+L9DttEuJbzUpoLifX4NRlxp90pggjuI2G5WiDLmGEBsjGXOCQRnp4vi54A1WyljtvGVjaNKjIsjv5EkZ5G4CVeCOoyCPYigCjb+E9YvdXubKb4heLfPht4bnekVrChSRpAq4EX3gYmzwOq/hT1TwPGl3NFqfxJ8fJMotlbyL1I1/fymKIAJF1LgjPbgnA5q6nxR8D2/jHU55fFWj+RJYWiJIlyHBZZLksMjjgMvfuPbOd4g+JvgS9u5DpWsSahqLSWLSpZWk9wvlQXSykgohHAds89wOtAFTxx8HtBm0rT01XUfEOsO2pWke/U9UmnwrToHAGQAShZM4yM56iuh+HfgHwt4b8VeI20TRbS18g29rGSDIyr5fmEhnJYEmTBwedi56Vl+L/iPp2t6da2vh3SfFGpXqahZ3G210edNqx3EcjBmkCKoZUZck4554zWhpd743vPE2ralpnhODTrC9trdUGs6gsT+ahk3SbIVlJJVo1wSv8AqxzQBi+JoNM+KXiPwfp+vRzx+HdT0W51a0tvN2NLKwhEZbHHmJHK7bQSAe5FZFvZ6jPfN8MfGt/NHq9qRf8AhTxLgF5fL5XOesidGHVl3Zxwzdpe/Dm8/wCFfaVptnqUK+JNDla60q/jjaGOB97FYdu5m8nYwiKktlQCQSMVl+ILZfi38OrkpaTaV400KctHCW2S2GoxAMFD9GRvlIYZBVgeo4AKscWoeNlkvIPsuifFfwsfstwo+aC5QjcEcdXtph8y55Qkkcg7r/wy8WxwRJbzwyWWjSXAs1tJvv6Je9GspCcfumJHktgDnZxmNa4Pw941bxyum6jZGPT/AIvaEJIXsZlNsNVhQ5ltjnjJGTtPKOCQAvzV1us20Hi3SJPH/gS0E2oyQNZ63od0m3+0okG2S1nTBK3CDIR8E9B8ykUAaniGKT4YeJ7nxRp8DN4Q1SQNrltCCTZTk4F6iDqp4EgHPAb5scepQyxzxJLC6yROoZXQ5DA8gg9xXnHw68S2+q6ZBpmozNf6VqSyLpd1dqS08QBD2dxuJJuI8ODn/WIu7kh8VfDU8nw08T2/hLU55X8K6k+NAu5yW+zS97F3PX1jLckZXJIGADR8ceF9SsNaPjPwNGn/AAkEaBL7T2ISLV4F/gc/wyqPuSdvunK9Op8H+JNP8W+HrXWNKZ/s84IaOVdskLg4aN17MpyCPyyMGtqo4YY4QwhjSMMxdgqgZYnJJ9z60AeP+NfCp8Hte6lpVlNe+DryT7RqukWxKy2MoORe2ZHKMpAYquOmRjHHqHhe9g1Hw7p13aamNVglgUrfAKPtHGN5CgAEnqABg5GB0rUrE8NeGNL8NNqP9jQtbQ31wbmS3Vz5SSEAMUTomcZIHGaANuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis7xFren+HNEvNX1m5S10+0TzJZX7DoAB3JJAAHJJAHJoAyPHvin/AIRywt4bGH7Zr+pSfZdLsQCTNNjO5sdI0HzO3QKPUjPmEthapbaroF9q13NpWnE6l4015k2/b5tob7GpH8JXbuVPuxqkecuavTXWvLerqEkcn/CeeJka30m08sFNB08EFpZAcjcuVdyfvybEAwKSy0Cx8Q6xbeB9KZ7nwh4cmFzrlzOWkbU7/cXEEjnhyGPmy/e52rhaANH4CeFJND0rVfEE/wBq063124e9ttGdtkOn25YmMbMlQ5TYSeMABcDBrf8ABaHxVrL+NbpD9kaNrbQo3VlKWpILzlT0aZlBB7RrH0JbJ44Z/E+sQ+CrVmFrNELrW5VLLssyWVYVYdGmZWU88Ish4JWun8RarbeHfDmo6rcgLa6fbSXDBR/Cik4A/DAFAHlGq+KY7fxV4q8ZSRi8TSGXwzoFmGw13euVaZVBHUybEyM/LE57Gu/+Gvhibwv4bEWpXH2vW72Vr3U7rOfOuXxvI4HyjAVRgcKOBXk/7PGm3Pim30nXdSS5TS9CWWOzjnPN1qMpZ7q7bHBAMjRpy2MMflIxX0HQAUUUUAFFFFABRRRQAUUUUAFYfjDwvpvi3SDYaqkg2OJre4hcxzWsy8pLE45V1PQ/gcgkVuUUAfP2reN/Fvw1vIrP4paQnijw4kqyWuv2luqvGynKmSM/IrglQOVPBILmtlvEXw81/QpY9A8T6Nawz2lvpTWeoXQtVgsUkzOqROAwZoi4z0O2PJwM17NLGk0bxyorxuNrKwyGHoRXmmufAz4f6tM8v9ifYZHOT9gne3T8I1OwfgtAHinxY+Imm2XiDUJPDV9BqV/L9olm1G35t7d3lsvJMbZ+d0iskzj5dzDryte2/s9eD5vBvw1sre+iaLUb5zfXMTZzEzABUORkFUVAR6g1574v+FfhP4Xx6D4qWXU7q10/WLd71r2bzgsJyobaqgHa5RvwPU4FfQ9ncwXtpDdWc0c9tOgkiliYMjqRkMpHBBHORQBNTZI0lXEiK69cMM0ksiQxPLK6xxopZnY4CgdST6Vkf8JZ4d/6D+k/+Bkf+NAGvHGkQIjRUB5O0Yp9Yv8Awlfh3/oPaT/4GR/41QHxD8Flwi+LvD7yE7QiajCzE+gAbJPtQB1NFcw3jjR/MVbePV7vdja9ppF3NG3OP9YsZTHfO7GOelPtde1e9vIoofCuo2sBcb7m/uLeNAmQCVWOSRy2MkAqucYJFAHSV5J4LZk/aM+Isa/Kkljp7sB/ERGACfoCRXpXiHXNN8OaPc6rrd5FZWFuu6SWU4A9AB1JPQAZJPAya8s+BFjea5rvir4j38UtrF4jlRLC1kXawtYhtSRuTywA46fKSMhhQB32q+A/DGq6/aa5e6LanWLWZLiO9jBil3p90syEFwMDhsjHGK5TxpZ3XgHXrnxzoSPLpFwV/wCEi01ASGQcfbIgOkiD7w6MoJOCN1eo0jAMCGAIPBB70AeL+OdCttLhufGHhlft3hbVhHda1YWbkbhkMuo2rLyk6cOSMbgueGG6ui02Sx8d+FZvC3i2S31B7u0E0N3CoSPUbfI2XUP91wSm9f4HxxtZC2fYA/CvxSunOmPAet3OLNwfl0q7fJMJHaGQ5KkcKxIIAOaxPGXh8fD66W4sp3s/BdzdCZJY1yfDl8xIW4iHT7O5Yq8R+X5yPusVIB2Xw71/U7XUp/BfjBxJ4g0+ES298OE1S1ztEwzyJAcB1OcHkEg8egV5jrGnv4+0URM8ej+P9BIntbmFsiCYr8skZ5320uCMEEEZVhuQgdF8OvF6+KtLmS9tzp+v6e4t9U05+HtpsduTmNvvIwJBHfINAHWUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeNa94osdcu28U38hufBGiXAi0y1t4jLJrOpbtqtGP41VjtjA4LhnJwoNbXju81rxhql94L8JTpYwRQj+2NYkQusAdcrbRqGUtI4wWORsRsg7mXGl4a8FXlrq9jf6/f2F3HpluLfS7CwsTa21l1DSBWkcs5XaoORtG4AfMTQByWpPq/hnTWuyyT/ABQ8ZuLW1ieUNHYKFLBEHIEMClmZgDuc5Odwx6V4L8N2fhLw3aaRYNLKkILSTzMWknlYlnkcnqzMST9cDgCuO+FrDxhr2rfECd2eCdpNM0eIsQIbON8O5UgYeSRCxBGQFUZrr7dNYn8aXc85a30O1tFgt4sqftUzkO8pwSQqBURc4OTLwRtJAJPDGgx6HHfuZ5Lq9v7p7y6uZBgyOcBQB2VUVEUDso75J4345QT+I9GsvA2lzNDqXiCUbpQjMtvawsrzSvjt9xACRuLgdzj0W+u7fT7K4vL2aOC1t42lllkOFRFGSxPYAAmuJ+GVncapLfeNdXt5INQ1oKtpBMoD2lgpPkxnBOGbJlbnq+P4aAOr8N6JYeHNCstH0iAQWFnGIokHoOpJ7knJJ7kk1pUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ3iHRdP8RaLeaTrNsl1p93GY5om4yPYjkEHBBHIIBFeJeBPBvivwP421nwt4V8Ww/2Rb2cN/Z2Wq2puUKyySK2SrIUYNG33eDvyRmvfq8/1ue00r4x6Rf3cwhS50Se1ZiPvMby0SIcerz4Gem7tk0AULvxD8SNFisIdX8P+F9RnvZ/syy2WozwxhyjuNyvE20HZtHzH5mUd6y28SfEsMQPg/YsAeo1y1wf0rS1WMw+DfH9vaxM76DqkmpWqgljJMqw6iB9DLIRj0rvr3WIbTUdItXRmXU5HihlH3d6xtKFP1RHP/AfcUAePXHir4ntqEWnRfDbQbS/uYpZ4I7jUI5P3cbRK7EqQDgzJxkHrxxVjw9rHxm8TeH7DVdLh8BWVle28dxAJvtRcKyggHGQDz07dK9I1VR/wnnh58DcLS9XdjnBMBI+nA/IVT+FC7PB3lbtyw6lqUKfNuAVL6dVAPoAAB7CgDzDVtP+Nq6hYW17400Cyk1G4EEEVhaiTohd2JeHIAVGPXkkLkZGOgt/hZqb3dq3ir4oeKbyeWT5YLS6FhHOQNxQIpJPCknBzgEjHWu+1CxuZPH+h36wlrODTr6CSTIwkkklqycdeRFJz7e9R6+62/jPwrLL9yZrq0TjP71ovNH/AI5BJz/jQB80fETwlpusXXwvtrGOc3fimSSee9lnknuDA5h2fvJSThIXbA9RnAJIr61sbSCwsrezsoUgtbeNYoooxhURRhVA7AAAV8/a5s0Pwn8DvGlzuGnaNb29veOqbvKiuLWNPMb0VSoH/AhjmvoZHWRFeNgyMMqynII9RQA6iiigDP8AEOjaf4h0W80nWbZLrT7uMxzRP0I9QeoIOCCOQQCORXAeDdQm0vUrn4c+OJDfu8T/ANlXl4oYarZY+aNz0aVAdrg8lcNgjJPp9c14/wDCsXi3RFtluZLDUraVbrT7+IAva3C/dcA9R2K91JHHBAB5dfaXf+Ate07RoL8RWMjlPC+qXhZltZG5fTLht2XhcIAhPIIGMsi43fECXt7InjzwbbSQ+KNKU2mr6JLjddxLhnt3xnEig7o5BkMGBG5WFa3hvULX4i+GNY8MeNdPtl1izb7FrGnq2V3feSaP+II4w6N1B6HK5rkdPm13wx4nTRbmY3Pia0iP9l3NzIEXxHp6En7NI+Av2mIHIY8gnJ+V3JAPXPC+v6d4o0Cy1nRp1nsbuMPGw6j1Vh2YHII7EGtWuG8P+F7nR/GtxrOhNHa6BrUP2jUdNmDI8d3gbZo1AIDMMiQccqDyenc0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfxA8Rv4a8PPcWVv9s1e5dbTTrMEA3Fy/CLyR8o5ZjnhVY9q6KR1jjZ5GVEUFmZjgADqSa888ERnxn4iPjm9jzpsSvbeHYZYSjRwtxLdENzulIG3gYjA/vGgDpPAnhqLwp4disFkFxeSO1zfXZXa13cucyTN7s35AAdAK6GiuQ8W6vfz6xZ+GPDjNHqN0nn3l8oVhp1rnG/ByDI5BWNSCMhmIIQggHNa3bt8P8A4i6VqejJI+keK9QWx1HTIRkLdupZbxF7cI3mkYyPmIJFeqV502PEXxwRfle08KaduPJyLy74HHQ4hQ/9/a6jxt4ij8L+G7vU3ha5nXEVrarndc3DnbFEuATlnKjODjOegoA5jxkw8ZeLLbwZbSBtNsjHqGvlWU5jzmC0YEH/AFrDcw4+RMfxivRBwOOlc18P/D82gaERqUq3Gt30rXupXAYsJLh8bgpPOxQAijsqLXS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXkV/LcePvFVxqnhaM3Ok6bp81nDeS/uoLq7F3bylI25LJ/o5UyBSoPTdyK6n406w+hfCnxTfxSSRTLYyRRyRkhkeQeWrAjkEFwc1v+FEso/C+kJpMaxacLSL7Mi4IWPYNo49sUAcRrMusjR/FsOleCdee/wBaEj7pbqw8nzTbpApB+0bgmIkJ4z1+lTnxNqkcVi2o/DjxE72D74njkspjG2xo9y4n6lXYHHZjXotFAHms/i24n1qz1N/AfjjzrSGaCNBDa7CJDGSSPP5I8sAezN68LoniO/0zT2tdF+HXikQ+dNMFuZbSMmSWRpXyWnJALOee34V6TRQB57F4k+IV5NLHb+AbOwjH3JdR1yP5uD1SFH9B37j3xBLofxH1oRtqmu+GdGeGXzYW07THvJYuGXKvOwUMUZl3bOjEYr0migDk/Dvgey0rwo3h6+vb7WdPa1SyKX7KVEKqVCKqKqgYPXG44GScCuJ+GU2o+APGj/DjW7yS+0qaBrvw7ezn94Yl+/bMe7IORjooPQFVHsVeV/E5kPxc+FEcQP203d8yHGQIhbjzB68/L+VAHqlFFFABRRRQBkzeHtMl8TW/iFrYLq8Fu9otwjFS0TEEowBwwBGQGzg8jFU/HfhOy8Y6A+nXrPBMjCe0vISRLaTr9yWMgghlPoRnkd66KigDivhx4l1LU1vdD8UWptfFGkbFvNinyblGyI7iJsYKPtbjqpDAgYrtaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoornPHviX/AIRfQWuoLZr7U7iRbXT7FGCtc3DnCICSMDqzHsqse1AHOeOpm8ZeIV8B6fIPsKotz4imjlZWitycx2wK9Gmwc8jEYb+8K9DgijghjhgRY4o1CIijAUAYAA9K57wB4bbwzoPk3l019q11I13qN64Gbi4fG5uAMKMBVHZVUVs6tqNppGl3eo6lOtvZWsTTTSt0RFGSaAMvxn4h/wCEe0yJ7e1a+1S8mW1sLJDgzzt0BP8ACigFmb+FVY84wcmBdP8Ahr4N1bWdfvzcXBL3+pXr/K1zOQAFQE8DhY40zwAo56mPwtbyXFxdeOfFJexkltSLW1uyI10uyHznfnhZHwHkJ6bVTomTwmiC9+K3xXsvEDM6+CNCjSe0tLgH/SLhg/lytGQNp2lZV3ZIRoWGPMIAB3/wn0a+03w5NqOuqV13W7l9TvkJJ8l5AAsQz2RFRMeoNUNJ/wCK38fyay4Y6B4blltNPB3Ktze42TT44DLGMxocH5jKQelaPxJ1W/W3s/Dnh2bydf1tmhhn8suLOBQDNcEAj7qkBckZd0HrXSaBpFloGi2WlaXCILGziWGGMHOFAxye57knqcmgC/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc58RfDv/AAlngXXNCBQSXtq8cTP91ZMZQn6MFP4V57+zZ40XUvDA8I6wfs3iXw9mzltJThzCh2qQO+3hDjoVBP3hXsteQ/FXwXol14+8F6yYJbLUL3UXsbi+sZntp3BtJinzoQdwKKAeuODxxQB69WBqPiqz065khurLWzsbb5lvpNzcKTjPBjRsj36Vw3iTTNe0XRddTwx4/wBcudV0mwN79ivba2uy4KyGNc+UrHcY2A+YnjnPSo5vDXxWntIBp3xK0yWEx7lujosSvLk7gSPmXocDGOO2eaAOz/4TvSP+fPxJ/wCE5qH/AMYqT/hLPNj3WOg+ILptu7Z9i+zn2H74oMn68d8V51eeHfinp1otxqvxYtrdHnit1KaBBIC8sixxj7oPLuo6YGck4zjW8NeH/F9++p2uq/E/ULm4sLr7PMLLSrW22MYo5ADuibPyyA5BxyO4NAHWLr3iC6DrZ+D7y2kGNp1O+t4oz+MLzN/47Ve7uPFRRHvNR8M6CvR0ZZL0nngrIzQAH6oefWuI8X/CpJYRcav488fXcM1xDbfZ4r9ACZJVjX5QgXALAk46AnHFOsf2evAukWsk8Wky61qUYLwnVLxwkkn8O/ywF2k4ydh47GgDvdX8feEtETGreJtHgkEfmbGuk3sBnkIDk9D0HXiuJ+H4ufH3xGufH91bSwaBY25sPD6XERR5Q3Mt1g8gMPlUjGVOCOOed+IOk6fo3wc+J974fsLLT4Li7FrF9igSLEURhgkQ7RyPMWcnPPzGvfogixIseNgAC4OeO1ADqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBsjrHGzyMqIoLMzHAAHUk1554JiPjTxEfHN9HnTYla38OwywlHjhPEt0Q3IaUgbeBiML/fNJ44mbxn4i/4QSwkzp8aJceIpopSjRQNzHbAryGmwd3IxGG/vCvRIo0iiSOJFSNAFVVGAoHQAdhQA6uBiI8feI1nVpR4W0O7YKuMLqV7GcbuR80MLZxjhpFz0jG6fxfqFxr+rP4O0C8ktrkxpNq17B96ytmPCK3aaUBgvdV3PwQu6n4ruZvMsfh/4MiezmltgLm7tvkXSbL7u5T2lbBWMDnILHheQDD8e6y3ii6vrVIln8HaPOkV6qnLazfl1WKxj7BBI0YdjwWOzgBjXe6HaQeE/C01xq9xAsqLJfaldj5UaUjdI/PIQY2qD91FVegFYXhjRNOfV7Ky0a2jt/DXhQtBZxJ92S9KlZHz/F5aO6k5O55ZN3zIDUPi0L428YQ+D1QS6Jp3lahrjEIyStu3QWhBycsVErcfdVR/HQBY+Gunz6lcXvjfWrZotU1hQlpDMgWSy09TmGE8nDNnzH5+8+MfKK72iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvP/izI0V94BdI3kb/AISSJVVRnk21yAT7DOSewzXoFZWu6Faa1caRNeNKG0y9F/AI2ABkEboA3HIxI3AxyBQByPg7Vf7Z8ZxassQjh1zwxYXflHkptkmbB9eLgD/gNQadq8egfCqzmlkngtdG1BdL3xSqp8m3v/soZ2YEbdiAv043YIPI7Pw94e0/QtO021s4g72FjFp8VzKqmYwxgAKzAD0yQMDPar9pZW1pA0NtBHFE8kkrIo4Lu5d2+pZmJ9yaAOd+JRx4esxnrrOk4/8ABhb1X8GkDxr4+jPDnUbaTaepU2NuoP0yjD/gJrsHjSQASIrgEMAwzgjkGlAAJIABPX3oAq6jatdfZtrBfJnSU57gdv1rH8fW9zP4fRrJJZJba+srsrECXMcV1FJIFA5JMauMDrnHeujooA86fw5d6x8KvFmgyQPDeXtxrCwiUFQTLdTvE3+6Q6HPoa6rwPLqE/g3Q5Nat3ttTayh+1ROMMsuwbgfxzW3RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc3498SnwxoJuLW1a+1W5kW10+xQgNc3D8KuSRgDlmPZVY9q6SuB8L6bdeIfF9z4u120eCKzaSy0O0uIWjlt4s7Zrhg3IeUrxwMRhf7xoA2vAXho+GNBFvdXTX2q3MjXWoXzgBrm4flmwAMAcKo7KqjtR411260q0hstDhhu/EWobo7C2lYhMjG6WTHIijBBY9+FHzMuekrHXRLGy1rUdfhtZLjVrm3SFmMm5vLjyVij3HagLEkgYBY5PbABy2o3sPw78PWmn2e7V/FesTlYEYYl1G8YDfNJj7sagAsfuoiqowAopltps/gXwwbe1u21Pxjr13sa9uFz9pvHUkyFRwsUUaMwQYASPA5PN/wLoOpG+uPFHi+KBPEl6nlJbxNvTTrbOVt1b+Js/M7jhm6fKq1c0e0uNS8Y6jrl/byww2StpumpKpUlMq082PR3VFGf4YQynEhoAr6xe2Xw48CQRWiNdTx7bSxt5JAJdQvJD8qlscySOSzNjuzHvV3wB4dk8NeHY7e9uTe6tcu13qN4QAbi5fl24A+UcKoxwqqO1Uf7F1DWPiOdV1eLydI0RPL0mIS58+eRP3twyjgbVbylByf9YeMiuyoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superior pole vessels demonstrated with right-angle clamp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20134=[""].join("\n");
var outline_f19_42_20134=null;
var title_f19_42_20135="Phenelzine: Drug information";
var content_f19_42_20135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenelzine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/35/32309?source=see_link\">",
"    see \"Phenelzine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nardil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nardil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Monoamine Oxidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial: 15 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Early phase:",
"     </i>",
"     Increase rapidly, based on patient tolerance, to 60-90 mg/day (may take 4 weeks of 60 mg/day therapy before clinical response)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     After maximum benefit is obtained, slowly reduce dose over several weeks; dose may be as low as 15 mg/day to 15 mg every other day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F208848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Select dose with caution; generally initiating at the lower end of the dosing range; some clinicians recommend an initial dose of 7.5 mg, with dose increases  of 7.5 mg/day every 4-8 days as tolerated to a usual therapeutic dose  of 22.5-60 mg/day in older adults  (Alexopoulos, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nardil&reg;: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088660.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088660.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of atypical, nonendogenous, or neurotic depression",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Phenelzine may be confused with phenytoin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nardil&reg; may be confused with Norinyl&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety (acute), ataxia, coma, delirium, dizziness, drowsiness, euphoria, fatigue, fever, headache, hyper-reflexia, hypersomnia, insomnia, mania, schizophrenia, seizure, twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased sexual ability (anorgasmia, ejaculatory disturbances, impotence), hypermetabolic syndrome, hypernatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice, necrotizing hepatocellular necrosis (rare), transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myoclonia, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, glaucoma, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Edema (glottis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, Lupus-like syndrome, transient cardiac or respiratory depression (following ECT), withdrawal syndrome (nausea, vomiting, malaise)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenelzine or any component of the formulation; congestive heart failure; pheochromocytoma; abnormal liver function tests or history of hepatic disease; renal disease or severe renal disease/impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Concurrent use of sympathomimetics (including amphetamines, cocaine, dopamine, epinephrine, methylphenidate, norepinephrine, or phenylephrine) and related compounds (methyldopa, levodopa, phenylalanine, tryptophan, or tyrosine), ophthalmic alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonists (apraclonidine, brimonidine), CNS depressants, cyclobenzaprine, dextromethorphan, ethanol, meperidine, bupropion, or buspirone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     At least 2 weeks should elapse between the discontinuation of serotoninergic agents (including SNRIs, SSRIs, and tricyclics) and other MAO inhibitors and the initiation of phenelzine. At least 5 weeks should elapse between the discontinuation of fluoxetine and the initiation of phenelzine. In all cases, a sufficient amount of time must be allowed for the clearance of the serotoninergic agent and any active metabolites prior to the initiation of phenelzine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     At least 2 weeks should elapse between the discontinuation of phenelzine and the initiation of the following agents: Serotoninergic agents (including SNRIs, SSRIs, fluoxetine, and tricyclics), bupropion, buspirone, and other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     General anesthesia, spinal anesthesia (hypotension may be exaggerated). Use caution with local anesthetics containing sympathomimetic agents. Phenelzine should be discontinued &ge;10 days prior to elective surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Foods high in tyramine or dopamine content; foods and/or supplements containing tyrosine, phenylalanine, tryptophan, or caffeine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Phenelzine is not FDA approved for the treatment of depression in children &le;18 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertensive crisis: Cases of hypertensive crisis (sometimes fatal) have occurred; symptoms include: severe headache, nausea/vomiting, neck stiffness/soreness, photophobia, and sweating. Monitor blood pressure closely in all patients. May occur with foods/supplements high in tyramine, tryptophan, phenylalanine, or tyrosine content; treatment with phentolamine is recommended for hypertensive crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; sensitization to the effects of insulin may occur, monitor blood glucose closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Phenelzine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Do not use with other MAO inhibitors or antidepressants. Do not use within 5 weeks of fluoxetine discontinuation or 2 weeks of other antidepressant discontinuation. Avoid products containing sympathomimetic stimulants or dextromethorphan. Concurrent use with antihypertensive agents may lead to exaggeration of hypotensive effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The MAO inhibitors are effective and generally well tolerated by older patients. It is the potential interactions with tyramine or tryptophan-containing foods and other drugs, and their effects on blood pressure that have limited their use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Phenelzine is not generally considered a first-line agent for the treatment of depression; phenelzine is typically used in patients who have failed to respond to other treatments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelography: Discontinue at least 48 hours prior to myelography.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyridoxine deficiency: Has occurred; symptoms include numbness and edema of hands; may respond to supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Phenelzine may enhance the neuromuscular-blocking effect of Succinylcholine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F208839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Beverages containing tyramine (eg, hearty red wine and beer) may increase toxic effects. Management: Avoid ethanol and beverages containing tyramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Concurrent ingestion of foods rich in tyramine, dopamine, tyrosine, phenylalanine, tryptophan, or caffeine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid foods containing dopamine, tyrosine, phenylalanine, tryptophan, or caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Kava kava, valerian, St John's wort, and SAMe may increase risk of serotonin syndrome and/or excessive sedation. Supplements containing caffeine, tyrosine, tryptophan, or phenylalanine may increase the risk of severe side effects like hypertensive reactions or serotonin syndrome. Management: Avoid kava kava, valerian, St John's wort, SAMe, and supplements containing caffeine, tyrosine, tryptophan, or phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13114430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safe use during pregnancy has not been established; use only if benefits outweigh the risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13114431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safe use during breast-feeding has not been established; use only if benefits outweigh the risks.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9603407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid tyramine-containing foods/beverages. Some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment where tyramine concentrations may increase.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nardil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $79.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phenelzine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $50.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F208819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate; diet, weight; mood (if depressive symptoms), suicide ideation (especially during the initial months of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F208831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Margyl (IT);",
"     </li>",
"     <li>",
"      Nardelzine (BE, ES, LU);",
"     </li>",
"     <li>",
"      Nardil (AU, GB, IE, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F208809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thought to act by increasing endogenous concentrations of norepinephrine, dopamine, and serotonin through inhibition of the enzyme (monoamine oxidase) responsible for the breakdown of these neurotransmitters",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F208827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: 2-4 weeks; geriatric patients receiving an average of 55 mg/day developed a mean platelet MAO activity inhibition of about 85%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: May continue to have a therapeutic effect and interactions 2 weeks after discontinuing therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Oxidized via monoamine oxidase (primary pathway) and acetylation (minor pathway)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (73% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alexopoulos GS,  Lerner DM, Salzman C, &ldquo;Treatment of Depression with Tricyclic Antidepressants, MAOIs, and Psychostimulants,&rdquo;",
"      <i>",
"       Clinical Geriatric Psychopharmacology",
"      </i>",
"      , 4th ed, Salzman C, ed, Baltimore, MD: Lippincott  Williams &amp; Wilkins, 2004, 233-304.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Georgotas A, Friedman E, McCarthy M, et al, &ldquo;Resistant Geriatric Depression and Therapeutic Response to Monoamine-Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 1983, 18:195-205.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goff DC and Jenike MA, &ldquo;Treatment-Resistant Depression in the Elderly,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(1):63-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huyse FJ, Touw DJ, van Schijndel RS, et al, &ldquo;Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery,&rdquo;",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 2006, 47(1):8-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/42/20135/abstract-text/16384803/pubmed\" id=\"16384803\" target=\"_blank\">",
"        16384803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenike MA, &ldquo;MAO Inhibitors as Treatment for Depressed Patients With Primary Degenerative Dementia (Alzheimer's Disease),&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1985, 142:763.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/42/20135/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Psychiatr Ann",
"      </i>",
"      , 2001, 31(6):378-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;Refining the MAOI Diet: Tyramine Content of Pizzas and Soy Products,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1999, 60(3):191-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stahl SM and Felker A, &ldquo;Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antigepressants,&rdquo;",
"      <i>",
"       CNS Spectr",
"      </i>",
"      , 2008, 13(10):855-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/42/20135/abstract-text/18955941/pubmed\" id=\"18955941\" target=\"_blank\">",
"        18955941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9762 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20135=[""].join("\n");
var outline_f19_42_20135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709208\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208843\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208844\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208865\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208847\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208848\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208822\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208806\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874963\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208825\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208875\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208863\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208828\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208810\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299861\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208815\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208839\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208817\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13114430\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208850\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13114431\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603407\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422272\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208819\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208831\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208809\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208827\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9762|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/35/32309?source=related_link\">",
"      Phenelzine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_42_20136="Physical activity in end-stage renal disease and renal transplantation";
var content_f19_42_20136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physical activity in end-stage renal disease and renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20136/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20136/contributors\">",
"     Brent W Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20136/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20136/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/42/20136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise rehabilitation has been extensively utilized for patients with severe cardiac, pulmonary, and neurologic diseases. Patients with chronic kidney disease (CKD), as well as those with a functional renal allograft, also have physiologic abnormalities that require physical rehabilitation for optimal health [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic review will discuss the underlying causes and treatment of deconditioning in patients with chronic kidney disease and renal transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of deconditioning among patients with chronic renal failure and renal transplant recipients may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Comorbid conditions, including diabetes, cardiac disease, and peripheral vascular disease",
"     </li>",
"     <li>",
"      Recurrent hospitalization episodes",
"     </li>",
"     <li>",
"      Uremic myopathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neuropathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2643?source=see_link\">",
"       \"Uremic mononeuropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14773?source=see_link\">",
"       \"Uremic polyneuropathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Secondary hyperparathyroidism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=see_link\">",
"       \"Indications for parathyroidectomy in end-stage renal disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"       \"Parathyroid and mineral metabolism after renal transplantation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"       \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"       \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Androgen abnormalities",
"     </li>",
"     <li>",
"      Dialysis related",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link\">",
"       \"Carnitine metabolism in renal disease and dialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"       \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Steroid myopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CKD are less active and perform at activity levels less than that observed in sedentary healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The following are some details concerning the causes of deconditioning and specific efforts to improve physical activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Androgen abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both male and female patients with chronic kidney disease exhibit abnormalities in androgen production. With males, uremia also impairs gonadal steroidogenesis. The serum total and free testosterone concentrations are typically reduced, although the binding capacity and concentration of sex hormone-binding globulin are normal. Another manifestation of diminished testosterone secretory capacity is the subnormal and delayed testosterone response to the administration of human chorionic gonadotropin, a compound with luteinizing hormone-like actions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20951?source=see_link\">",
"     \"Sexual dysfunction in uremic men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36484?source=see_link\">",
"     \"Reproductive and sexual dysfunction in uremic women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to the availability of recombinant erythropoietin, androgen therapy was successfully utilized to increase erythropoiesis in some hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/5\">",
"     5",
"    </a>",
"    ]. This agent has now been reintroduced to help improve body composition and muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one study, 79 patients were randomly assigned in a 2 x 2 factorial fashion to anabolic steroid administration and resistance exercise training [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/7\">",
"     7",
"    </a>",
"    ]. Nandrolene administration increased lean body mass and quadriceps muscle size, while exercise increased muscle size alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As observed in a large number of studies, the correction of anemia with erythropoietin improves endurance, strength, and quality-of-life in patients with chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/8\">",
"     8",
"    </a>",
"    ]. In one study, for example, the correction of anemia with erythropoietin to a target hemoglobin of 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in 11 previously transfusion-dependent hemodialysis patients resulted in a 10 to 30 percent increase in arm and leg muscle strength in three months, although this improvement still left the patients significantly less strong than healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/9\">",
"     9",
"    </a>",
"    ]. Muscle structure may also improve with erythropoietin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, correction of anemia with transfusion in non-uremic patients does not appear to improve muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, the maintenance of an adequate hemoglobin with iron and erythropoietin failed to help exercise performance in predialysis patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/12\">",
"     12",
"    </a>",
"    ]. These findings are likely due to the deleterious effects of decreasing kidney function on muscle strength and aerobic performance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vitamin D metabolism and secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of 1,25 dihydroxyvitamin D(3), phosphate retention, and elevated parathyroid hormone may also contribute to poor conditioning in patients with chronic renal failure. This is indirectly shown in vitamin D dependent rickets, in which a significant clinical feature is muscle weakness; this can be corrected in part by supplementation with appropriate doses of vitamin D and calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    .)&nbsp;Calcitriol levels begin to decrease in stage 2 CKD (estimated GFR",
"    <span class=\"nowrap\">",
"     &lt;60mL/min/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    so this could affect millions of patients.",
"   </p>",
"   <p>",
"    Although many patients with chronic kidney disease receive active vitamin D analogues for the treatment of secondary hyperparathyroidism, no controlled studies have correlated vitamin D analogue administration with improved strength or endurance. Whether chronic kidney disease patients with adequate control of PTH and normal calcium and phosphate levels should receive some form of vitamin D supplementation for muscle function is unclear. However, there is a very high incidence of 25 hydroxyvitamin D(3) deficiency or insufficiency (&lt;30",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    in chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/14\">",
"     14",
"    </a>",
"    ]. Improvement in the large number of musculoskeletal complaints after supplementation in the general population with vitamin D insufficiency suggests this strategy may work in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parathyroid receptors are also found in skeletal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/16\">",
"     16",
"    </a>",
"    ]. The effect of PTH on muscle function in the setting of secondary hyperparathyroidism in renal failure has also not been exhaustively studied. However, most investigators feel that extremely high PTH levels adversely affect muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Support for this is provided by numerous reports claiming consistent improvement in muscle function after removal of parathyroid adenomas in primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abnormal calcium and phosphorus metabolism in CKD also likely contributes to musculoskeletal dysfunction. Although placing patients in positive calcium balance has been implicated in vascular calcifications and increased mortality, negative calcium balance has detrimental effects upon CKD patients also. Extremely high phosphorus levels in dialysis patients have been implicated in spontaneous ruptures of tendons with exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dialysis access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have addressed the impact upon physical function of presence of a hemodialysis vascular access or a peritoneal dialysis catheter. A forearm access, for example, likely affects the function of both large and fine motor skills in the affected arm [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/20\">",
"     20",
"    </a>",
"    ]. Although restrictions are often placed upon patients with various access (eg, swimming and heavy lifting with peritoneal catheters, lifting with the vascular access arm, heavy perspiration or swimming with a hemodialysis catheter, etc), these recommendations are largely based on anecdotal practices. Most surgeons recommend hand isometric exercises after placement of a forearm fistula to improve development of the fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dialysis-related L-carnitine disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    in hemodialysis patients remains controversial. The biochemical diagnosis of this disorder is difficult since nearly all dialysis patients have abnormalities and no study has demonstrated a correlation between various",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    measurements and muscle function.",
"   </p>",
"   <p>",
"    The response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    can be idiosyncratic, some patients clearly respond with improved muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/22\">",
"     22",
"    </a>",
"    ]. The usual dose is 1000 mg intravenously at hemodialysis three times weekly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link\">",
"     \"Carnitine metabolism in renal disease and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recombinant human growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anabolic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH) have been reported in many muscle wasting conditions, including chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/23\">",
"     23",
"    </a>",
"    ]. There is a paucity of data relating to sustained improvement in physical function and strength with rhGH administration. One study of 20 patients who received subcutaneous rhGH at 66.7",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    or placebo thrice weekly following hemodialysis reported increased handgrip strength and anabolic effects with active therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/24\">",
"     24",
"    </a>",
"    ]. However, given the expense and lack of consistent improvements, most investigators do not currently recommend the widespread use of growth hormone in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/25\">",
"     25",
"    </a>",
"    ]. There is an ongoing phase III international, multicenter trial of over 2000 hemodialysis patients that is evaluating mortality and morbidity after treatment with rhGH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Uremic myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies and multiple reports of muscle biopsies in patients receiving dialysis reveal structural, electrolyte, and enzymatic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Imaging by MRI also demonstrates gross structural abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/30\">",
"     30",
"    </a>",
"    ]. What role each abnormality contributes to the decreased functional status of patients with chronic renal failure is not clear.",
"   </p>",
"   <p>",
"    When such changes occur during the course of progressive renal disease is also unclear. Patients with chronic renal failure not yet on dialysis clearly have functional limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few studies have evaluated changes in muscle structure after interventions. This issue was addressed in a study of 18 dialysis patients who participated in a six month aerobic exercise program [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/33\">",
"     33",
"    </a>",
"    ]. All patients underwent a pre-exercise muscle biopsy, while nine agreed to a post-training biopsy. Among those with pre- and post-exercise biopsy of skeletal muscle, the histologic benefits with exercise included correction of fiber atrophy and improved capillarization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effects of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some modest improvement in exercise ability, strength, and other outcomes can be observed with proper training in patients with chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. In the Renal Exercise Demonstration Project, for example, 286 hemodialysis patients underwent a 16-week exercise program of stationary cycling at the dialysis center [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/34\">",
"     34",
"    </a>",
"    ]. Even with marked improvement at study end, scores in several standard tests of fitness and strength were relatively low, with sit-to-stand test scores and gait speed being 38 and 66 percent of normal values. Similar low levels of physical function, in combination with some improvement with training, have been demonstrated in peritoneal dialysis patients with 12 weeks of thrice weekly aerobic exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, high intensity exercise training, compared with usual exercise, does not significantly improve muscle mass [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predialysis patients with chronic renal dysfunction also have functional limitations, although rapid improvement can occur with an exercise regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/40\">",
"     40",
"    </a>",
"    ]. As an example, 16 patients with a mean creatinine clearance of 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    had a 12 percent improvement in peak oxygen consumption (VO(2max)) after four months of exercise three times a week on treadmills and stationary cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A compelling reason for exercise in the predialysis patient may be to help preserve muscle mass among those on a low-protein diet. This was found in a 12 week study of 26 patients with chronic renal failure (mean glomerular filtration rate of 26",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    who were placed on a 0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day protein restriction and randomly assigned to resistance training or sham exercise. Strength improved in the exercise group (32 percent) but declined in the control group (13 percent). In addition, skeletal muscle fiber area, total body potassium, glomerular filtration rate, hematocrit, and body mass had all improved in the exercise group as compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A paucity of data exists concerning the association between survival and exercise in dialysis patients. This was examined using data for 2,507 patients from the Dialysis Morbidity and Mortality Wave 2 study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/43\">",
"     43",
"    </a>",
"    ]. Decreased mortality was associated in patients who exercised two to three and four to five",
"    <span class=\"nowrap\">",
"     times/week.",
"    </span>",
"    However, for unclear reasons, daily exercise provided no survival benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RENAL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients tested before and shortly after renal transplantation show improvement in exercise capacity. In one study, 20 nondiabetic renal transplant recipients underwent maximal exercise testing one week before and at two months following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/44\">",
"     44",
"    </a>",
"    ]. Maximal oxygen consumption increased 25 percent with an increase in maximal energy expenditure from 6.7 METS to 8.5 METS; this increase was not correlated with improvement in anemia.",
"   </p>",
"   <p>",
"    Although renal transplant candidates are a select group of relatively highly functioning individuals, even these individuals have significant exercise deficits prior to transplantation. As an example, 26 consecutive patients referred to a university transplant program had marked deficits in upper and lower strength and gait performance, measuring about 60 percent of healthy control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/45\">",
"     45",
"    </a>",
"    ]. A follow-up study in 110 renal transplant candidates by the same investigators using simple tests of lower extremity strength and gait (sit-to-stand test, grip strength, gait speed, and gait independence) again demonstrated marked abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/46\">",
"     46",
"    </a>",
"    ]. The limitations in the vast majority of patients were not readily apparent by simple observation, with many scoring highly on simple tests of gait function. Diabetics performed worse than nondiabetics.",
"   </p>",
"   <p>",
"    After transplantation, abnormalities in strength and endurance remain. Sixteen renal transplant recipients who participated in a six-month program of thrice weekly 60-minute aerobic exercise sessions and stretching demonstrated substantial improvement in VO(2max) and strength measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/47\">",
"     47",
"    </a>",
"    ]. Interestingly, no difference was seen between patients on different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . However, the trained transplant recipients still had lower exercise capacity than untrained, sedentary control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/47\">",
"     47",
"    </a>",
"    ]. In a review of four studies measuring VO(2max) before and following renal transplantation, untrained patients were found to be well below the level of a sedentary female control in the general population and improvement to near the level of a sedentary male with training [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating muscle structure also demonstrate abnormalities among renal transplant recipients. Muscle biopsy specimens of 12 stable renal transplant recipients possessed 25 percent less cross-sectional area of all three skeletal muscle fiber types [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium, magnesium, calcium and phosphate abnormalities frequently occur following transplantation. All such abnormalities may affect muscle function, but have not been specifically studied in transplant patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adverse drug effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins (HMG CoA reductase inhibitors), particularly in combination with calcineurin inhibitors, can also cause rhabdomyolysis with symptoms often beginning as muscle weakness and pain. This complication is least likely to occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , in part because they are not metabolized by CYP3A4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Steroid myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of systemic glucocorticoids causes both acute and chronic muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/50\">",
"     50",
"    </a>",
"    ]. Although animal models and clinical experience confirm the detrimental effects of steroids on muscle structure and function, studies in patients with Cushing's syndrome do not uniformly show muscle atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/51\">",
"     51",
"    </a>",
"    ]. Only one-half of the patients in Cushing's original series described muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/52\">",
"     52",
"    </a>",
"    ]. Thus, other factors may account in part for the consistent findings of deficits in structure and functions in renal transplant recipients. Nevertheless, early data with steroid withdrawal and avoidance following renal transplantation reveal improved muscle function with lower steroid regimens and less bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Effects of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both aerobic and strength training benefit renal transplant recipients. As an example, 39 stable, sedentary patients administered an average",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose of 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    underwent 50 days of isokinetic exercise three times weekly, resulting in increased quadriceps function and muscle mass as measured by dynamometer and computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This benefit also applies to other organ transplant recipients. In 27 cardiac transplant recipients randomly assigned to a structured exercise program or no formal exercise training, the exercise group was found to have increased VO(2max) 2.7 times that of the control group at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nearly every patient group and disease state studied, the patients who benefit the most from physical activity tend to be the most frail. The largest incremental gain in function is observed when moving from the sedentary state to even minimal activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     CKD prior to dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of physical function can be insidious in predialysis patients with CKD and should be prevented or identified early. We counsel predialysis patients to maintain an active lifestyle; we also measure 25 hydroxyvitamin D levels and supplement, as necessary. Patients placed on a low-protein diet are particularly prone to loss of muscle mass and should be followed closely by a renal dietician and encouraged to maintain both aerobic and strengthening activities. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dialysis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;At our center, all patients undergoing hemodialysis are encouraged to participate in an exercise program, including stationary cycling at the dialysis center during dialysis. Improvement occurs within 12 weeks of this simple program, although only about 20 percent of patients participate regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/57\">",
"     57",
"    </a>",
"    ]. For peritoneal dialysis patients, a stretching and walking program is recommended at home. This is consistent with the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines that recommend increased physical activity among dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20136/abstract/58\">",
"     58",
"    </a>",
"    ]. The routine use of exercise physiologists and physical therapists in the outpatient dialysis setting remains unclear mainly due to reimbursement considerations, but referral for appropriate conditions (particularly after a decline following hospitalization) is practiced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplant recipients begin a walking program immediately following discharge from the hospital, averaging 30 minutes daily. Multiple benefits ensue in patients compliant with these regimens. For patients with substantial obstacles, formal physical therapy consultation is obtained. Our experience is that patients with comorbid conditions and worse deconditioning benefit the most. The routine use of long-term high dose steroids should be abandoned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Androgen deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predialysis, dialysis and transplant patients with measurable androgen deficiencies (clearly reduced serum free testosterone) should receive supplemental therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men, we use testosterone (testosterone gel 1 percent, 2.5 to 5 g topically daily or depo-testosterone 200 mg intramuscularly every two weeks) and measure levels.",
"     </li>",
"     <li>",
"      For women with no contraindications for estrogen therapy, combined estrogen-testosterone supplementation is considered for those who are also estrogen deficient as defined by FSH, LH, and estradiol levels along with unmeasurable androgen levels.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/1\">",
"      Johansen KL. Exercise in the end-stage renal disease population. J Am Soc Nephrol 2007; 18:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/2\">",
"      Johansen KL, Chertow GM, Ng AV, et al. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 2000; 57:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/3\">",
"      Painter P. Physical functioning in end-stage renal disease patients: update 2005. Hemodial Int 2005; 9:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/4\">",
"      Hsieh RL, Lee WC, Chang CH. Maximal cardiovascular fitness and its correlates in ambulatory hemodialysis patients. Am J Kidney Dis 2006; 48:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/5\">",
"      DeGowin RL, Lavender AR, Forland M, et al. Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone. Ann Intern Med 1970; 72:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/6\">",
"      Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/7\">",
"      Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 2006; 17:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/8\">",
"      Guthrie M, Cardenas D, Eschbach JW, et al. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 1993; 39:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/9\">",
"      Davenport A. The effect of treatment with recombinant human erythropoietin on skeletal muscle function in patients with end-stage renal failure treated with regular hospital hemodialysis. Am J Kidney Dis 1993; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/10\">",
"      Davenport A, King RF, Ironside JW, et al. The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis. Nephron 1993; 64:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/11\">",
"      Thompson CH, Kemp GJ, Taylor DJ, et al. No effect of blood transfusion on muscle metabolism. Q J Med 1992; 85:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/12\">",
"      Lejkis, MJ, McKenna, MJ, Petersen, AC, et al. Exercise performance falls over time in patients with chronic kidney disease despite maintenance of hemoglobin concentration. Clin J AmSoc Nephrol 2006; 1:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/13\">",
"      Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000; 160:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/14\">",
"      Llach, F, Prados, MD, Hervas, J, et al. Vitamin D insufficiency and secondary hyperparathyroidism in 210 patients with CKD 2, 3, and 4 (abstract). J Am Soc Nephrol 2005; 16:756A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/15\">",
"      Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/16\">",
"      Ure&ntilde;a P, Kong XF, Abou-Samra AB, et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 1993; 133:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/17\">",
"      Ritz E, Stefanski A, Rambausek M. The role of the parathyroid glands in the uremic syndrome. Am J Kidney Dis 1995; 26:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/18\">",
"      Chou FF, Lee CH, Chen JB. General weakness as an indication for parathyroid surgery in patients with secondary hyperparathyroidism. Arch Surg 1999; 134:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/19\">",
"      Joborn C, Rastad J, St&aring;lberg E, et al. Muscle function in patients with primary hyperparathyroidism. Muscle Nerve 1989; 12:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/20\">",
"      Tawney, KW, Dinwiddie, L, Schrodt, et al. Changes in upper extremity function associated with vascular access creation. J Am Soc Nephrol 2001; 12:251A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/21\">",
"      Oder TF, Teodorescu V, Uribarri J. Effect of exercise on the diameter of arteriovenous fistulae in hemodialysis patients. ASAIO J 2003; 49:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/22\">",
"      Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/23\">",
"      Kopple JD. The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure. Miner Electrolyte Metab 1992; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/24\">",
"      Johannsson G, Bengtsson BA, Ahlm&eacute;n J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999; 33:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/25\">",
"      Iglesias P, D&iacute;ez JJ. Recombinant human growth hormone therapy in adult dialysis patients. Int J Artif Organs 2000; 23:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/26\">",
"      Diesel W, Emms M, Knight BK, et al. Morphologic features of the myopathy associated with chronic renal failure. Am J Kidney Dis 1993; 22:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/27\">",
"      Moore GE, Parsons DB, Stray-Gundersen J, et al. Uremic myopathy limits aerobic capacity in hemodialysis patients. Am J Kidney Dis 1993; 22:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/28\">",
"      Campistol JM. Uremic myopathy. Kidney Int 2002; 62:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/29\">",
"      Sun DF, Chen Y, Rabkin R. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 2006; 70:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/30\">",
"      Johansen KL, Shubert T, Doyle J, et al. Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. Kidney Int 2003; 63:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/31\">",
"      Clyne N, Esbj&ouml;rnsson M, Jansson E, et al. Effects of renal failure on skeletal muscle. Nephron 1993; 63:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/32\">",
"      Painter P, Taylor J, Wolcott S, et al. Exercise capacity and muscle structure in kidney recipient and twin donor. Clin Transplant 2003; 17:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/33\">",
"      Sakkas GK, Sargeant AJ, Mercer TH, et al. Changes in muscle morphology in dialysis patients after 6 months of aerobic exercise training. Nephrol Dial Transplant 2003; 18:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/34\">",
"      Painter P, Carlson L, Carey S, et al. Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis 2000; 35:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/35\">",
"      Lo CY, Li L, Lo WK, et al. Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1998; 32:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/36\">",
"      DePaul V, Moreland J, Eager T, Clase CM. The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial. Am J Kidney Dis 2002; 40:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/37\">",
"      Mustata S, Chan C, Lai V, Miller JA. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. J Am Soc Nephrol 2004; 15:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/38\">",
"      van Vilsteren MC, de Greef MH, Huisman RM. The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. Nephrol Dial Transplant 2005; 20:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/39\">",
"      Cheema B, Abas H, Smith B, et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: the Progressive Exercise for Anabolism in Kidney Disease (PEAK) study. Am J Kidney Dis 2007; 50:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/40\">",
"      Clyne N. The importance of exercise training in predialysis patients with chronic kidney disease. Clin Nephrol 2004; 61 Suppl 1:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/41\">",
"      Boyce ML, Robergs RA, Avasthi PS, et al. Exercise training by individuals with predialysis renal failure: cardiorespiratory endurance, hypertension, and renal function. Am J Kidney Dis 1997; 30:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/42\">",
"      Castaneda C, Gordon PL, Uhlin KL, et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 2001; 135:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/43\">",
"      Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/44\">",
"      Painter P, Hanson P, Messer-Rehak D, et al. Exercise tolerance changes following renal transplantation. Am J Kidney Dis 1987; 10:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/45\">",
"      Bohannon RW, Hull D, Palmeri D. Muscle strength impairments and gait performance deficits in kidney transplantation candidates. Am J Kidney Dis 1994; 24:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/46\">",
"      Bohannon RW, Smith J, Hull D, et al. Deficits in lower extremity muscle and gait performance among renal transplant candidates. Arch Phys Med Rehabil 1995; 76:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/47\">",
"      Kempeneers G, Noakes TD, van Zyl-Smit R, et al. Skeletal muscle limits the exercise tolerance of renal transplant recipients: effects of a graded exercise training program. Am J Kidney Dis 1990; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/48\">",
"      Painter P. Exercise after renal transplantation. Adv Ren Replace Ther 1999; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/49\">",
"      Horber FF, Hoppeler H, Herren D, et al. Altered skeletal muscle ultrastructure in renal transplant patients on prednisone. Kidney Int 1986; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/50\">",
"      PERKOFF GT, SILBER R, TYLER FH, et al. Studies in disorders of muscle. XII. Myopathy due to the administration of therapeutic amounts of 17-hydroxycorticosteroids. Am J Med 1959; 26:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/51\">",
"      Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983; 18:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/52\">",
"      Cushing, H. Basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/53\">",
"      Topp KS, Painter PL, Walcott S, et al. Alterations in skeletal muscle structure are minimized with steroid withdrawal after renal transplantation. Transplantation 2003; 76:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/54\">",
"      Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/55\">",
"      Horber FF, Scheidegger JR, Gr&uuml;nig BE, Frey FJ. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 1985; 15:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/56\">",
"      Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med 1999; 340:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/57\">",
"      Miller BW, Cress CL, Johnson ME, et al. Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis 2002; 39:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20136/abstract/58\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7324 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20136=[""].join("\n");
var outline_f19_42_20136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Androgen abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vitamin D metabolism and secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dialysis access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dialysis-related L-carnitine disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recombinant human growth hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Uremic myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effects of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adverse drug effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Steroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Effects of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CKD prior to dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Androgen deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=related_link\">",
"      Carnitine metabolism in renal disease and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36484?source=related_link\">",
"      Reproductive and sexual dysfunction in uremic women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20951?source=related_link\">",
"      Sexual dysfunction in uremic men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2643?source=related_link\">",
"      Uremic mononeuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14773?source=related_link\">",
"      Uremic polyneuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_42_20137="Gastrointestinal toxicity of radiation therapy";
var content_f19_42_20137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastrointestinal toxicity of radiation therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Brian G Czito, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Jeffrey J Meyer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20137/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/42/20137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal toxicity can occur following irradiation of thoracic, abdominal, or pelvic malignancies whenever normal gastrointestinal structures are located within the radiation therapy (RT) field. These toxicities can limit the maximum dose of RT and chemotherapy, and thus may limit the efficacy of treatment.",
"   </p>",
"   <p>",
"    The gastrointestinal side effects of RT include early (acute) toxicity, such as diarrhea and nausea, that are experienced during or shortly after the completion of a course of therapy. In addition, late effects may be observed months to years after RT. These late reactions include ulceration, stricture formation, and bowel obstruction.",
"   </p>",
"   <p>",
"    The adverse effects of radiation on the esophagus, stomach, small and large intestine, anus, and liver are discussed here. Radiation proctitis, which is of particular concern in the treatment of prostate cancer and selected gynecologic malignancies, is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESOPHAGITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis and clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal esophageal mucosa undergoes continuous cell turnover and renewal. Acute radiation esophagitis is primarily due to effects on the basal epithelial layer. This causes a thinning of the mucosa, which can progress to denudation.",
"   </p>",
"   <p>",
"    Acute toxicity is manifested clinically as dysphagia, odynophagia, and substernal discomfort, and usually occurs within two to three weeks after the initiation of RT. Patients may describe a sudden, sharp, severe chest pain radiating to the back. The symptoms of acute radiation esophagitis may be confused with Candida esophagitis, which can occur as a complication of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\", section on 'Esophageal candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopically, mucositis and ulceration may be observed, although acute toxicity rarely causes esophageal perforation or bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/1\">",
"     1",
"    </a>",
"    ]. After completion of treatment, basal proliferation and regeneration occur, usually within three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The late effects of RT are believed to be due to inflammation and scar formation within the esophageal musculature. Histologic studies in previously irradiated patients have shown epithelial thickening, chronic inflammation, and submucosal or muscularis fibrosis.",
"   </p>",
"   <p>",
"    Late effects typically are seen three months or more after completion of RT, with a median time to onset of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Clinical manifestations can include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysphagia, which may be secondary to stricture or altered motility caused by",
"      <span class=\"nowrap\">",
"       fibrosis/muscular",
"      </span>",
"      damage or nerve injury",
"     </li>",
"     <li>",
"      Chronic ulceration, which is less uncommon and appears to be related to the total dose of radiation",
"     </li>",
"     <li>",
"      Fistula formation, which is rare",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    swallow may demonstrate disrupted peristalsis, with repetitive, nonperistaltic waves above and below the irradiated segment of the esophagus. Evidence of abnormal peristalsis may be observed as early as one to three months after completion of treatment. Barium swallow is also useful to diagnose strictures, most of which are diagnosed four to eight months after RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RT dose and technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique used for RT administration, the radiation dose to the esophagus, and the use of concurrent chemotherapy all influence the likelihood of esophageal complications.",
"   </p>",
"   <p>",
"    The dose-response relationship for the development of late, treatment-related complications was initially established in patients treated for esophageal cancer. In this setting, the dose at which 5 percent of patients will develop complications at five years (the",
"    <span class=\"nowrap\">",
"     TD5/5)",
"    </span>",
"    was estimated to be 60 Gy when one-third of the esophageal length was irradiated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brachytherapy has also been used alone or in conjunction with external beam RT to treat esophageal cancer. There are conflicting results about the safety of adding brachytherapy to external beam RT, with at least one report suggesting an increased risk of fistula formation. The results of these studies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30106?source=see_link&amp;anchor=H31#H31\">",
"     \"Management of locally advanced unresectable esophageal cancer\", section on 'Brachytherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional information about the dose-response relationship for esophageal toxicity has been derived from contemporary studies that used conformal RT techniques in patients with non-small cell lung cancer. These studies also provide insight into the effect of concurrent chemotherapy and the impact of delivering RT on a hyperfractionated schedule.",
"   </p>",
"   <p>",
"    These results are illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 91 patients who were treated with high-dose conformal RT, the percentage of esophageal volume and surface area treated to &gt;50 Gy predicted late esophageal toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients who had preexisting gastroesophageal reflux disease or esophageal erosion secondary to tumor were at increased risk. Hyperfractionation was associated with increased incidence of acute toxicity.",
"     </li>",
"     <li>",
"      A study of 207 patients who received conformal daily RT with or without concurrent chemotherapy found that a maximal esophageal 'point' dose of 69 Gy with RT alone and 58 Gy with concurrent chemotherapy predicted significant esophageal toxicity. Severe toxicity was more common in those receiving concurrent chemotherapy (26 versus 1 percent with RT alone) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple trials conducted by the Radiation Therapy Oncology Group (RTOG) found that the incidence of severe esophageal toxicity was significantly increased when chemotherapy was given concurrently with hyperfractionated RT, compared to sequential use of chemotherapy followed by RT or to sequential and concurrent chemotherapy with once daily RT (34 versus 1 and 6 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute esophagitis is managed symptomatically. Although interruption of RT is occasionally necessary because of severe symptoms, this approach may compromise treatment efficacy and should be avoided whenever possible.",
"   </p>",
"   <p>",
"    Treatment measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical anesthetics (viscous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ), analgesics (antiinflammatory agents, narcotics), antacid therapy (proton pump inhibitors, H2 receptor blockers), and promotility agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Dietary modification (bland, pureed, or soft foods, soups), to help a patient maintain adequate caloric and liquid intake [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/12\">",
"       12",
"      </a>",
"      ]. Eating more frequent, smaller meals, and avoiding foods that are very hot or very cold may also be useful. Avoidance of smoking, alcohol, coffee, spicy or acidic foods or liquids, chips, crackers, fatty, and indigestible foods can be helpful.",
"     </li>",
"     <li>",
"      Treatment of any superimposed candida infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations of oropharyngeal and esophageal candidiasis\", section on 'Esophageal candidiasis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Esophageal strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal strictures are generally managed with endoscopic dilation. This approach usually results in symptomatic improvement, although multiple dilations may be required. Extended use of antacid therapy and prokinetic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ) has been recommended to decrease reflux and the likelihood of restenosis. Tube feedings are only rarely required for patients with significant weight loss or those able to ingest only liquids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dilation of a stricture can cause esophageal rupture and this approach should be used with caution. Surgical intervention may be required for patients who develop a perforation or fistula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=see_link\">",
"     \"Complications of endoscopic esophageal stricture dilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal strictures or ulcerations due to chronic radiation changes must be differentiated from malignancy, since the clinical symptoms associated with late radiation side effects are often difficult to distinguish from those caused by a recurrent or new cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various chemopreventive agents have been investigated to reduce radiation-induced normal tissue toxicity, although none has an established role in preventing esophageal toxicity.",
"   </p>",
"   <p>",
"    The best studied of these is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    , a free radical scavenger. Amifostine has an established role in preventing some of the acute toxicities associated with radiation therapy in head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454217#H722454217\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Amifostine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GASTRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rat models, a single fraction of high-dose radiation caused an erosive or ulcerative gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/13\">",
"     13",
"    </a>",
"    ]. Lower single doses (23 Gy) caused stomach dilation and gastroparesis, with replacement of the normal mucosa by hyperkeratinized squamous epithelium. At still lower doses, gastric obstruction was observed, occurring months after irradiation with atrophic mucosa and intestinal metaplasia seen in surviving animals.",
"   </p>",
"   <p>",
"    In man, irradiation of the stomach as a consequence of treatment of a range of tumors can cause early",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed toxicity. Historically, low doses of RT were also used to decrease acid production in patients with peptic ulcer disease. Serial biopsies in this setting found coagulation necrosis of chief and parietal cells and mucosal thinning, edema, and chronic inflammatory infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early clinical effects of stomach irradiation include nausea, vomiting, dyspepsia, anorexia, abdominal pain, and malaise. This may be accompanied by evidence of acute ulceration, occurring shortly after completion of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/15\">",
"     15",
"    </a>",
"    ]. These effects may be exacerbated by the concurrent administration of chemotherapy. Symptoms generally resolve within one to two weeks following completion of RT.",
"   </p>",
"   <p>",
"    Nausea and vomiting may occur within 24 hours after the start of treatment. Approximately one-half of patients receiving upper abdominal irradiation will experience emesis within two to three weeks of the start of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea and vomiting are generally managed with antiemetics. Eating a light meal prior to each course of RT may also be helpful. The management of radiation-induced nausea and vomiting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3847?source=see_link\">",
"     \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain can be treated with narcotic and non-narcotic analgesic agents as needed. Additionally, patients should be placed on antacid medications, including a proton pump inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Late",
"    </span>",
"    &nbsp;&mdash;&nbsp;The late effects of gastric irradiation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic gastritis, manifested by smoothened mucosal folds and mucosal atrophy on endoscopy accompanied by radiographic evidence of antral stenosis, one to 12 months after irradiation",
"     </li>",
"     <li>",
"      Dyspepsia, consisting of vague gastric symptoms without obvious clinical correlate, which is usually reported six months to four years after treatment",
"     </li>",
"     <li>",
"      Late ulceration, averaging five months after irradiation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late gastritis-related symptoms are often treated with antacids, H2 receptor antagonists, proton pump inhibitors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    . These may be helpful on a long-term basis to avoid late ulceration.",
"   </p>",
"   <p>",
"    In rare instances, surgery is required to treat severe bleeding, ulceration, gastric outlet obstruction, fistula formation, or perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     RT dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     TD5/5",
"    </span>",
"    (the dose at which 5 percent of patients develop complications at five years) when the entire stomach is irradiated is estimated to be 50 Gy. The risk of late effects appears to be increased when larger dose fractions are used or when the patient has had prior abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of RT dose on the incidence of toxicity is illustrated by a retrospective series of 233 men who received abdominal irradiation as part of their treatment for testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/18\">",
"     18",
"    </a>",
"    ]. Higher RT doses led to an increased risk of late gastric or duodenal ulceration and perforation (6, 10, and 38 percent with doses of 40 to 50, 50 to 60, and greater than 60 Gy, respectively). No ulceration was seen in patients treated with less than 45 Gy. Other series have reported similar results for patients who received RT for Hodgkin lymphoma, gastric cancer, or esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concurrent chemotherapy decreases the tolerance of the gastric mucosa to radiation. Chemotherapy is integrated into the management of patients with cancers of the gastroesophageal junction, stomach, pancreas, and biliary tract. The most common agent delivered concurrently with RT for these malignancies is 5-fluorouracil (5-FU). Although 5-FU is a radiation sensitizer, it has been given with RT at doses of 45 to 50 Gy without substantial increases in toxicity.",
"   </p>",
"   <p>",
"    Acute gastric side effects are increased when RT is given with newer systemic agents, such as taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , and epidermal growth factor tyrosine kinase inhibitors. Chemoradiotherapy regimens containing these agents remain the subject of active investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIATION ENTERITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT can cause an acute injury to the small and large intestines that develops during or shortly after treatment of a variety of malignancies. The initial toxicity generally resolves within a matter of weeks, but chronic changes can develop months or years after therapy. The pathogenesis, clinical manifestations, and factors associated with an increased risk of chronic radiation enteritis are discussed here, while its diagnosis and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=see_link\">",
"     \"Diagnosis and management of chronic radiation enteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation proctitis occurs when the radiation injury predominantly involves the rectum. The diagnosis, treatment, and prevention of radiation proctitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal epithelium has a high proliferative rate, making it susceptible to injury from both radiation and chemotherapy. The primary effect of radiation is on mucosal stem cells within the crypts of Lieberkuhn. Stem cell damage, either acutely as a direct consequence of radiation or subsequently as a result of microvascular damage, leads to a decrease in cellular reserves for the intestinal villi, resulting in mucosal denudement with associated intestinal inflammation and edema, shortened villi, and decreased absorptive area.",
"   </p>",
"   <p>",
"    The initial histologic evidence of damage is seen within hours of irradiation. This is followed by an infiltration of leukocytes with crypt abscess formation within two to four weeks; ulceration may also occur. Subsequent changes include a progressive occlusive vasculitis with foam cell invasion of the intima and hyaline thickening of the arteriolar walls, as well as collagen deposition and fibrosis, often in the submucosal layer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The small bowel becomes thickened [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/22\">",
"     22",
"    </a>",
"    ]. The vessel walls of small arterioles are obliterated, causing ischemia. Lymphatic damage results in constriction of the lymphatic channels, which contributes to mucosal edema and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/23\">",
"     23",
"    </a>",
"    ]. The mucosa is atrophied, with atypical hyperplastic glands and intestinal wall fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/24\">",
"     24",
"    </a>",
"    ]. Telangiectasias may be present and can cause bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mucosal ulcerations may be present and can progress to perforation, fistulae, or abscess formation. As the ulcers heal, there can be fibrosis with narrowing of the intestinal lumen and stricture formation or even obstruction. Even if the intestine appears normal, patients are at risk of spontaneous perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These chronic changes can impair absorption of fats, carbohydrates, protein, bile salts, and vitamin B12, leading to loss of water, electrolytes, and protein in the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Lactose degradation may be impaired, which can lead to increased bacterial fermentation and associated flatulence, abdominal distention, and diarrhea, possibly accompanied by bacterial overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/28\">",
"     28",
"    </a>",
"    ]. There is also evidence of altered gut motility acutely following RT. Bile salt resorption may be impaired, causing increased amounts of conjugated bile salts to enter the colon. These bile salts are then deconjugated by bacteria, resulting in intraluminal water retention with resultant diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute radiation enteritis experience diarrhea, abdominal pain, nausea and vomiting, anorexia, and malaise. Radiation-induced diarrhea often appears during the third week of treatment, with reports of frequency ranging from 20 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/29\">",
"     29",
"    </a>",
"    ]. Diarrhea may occur after doses of 18 to 22 Gy delivered using conventional fractionation and will occur in most patients who receive doses of 40 Gy.",
"   </p>",
"   <p>",
"    The symptoms subside as the acute pathologic effects resolve and typically disappear two to six weeks after the completion of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/30\">",
"     30",
"    </a>",
"    ]. There is some evidence that patients who develop acute intestinal toxicity are at increased risk for chronic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chronic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late radiation effects typically are manifested 8 to 12 months after RT, although toxicity may not appear until years later in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. In some cases, the clinical manifestations of chronic radiation enteritis worsen over time.",
"   </p>",
"   <p>",
"    Late effects include malabsorption and diarrhea, with more rapid transit times occurring in the affected bowel. In rare cases, chronic malnutrition may develop, resulting in anemia and hypoalbuminemia. Bleeding from ulceration and pain and bloating from strictures, as well as fevers from abscess formation, may be present. Patients with severe disease may develop intermittent, partial or complete small bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacterial overgrowth causes malabsorption and contributes to the nausea, abdominal pain and diarrhea. Bacterial overgrowth should be suspected in patients with intestinal strictures. The new onset of lactose intolerance also suggests bacterial overgrowth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"     \"Treatment of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonspecific symptoms of chronic radiation enteritis include diarrhea, bloating, excessive gas, borborygmi, and nausea. Rare patients with severe malabsorption may present with a severe clinical and laboratory profile. A high index of suspicion is required to establish the diagnosis since most patients have only subtle laboratory or clinical findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, vitamin B12 deficiency has been observed in cervical cancer survivors who were previously treated with pelvic RT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/34\">",
"     34",
"    </a>",
"    ]. In a series of 55 patients assessed 6 to 11 years after RT, significant B12 deficiency was identified in 11 (20 percent).",
"   </p>",
"   <p>",
"    The large intestine is generally believed to be less radiosensitive than the small intestine. When radiation injury does involve the colon, patients can develop a pancolitis that mimics inflammatory bowel disease. Prior pelvic irradiation is also associated with an increased risk of rectal cancer in subsequent years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors can affect the risk of developing radiation enteritis, including the dose of radiation to the intestines and the use of concomitant chemotherapy",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dose and schedule of RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total RT dose, fraction size, treatment duration, and volume of intestine within the RT field all influence the likelihood of enterotoxicity.",
"   </p>",
"   <p>",
"    The radiation dose at which 5 percent of patients will develop complications at five years",
"    <span class=\"nowrap\">",
"     (TD5/5)",
"    </span>",
"    for limited volumes of small bowel is estimated to be 50 Gy. Significant intestinal toxicity is rare when treatment is limited to 45 to 50 Gy in 1.8 to 2.0 Gy daily fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicity is more frequent in patients who have had abdominal surgery. In one series, surgery was required for small bowel obstruction in approximately 5 percent of postoperative patients who had received 45 to 50 Gy of RT over five weeks; the incidence rose to 25 to 50 percent at doses &gt;50 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/37\">",
"     37",
"    </a>",
"    ]. Dose fractions &gt;2 Gy also increase the risk of toxicity in the postoperative setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining chemotherapy with RT increases the risk of radiation enteritis. Several studies in patients treated with 5-FU-based chemoradiotherapy for rectal cancer have found a strong correlation between acute toxicity and the amount of small bowel irradiated at each dose level analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Limiting the volume of small bowel receiving &gt;15 Gy may decrease the occurrence of severe diarrhea and improve treatment tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New chemotherapy agents and molecularly targeted agents are being evaluated in combination with RT in the neoadjuvant treatment of gastrointestinal cancers. Data from phase I and II studies suggest that integration of agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and EGFR inhibitors with RT may significantly increase the frequency of severe gastrointestinal toxicity compared to 5-FU-based regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that decrease bowel mobility within the abdomen increase the amount of radiation delivered to a specific segment of the intestines. This increased focal irradiation can cause increased toxicity.",
"   </p>",
"   <p>",
"    Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women, older patients, and thin patients, who may have more small bowel in the pelvic cul-de-sac [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prior abdominal or pelvic surgery, which can cause adhesions that limit intestinal mobility [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Previous pelvic inflammatory disease or endometriosis that may result in scarring and decreased bowel mobility [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contemporary treatment techniques that allow direct visualization of the intestines as a part of treatment planning may minimize the risks in these groups.",
"   </p>",
"   <p>",
"    Preexisting vascular disease due to diabetes, hypertension, or atherosclerosis can increase the risk of radiation-induced enteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/50\">",
"     50",
"    </a>",
"    ]. The pretreatment abnormalities are exacerbated by the pathologic changes of chronic radiation injury, which include vasculitis obliterans and ischemia.",
"   </p>",
"   <p>",
"    Patients with collagen vascular disease (eg, rheumatoid arthritis, systemic lupus erythematosus, polymyositis) or inflammatory bowel disease have a lower gastrointestinal tolerance to radiation and an increased risk of acute and chronic radiation-induced injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. The late effects induced by RT can be additive to these preexisting changes that include transmural fibrosis, collagen deposition, and inflammatory infiltration of the mucosa. Patients whose comorbid disease is quiescent or well controlled appear to fare better than patients with active disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT planning techniques that minimize the amount of small bowel within the treatment fields are used to decrease toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/55\">",
"     55",
"    </a>",
"    ]. Treating patients in the prone position with a 'false tabletop'",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bladder distension may decrease side effects by excluding portions of the bowel from the RT field. Another study treating patients postoperatively with RT to the pelvis noted a decrease in small bowel toxicity when patients were placed in the decubitus position [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic use of various medical approaches has failed to reduce the incidence or severity of acute radiation enterotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RADIATION PROCTITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation proctitis is usually encountered following treatment of cancers of the anus, rectum, cervix, uterus, prostate, urinary bladder, and testes. Radiation proctitis is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ANUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anal canal is typically spared from significant radiation exposure except when RT is used to treat anal, low rectal, or gynecologic cancers. In these settings, the acute toxicity includes diarrhea caused by exposure of the rectum to irradiation. Damage to the anus itself can cause mucosal edema and friability, which can progress to desquamation or ulceration. These changes may be exacerbated by diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doses of 45 to 60 Gy in fractions of 1.8 to 2.0 Gy are considered safe, resulting in severe toxicity in 0 to 22 percent of cases. Doses above 65 Gy or fraction size above 2 Gy result in a higher incidence of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/58\">",
"     58",
"    </a>",
"    ]. There does not appear to be an increase in chronic anal toxicity when chemotherapy is combined with RT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/59-70\">",
"     59-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HIV who are treated with combined chemotherapy and RT have an increased risk of acute and late anal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Acute toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute anal toxicity presents as a perianal skin reaction that ranges from minimal skin changes to moist desquamation and erythema.",
"   </p>",
"   <p>",
"    Treatment of acute toxicity is supportive and includes proper skin care, dietary modifications, pain medications, and topical corticosteroids. The acute RT side effects are generally self-limited, and usually resolve within weeks after the end of therapy. However, treatment interruptions may be required if toxicity is severe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/57,60,72\">",
"     57,60,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute toxicity is relatively common, and its incidence is increased with concurrent chemotherapy or large RT fraction size [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/58,61,73,74\">",
"     58,61,73,74",
"    </a>",
"    ]. Conformal RT techniques may significantly decrease the incidence of skin toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/72,75\">",
"     72,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Late toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late toxicity can appear months to years after completion of therapy. The most common late complication is anorectal ulceration. For severe or refractory ulcerations, case reports have suggested that hyperbaric oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/76\">",
"     76",
"    </a>",
"    ] or oral vital A [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/57\">",
"     57",
"    </a>",
"    ] may be useful in treating anorectal ulcerations.",
"   </p>",
"   <p>",
"    Anal strictures or stenosis, anal incontinence, pain, or anorectal fistulae may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/58,59,61,66\">",
"     58,59,61,66",
"    </a>",
"    ]. Sphincter dilation is the standard treatment for anal strictures or stenosis. Rare patients may require a colostomy if symptoms are severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     HEPATIC TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of radiation-induced liver disease is not fully understood. Radiation hepatitis is manifested by venoocclusive disease with central vein thrombosis at the lobular level. This results in retrograde congestion leading to hemorrhage and secondary alterations in surrounding hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/77\">",
"     77",
"    </a>",
"    ]. Acute radiation hepatitis can be fatal, and hepatic toxicity can progress to fibrosis, cirrhosis, and liver failure.",
"   </p>",
"   <p>",
"    Fibrin deposition in the central veins is thought to be the cause of the venoocclusive injury. The etiology of the fibrin deposition is unknown. TGF-beta is increased during exposure to radiation, and this may stimulate fibroblast migration to the site of injury, causing fibrin and collagen deposition. Foci of necrosis are found in the affected portion of the lobules [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, radiation-induced liver disease causes anicteric hepatomegaly, ascites, and elevated liver enzymes. Alkaline phosphatase levels are often elevated out of proportion to the transaminases or bilirubin. This typically occurs from two weeks to four months after completion of RT. Patients note fatigue, weight gain, increased abdominal girth, and occasionally right upper quadrant pain. Abdominal imaging with CT scan or MRI can be useful in establishing the diagnosis.",
"   </p>",
"   <p>",
"    The likelihood of radiation-induced hepatic disease is directly related to the extent of liver irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/78\">",
"     78",
"    </a>",
"    ]. Radiation hepatitis occurs in approximately 5 percent of patients when the dose of radiation to the whole liver reaches 30 to 35 Gy in 2 Gy fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Significantly higher doses can be given safely if sufficient normal liver is not irradiated. The doses of radiation associated with a 5 percent risk of hepatitis for irradiation of one-third, two-thirds, and the whole liver are estimated to be 90 Gy, 47 Gy, and 31 Gy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combining chemotherapy and radiation can increase liver damage, particularly when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    or platinum agents are used. This is a particular problem when RT is part of the conditioning regimen for bone marrow transplantation. In contrast, fluoropyrimidines do not seem to increase radiation-related hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20137/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal toxicity is a significant problem in the management of many malignancies when treatment includes radiation therapy (RT) to the thorax, abdomen, or pelvis. In addition to the risk of causing damage to normal tissues, the constraints on RT dose potentially limit tumor control.",
"   </p>",
"   <p>",
"    Minimizing irradiation of normal tissue is an important goal for the radiation oncologist. Multiple techniques are used to decrease the volumes of non-target gastrointestinal tissues treated, including the use of multiple treatment fields to avoid 'hot-spots', treating in the prone position, use of a 'belly-board' or false table-top, as well as treating with a full bladder to displace bowel out of the RT field.",
"   </p>",
"   <p>",
"    Improved imaging and computer capabilities have made three-dimensional (3D) treatment planning widely available, in contrast to the two-dimensional approaches used in the past. Intensity modulated radiation therapy (IMRT), an advanced from of 3D planning, is gaining wider acceptance and utilization and may permit further dose escalation while decreasing toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/1\">",
"      Chowhan NM. Injurious effects of radiation on the esophagus. Am J Gastroenterol 1990; 85:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/2\">",
"      Phillips TL, Ross G. Time-dose relationships in the mouse esophagus. Radiology 1974; 113:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/3\">",
"      O'Rourke IC, Tiver K, Bull C, et al. Swallowing performance after radiation therapy for carcinoma of the esophagus. Cancer 1988; 61:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/4\">",
"      Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995; 31:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/5\">",
"      Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/6\">",
"      SEAMAN WB, ACKERMAN LV. The effect of radiation on the esophagus; a clinical and histologic study of the effects produced by the betatron. Radiology 1957; 68:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/7\">",
"      Morichau-Beauchant M, Touchard G, Battandier D, et al. [Chronic radiation-induced esophagitis after treatment of oropharyngolaryngeal cancer: a little-known anatomo-clinical entity]. Gastroenterol Clin Biol 1983; 7:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/8\">",
"      Kramer, S, Gelberr, R, Snow, J. Preopertive versus postoperative radiation therapy in advanced squamous cell carcinoma of the head and neck: Final report on RTOG 73-03. Am J Clin Oncol (CCT) 1983; 6:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/9\">",
"      Maguire PD, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/10\">",
"      Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/11\">",
"      Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998; 42:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/12\">",
"      Sasso FS, Sasso G, Marsiglia HR, et al. Pharmacological and dietary prophylaxis and treatment of acute actinic esophagitis during mediastinal radiotherapy. Dig Dis Sci 2001; 46:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/13\">",
"      Breiter N, Trott KR, Sassy T. Effect of X-irradiation on the stomach of the rat. Int J Radiat Oncol Biol Phys 1989; 17:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/14\">",
"      GOLDGRABER MB, RUBIN CE, PALMER WL, et al. The early gastric response to irradiation; a serial biopsy study. Gastroenterology 1954; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/15\">",
"      Sell A, Jensen TS. Acute gastric ulcers induced by radiation. Acta Radiol Ther Phys Biol 1966; 4:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/16\">",
"      Henriksson R, Bergstr&ouml;m P, Franz&eacute;n L, et al. Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Acta Oncol 1999; 38:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/17\">",
"      Cosset JM, Henry-Amar M, Burgers JM, et al. Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: emphasis on the role of exploratory laparotomy and fractionation. Radiother Oncol 1988; 13:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/18\">",
"      Hamilton CR, Horwich A, Bliss JM, Peckham MJ. Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother Oncol 1987; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/19\">",
"      Pearson JG. The present status and future potential of radiotherapy in the management of esophageal cancer. Cancer 1977; 39:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/20\">",
"      Gunderson LL, Hoskins RB, Cohen AC, et al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 1983; 9:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/21\">",
"      Hasleton PS, Carr N, Schofield PF. Vascular changes in radiation bowel disease. Histopathology 1985; 9:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/22\">",
"      Schofield PF, Carr ND, Holden D. Pathogenesis and treatment of radiation bowel disease: discussion paper. J R Soc Med 1986; 79:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/23\">",
"      Greenberger, N, Isselbacher, K. Malabsorption following radiation injury to the gastrointestinal tract. Am J Med 1964; 36:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/24\">",
"      Berthrong M, Fajardo LF. Radiation injury in surgical pathology. Part II. Alimentary tract. Am J Surg Pathol 1981; 5:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/25\">",
"      Galland RB, Spencer J. Spontaneous postoperative perforation of previously asymptomatic irradiated bowel. Br J Surg 1985; 72:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/26\">",
"      Yeoh E, Horowitz M, Russo A, et al. Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study. Am J Med 1993; 95:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/27\">",
"      Husebye E, Hauer-Jensen M, Kj&oslash;rstad K, Skar V. Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine. Dig Dis Sci 1994; 39:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/28\">",
"      Wedlake L, Thomas K, McGough C, Andreyev HJ. Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study. Eur J Cancer 2008; 44:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/29\">",
"      Classen J, Belka C, Paulsen F, et al. Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol 1998; 174 Suppl 3:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/30\">",
"      Hauer-Jensen M. Late radiation injury of the small intestine. Clinical, pathophysiologic and radiobiologic aspects. A review. Acta Oncol 1990; 29:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/31\">",
"      Buchler DA, Kline JC, Peckham BM, et al. Radiation reactions in cervical cancer therapy. Am J Obstet Gynecol 1971; 111:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/32\">",
"      Kwitko AO, Pieterse AS, Hecker R, et al. Chronic radiation injury to the intestine: a clinico-pathological study. Aust N Z J Med 1982; 12:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/33\">",
"      Sher ME, Bauer J. Radiation-induced enteropathy. Am J Gastroenterol 1990; 85:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/34\">",
"      Vistad I, Kristensen GB, Foss&aring; SD, et al. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2009; 73:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/35\">",
"      Kimura T, Iwagaki H, Hizuta A, et al. Colorectal cancer after irradiation for cervical cancer--case reports. Anticancer Res 1995; 15:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/36\">",
"      Kao MS. Intestinal complications of radiotherapy in gynecologic malignancy--clinical presentation and management. Int J Gynaecol Obstet 1995; 49 Suppl:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/37\">",
"      Letschert JG, Lebesque JV, Aleman BM, et al. The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol 1994; 32:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/38\">",
"      Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies. Results of the national practice in cancer of the cervix. Cancer 1983; 51:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/39\">",
"      Baglan KL, Frazier RC, Yan D, et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002; 52:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/40\">",
"      Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006; 66:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/41\">",
"      Gunnlaugsson A, Kjell&eacute;n E, Nilsson P, et al. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 2007; 46:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/42\">",
"      Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006; 24:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/43\">",
"      Cancer and Leukemia Group B 89901, Ryan DP, Niedzwiecki D, et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/44\">",
"      Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/45\">",
"      Louidice, T, Baxter, D, Bailint, J. Effects of abdominal surgery on the development of radiation enteropathy. Gastroenterol 1977; 73:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/46\">",
"      Green N. The avoidance of small intestine injury in gynecologic cancer. Int J Radiat Oncol Biol Phys 1983; 9:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/47\">",
"      Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/48\">",
"      Stockbrine, M, Hancock, J, Fletcher, G. Complications in 831 patients with squamous cell carcinoma of the intact uterine cervix treated with 3000 rads or more whole pelvis radiation. Am J Roentgenol 1970; 108:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/49\">",
"      Loiudice TA, Lang JA. Treatment of radiation enteritis: a comparison study. Am J Gastroenterol 1983; 78:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/50\">",
"      DeCosse JJ, Rhodes RS, Wentz WB, et al. The natural history and management of radiation induced injury of the gastrointestinal tract. Ann Surg 1969; 170:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/51\">",
"      Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist 2002; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/52\">",
"      Song DY, Lawrie WT, Abrams RA, et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2001; 51:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/53\">",
"      Willett CG, Ooi CJ, Zietman AL, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys 2000; 46:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/54\">",
"      Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008; 113:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/55\">",
"      Gallagher MJ, Brereton HD, Rostock RA, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 1986; 12:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/56\">",
"      Duttenhaver JR, Hoskins RB, Gunderson LL, Tepper JE. Adjuvant postoperative radiation therapy in the management of adenocarcinoma of the colon. Cancer 1986; 57:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/57\">",
"      Levitsky J, Hong JJ, Jani AB, Ehrenpreis ED. Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case. Dis Colon Rectum 2003; 46:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/58\">",
"      Mitchell SE, Mendenhall WM, Zlotecki RA, Carroll RR. Squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2001; 49:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/59\">",
"      Gabriele AM, Rovea P, Sola B, et al. Radiation therapy and chemotherapy in the conservative treatment of carcinoma of the anal canal: survival and late morbidity in a series of 25 patients. Anticancer Res 1997; 17:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/60\">",
"      Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/61\">",
"      Flam MS, John MJ, Mowry PA, et al. Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease. Dis Colon Rectum 1987; 30:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/62\">",
"      Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/63\">",
"      Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/64\">",
"      Rich TA, Ajani JA, Morrison WH, et al. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 1993; 27:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/65\">",
"      John M, Flam M, Palma N. Ten-year results of chemoradiation for anal cancer: focus on late morbidity. Int J Radiat Oncol Biol Phys 1996; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/66\">",
"      Peiffert D, Bey P, Pernot M, et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 1997; 37:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/67\">",
"      Cantril ST, Green JP, Schall GL, Schaupp WC. Primary radiation therapy in the treatment of anal carcinoma. Int J Radiat Oncol Biol Phys 1983; 9:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/68\">",
"      Eschwege F, Lasser P, Chavy A, et al. Squamous cell carcinoma of the anal canal: treatment by external beam irradiation. Radiother Oncol 1985; 3:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/69\">",
"      Tanum G, Tveit K, Karlsen KO, Hauer-Jensen M. Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 1991; 67:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/70\">",
"      John M, Pajak T, Flam M, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996; 2:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/71\">",
"      Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum 2001; 44:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/72\">",
"      Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007; 25:4581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/73\">",
"      Cummings B, Keane T, Thomas G, et al. Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. Cancer 1984; 54:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/74\">",
"      Myerson RJ, Kong F, Birnbaum EH, et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol 2001; 61:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/75\">",
"      Vuong T, Devic S, Belliveau P, et al. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys 2003; 56:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/76\">",
"      Bem J, Bem S, Singh A. Use of hyperbaric oxygen chamber in the management of radiation-related complications of the anorectal region: report of two cases and review of the literature. Dis Colon Rectum 2000; 43:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/77\">",
"      Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005; 15:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/78\">",
"      OGATA K, HIZAWA K, YOSHIDA M, et al. HEPATIC INJURY FOLLOWING IRRADIATION--A MORPHOLOGIC STUDY--. Tokushima J Exp Med 1963; 43:240.",
"     </a>",
"    </li>",
"    <li>",
"     Constine, L, Williams, J, Morris, M, et al. Late effects of cancer treatment on normal tissue: Lippincott; 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/80\">",
"      Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20137/abstract/81\">",
"      Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992; 23:781.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7054 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20137=[""].join("\n");
var outline_f19_42_20137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESOPHAGITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RT dose and technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute esophagitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GASTRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acute",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Late",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RT dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIATION ENTERITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Acute",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chronic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dose and schedule of RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RADIATION PROCTITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ANUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Acute toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Late toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HEPATIC TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=related_link\">",
"      Complications of endoscopic esophageal stricture dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=related_link\">",
"      Diagnosis and management of chronic radiation enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30106?source=related_link\">",
"      Management of locally advanced unresectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3847?source=related_link\">",
"      Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_42_20138="Role of stress testing after coronary revascularization";
var content_f19_42_20138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of stress testing after coronary revascularization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Georgios I Papaioannou, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Gary V Heller, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/42/20138/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/42/20138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 10, 2008.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive stress testing is an important tool in the evaluation and assessment of patients prior to coronary revascularization. In addition, stress testing is useful for identifying patients with recurrent ischemia after revascularization with either percutaneous coronary intervention (PCI, with or without stenting) or coronary artery bypass graft surgery (CABG).",
"   </p>",
"   <p>",
"    The possible necessity for stress testing after coronary revascularization is based upon two observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possible presence of incomplete revascularization, since certain lesions or arteries may not be amenable to PCI or CABG.",
"     </li>",
"     <li>",
"      The late occurrence of restenosis at PCI sites, the development of new disease in bypass grafts, and the progression of native coronary disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion focuses on evidence from clinical trials regarding the appropriate use of stress testing, particularly stress radionuclide myocardial perfusion imaging (rMPI) or stress echocardiography, in patients who have undergone a revascularization procedure. Current guidelines and how they can be translated into clinical practice will also be reviewed.",
"   </p>",
"   <p>",
"    The use of imaging prior to revascularization to detect hibernating myocardium (ie, dysfunctional but viable myocardium) and general considerations on the role of stress testing for the diagnosis and prognosis of coronary heart disease (CHD) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES OF STRESS TEST PERFORMANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will review some general issues of stress test performance, why the specific needs are different in patients who have undergone revascularization, and why stress rMPI may be preferable to stress echocardiography. Specific data on test performance in patients who have undergone PCI or CABG are presented in the relevant sections below.",
"   </p>",
"   <p>",
"    Guidelines from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association task forces on the management of chronic stable angina and exercise testing recommend exercise ECG testing as the initial test of choice in most patients with known or suspected CHD who are able to exercise adequately and who do not have baseline ECG abnormalities that might interfere with interpretation of the test (",
"    <a class=\"graphic graphic_table graphicRef74054 \" href=\"UTD.htm?23/59/24508\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, when stress testing is performed for diagnosis among patients who have undergone either PCI or CABG, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend exercise stress with imaging using radionuclide myocardial perfusion imaging or echocardiography for patients who are able to exercise and vasodilator (adenosine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ) rMPI or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography for patients who cannot (",
"    <a class=\"graphic graphic_table graphicRef52995 \" href=\"UTD.htm?17/42/18093\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Similar recommendations were made for risk stratification to assess the functional significance of coronary lesions, if not already known, when PCI is planned (",
"    <a class=\"graphic graphic_table graphicRef74428 \" href=\"UTD.htm?32/46/33516\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two main reasons for recommending stress testing with imaging rather than exercise ECG testing after coronary revascularization. The data supporting these conclusions are presented in the next section:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitivity of an evaluation to identify ischemia is significantly lower with exercise ECG testing alone compared to imaging after revascularization.",
"     </li>",
"     <li>",
"      There is a need to document both the site and extent of ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radionuclide myocardial perfusion imaging versus echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide myocardial perfusion imaging and echocardiography are both useful approaches to the evaluation of patients with CHD. The choice of test may rest upon local expertise and local availability as well as the clinical scenario.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     General use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data evaluating the use of exercise or pharmacologic stress radionuclide myocardial perfusion imaging and echocardiography are discussed in detail separately. Perhaps the most serious obstacle to the accuracy of stress echocardiography is that the images are subjectively interpreted with an accuracy that is dependent upon physician experience [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/4\">",
"     4",
"    </a>",
"    ]. In comparison, radionuclide myocardial perfusion imaging lends itself well to semi-automated computer quantification, increasing both accuracy and reproducibility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When performance of the two tests is compared, stress radionuclide myocardial perfusion imaging is generally more sensitive and less specific than stress echocardiography (",
"    <a class=\"graphic graphic_table graphicRef70485 \" href=\"UTD.htm?27/3/27707\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This was illustrated in meta-analysis that evaluated the accuracy of the different stress tests (compared to coronary angiography) in patients with an intermediate pretest risk of CHD (25 to 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/5\">",
"     5",
"    </a>",
"    ]. Thallium SPECT rMPI (including both exercise and pharmacologic testing) had a sensitivity and specificity of 88 and 77 percent, respectively, in eight studies involving 862 patients. In contrast, stress echocardiography had a sensitivity and specificity of 76 and 88 percent, respectively, in 10 studies involving 1174 patients.",
"   </p>",
"   <p>",
"    In another meta-analysis, 44 articles met criteria for determining the sensitivity and specificity (compared to coronary angiography) of exercise SPECT rMPI and exercise echocardiography for the diagnosis of CHD in general (ie, not related to revascularization) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/7\">",
"     7",
"    </a>",
"    ]. The two tests had similar sensitivity (85 and 87 percent), but the specificity was significantly lower (ie, more false positives) with exercise rMPI (77 versus 64 percent).",
"   </p>",
"   <p>",
"    Stress radionuclide myocardial perfusion imaging and stress echocardiography may have specific advantages and disadvantages in certain clinical settings. Stress echocardiography appears to be more specific than stress radionuclide myocardial perfusion imaging in patients with left ventricular hypertrophy (94 versus 59 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, the specificity of exercise echocardiography is reduced in patients with a prior myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/9\">",
"     9",
"    </a>",
"    ]; this modality is also not well established for the evaluation of patients with left bundle branch block [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/10\">",
"     10",
"    </a>",
"    ]. Because the interpretation of stress echocardiography is subjective rather than semi-quantitative as with stress radionuclide myocardial perfusion imaging, stress echocardiograms may be difficult to interpret in patients with irregular cardiac rhythms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link&amp;anchor=H7#H7\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Exercise echocardiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link&amp;anchor=H18#H18\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Dobutamine stress echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, we generally prefer stress radionuclide myocardial perfusion imaging for patients with left bundle branch block, non-sinus rhythm, or prior infarction with resting wall motion abnormalities; on the other hand, stress echocardiography is preferred in patients with left ventricular hypertrophy and preserved resting systolic function. For other patients, the choice of stress radionuclide myocardial perfusion imaging or exercise echocardiography is based upon local availability and expertise. Radionuclide myocardial perfusion imaging may be more sensitive than stress echocardiography for demonstrating myocardial ischemia superimposed upon an area of infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     After revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines expressed no preference between radionuclide myocardial perfusion imaging and echocardiography in patients who have undergone revascularization (",
"    <a class=\"graphic graphic_table graphicRef52995 \" href=\"UTD.htm?17/42/18093\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In a meta-analysis of studies that evaluated rMPI and echocardiography, largely for the recognition of restenosis, the two tests had similar sensitivity (83 versus 82 percent) and specificity (79 versus 86 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13\">",
"     13",
"    </a>",
"    ]. However, almost all patients were treated with PTCA without stenting and studies were excluded if they included only asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     APPLICABILITY TO CURRENT PRACTICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remainder of this topic will review the data on stress testing in symptomatic and asymptomatic patients who have undergone coronary revascularization. The goal in asymptomatic patients is to detect silent restenosis and development of graft disease as well as progression of native disease in vessels that have not been revascularized.",
"   </p>",
"   <p>",
"    One limitation of most of the studies that have evaluated the role of stress testing to detect silent restenosis is that they were performed at a time when restenosis was a common problem. However, as described in the following sections, the current incidence of restenosis is much lower because of major advances that have been made in both PCI (particularly drug-eluting stents) (",
"    <a class=\"graphic graphic_figure graphicRef71236 \" href=\"UTD.htm?24/16/24845\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53472 \" href=\"UTD.htm?35/25/36254\">",
"     figure 2",
"    </a>",
"    ) and CABG (use of internal mammary artery grafts) (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"UTD.htm?23/28/24013\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of these advances, previous data on screening asymptomatic patients for evidence of silent restenosis may not be as applicable to current practice, since the risk of restenosis is so much lower and therefore the prior probability of obstructive disease is much lower. Furthermore, patients with known CHD are now treated with aggressive risk factor reduction (eg, aggressive antihypertensive and lipid lowering therapy), which slows the rate of progression or may even promote regression of native vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION OF PATIENTS AFTER PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will review the role of stress testing in the detection of restenosis or progressive native disease sufficient to produce ischemia after PCI. A second issue, the use of stress radionuclide myocardial perfusion imaging or echocardiography prior to PCI to detect hibernating myocardium (eg, myocardial viability), is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ischemic chest pain within 48 hours after PCI (with or without stenting) usually results from procedural events such as abrupt vessel closure (largely eliminated by stenting), transient coronary spasm, nonocclusive thrombus, side branch occlusion, or distal embolization. Stress testing is",
"    <strong>",
"     not",
"    </strong>",
"    warranted in such patients, who should undergo repeat cardiac catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H20#H20\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Myocardial ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who undergo PCI, angiographic restenosis occurs at one to twelve months in 30 to 40 percent of patients treated with percutaneous transluminal coronary angioplasty (PTCA) alone and 20 to 30 percent of those treated with bare metal stents (",
"    <a class=\"graphic graphic_figure graphicRef71236 \" href=\"UTD.htm?24/16/24845\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, clinical restenosis is present in only about one-half of these patients, primarily in lesions with more than 70 percent diameter stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of drug-eluting stents, such as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stents, has markedly reduced the incidence of in-stent restenosis. With the increasing use of drug-eluting stents, new guidelines for noninvasive testing will be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnostic accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not surprisingly, test performance among studies is variable, related in part to differences in populations evaluated and the criteria for restenosis. Factors influencing the correlation between stress testing and angiography include incomplete revascularization, angiographically unrecognized plaque fissures, and the failure of angiographically moderate single-vessel stenoses to lead to significant ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Comparison to exercise ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress imaging is superior to exercise ECG testing alone for identifying restenosis after PTCA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13,18-23\">",
"     13,18-23",
"    </a>",
"    ]. The magnitude of this difference was illustrated in a meta-analysis of studies that evaluated the performance of exercise ECG testing, stress radionuclide myocardial perfusion imaging, and stress echocardiography at approximately six months after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13\">",
"     13",
"    </a>",
"    ]. Almost all of the patients were treated with PTCA without stenting and studies were excluded if they included only asymptomatic patients. The sensitivity of the exercise ECG alone was 54 percent compared to 83 and 82 percent with stress radionuclide myocardial perfusion imaging and echocardiography, respectively. The specificity of the three tests was comparable (77, 78, and 87 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stress radionuclide myocardial perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have evaluated the test performance of stress rMPI after PCI, mostly percutaneous transluminal coronary angioplasty (PTCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13,18-21,24-29\">",
"     13,18-21,24-29",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the preceding meta-analysis, the sensitivity and specificity for stress rMPI to detect restenosis after PTCA were 83 and 79 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13\">",
"       13",
"      </a>",
"      ]. Similar values (79 percent for both sensitivity and specificity) were noted in another review of eight studies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/24\">",
"       24",
"      </a>",
"      ]. These values are comparable to those with stress echocardiography (82 and 86 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stress SPECT rMPI was directly compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography in 53 patients who were evaluated for possible restenosis, which was present in 43 percent, at a mean of five months after angiographically successful PTCA [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/25\">",
"       25",
"      </a>",
"      ]. The sensitivity (74 versus 78 percent) and specificity (93 percent) were similar with both tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although data are more limited, stress rMPI appears to produce similar results after PCI with stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. In two studies, for example, evidence of ischemia was noted in 23 percent of patients, many of whom had silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The prognostic significance of detecting these abnormalities is discussed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'More than three months'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have evaluated the test performance of stress echocardiography after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13,22,23,25,31\">",
"     13,22,23,25,31",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis cited above, the sensitivity and specificity of stress echocardiography for detection of coronary stenosis after coronary revascularization were 82 and 86 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13\">",
"       13",
"      </a>",
"      ]. These values were comparable to those with stress rMPI (83 and 79 percent).",
"     </li>",
"     <li>",
"      One study evaluated 80 patients who had undergone PTCA alone a mean of six months previously, 60 of whom (75 percent) had angiographic restenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/22\">",
"       22",
"      </a>",
"      ]. The sensitivity of exercise echocardiography was significantly higher than that of exercise ECG testing (87 versus 75 percent). A similar increase in sensitivity was noted in another report (95 versus 51 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a previously mentioned report that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography to stress SPECT rMPI, the sensitivity (78 versus 74 percent) and specificity (93 percent) were similar with both tests [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/25\">",
"       25",
"      </a>",
"      ]. In terms of detecting restenosis in individual vascular regions, the sensitivity and specificity of dobutamine stress echocardiography were 76 and 94 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Time after PCI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Within one month",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, ischemic chest pain within 48 hours after PCI (with or without stenting) usually results from procedural events. Routine stress testing is",
"    <strong>",
"     not",
"    </strong>",
"    warranted in such patients, who should undergo repeat cardiac catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H20#H20\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Myocardial ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress imaging during the first week after PTCA reveals reversible defects consistent with ischemia in the distribution of the dilated vessel in 18 to 47 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Resolution of these perfusion defects without revascularization was noted during subsequent stress testing in one report suggesting that the findings could represent false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/36\">",
"     36",
"    </a>",
"    ]. However, other studies have shown that early stress rMPI after PTCA usually confirms the success of the procedure and that perfusion defects can often be explained by a causative abnormality, and that such defects predict late restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above studies were performed during the era of PTCA alone, without stent placement. PTCA may have contributed to the positive tests by inducing early postprocedural vasoconstriction. In addition, radionuclide myocardial perfusion imaging was performed with planar imaging, which has a high incidence of false positive results.",
"   </p>",
"   <p>",
"    The advent of stenting and the development of SPECT imaging techniques should overcome these issues. Although data are limited, patients with perfusion defects at two to six days after PCI with stenting may have residual stenoses that are more severe than those without perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/37\">",
"     37",
"    </a>",
"    ] and may be at increased risk for late restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent ischemia at one week to one month is most often due to subacute stent thrombosis rather than restenosis, the incidence of which is very low at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13\">",
"     13",
"    </a>",
"    ]. Subacute stent thrombosis usually occurs within the first four weeks, with a reported incidence at one month ranging from as low as 0.5 percent in multicenter trials to 2.5 percent in a single center experience [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Early post-release data on the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stent suggest that stent thrombosis rates are similar to that anticipated with traditional bare metal stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H17#H17\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Stent thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     More than three months",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of clinically significant restenosis after PCI with placement of bare metal stents was evaluated in a review of 6186 patients in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/16\">",
"     16",
"    </a>",
"    ]. At one year, target lesion revascularization was performed in 12.0 percent and target vessel revascularization in 14.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/16\">",
"     16",
"    </a>",
"    ]. These values were more than two-thirds higher than those at six months (6.9 and 8.0 percent), demonstrating a more delayed presentation than had been appreciated. Clinical trial data represent an underestimate of true risk given the favorable lesion characteristics in these studies. Restenosis rates are considerably higher in more complex lesion subsets, such as small vessels, long lesions, and bifurcations. On the other hand, the incidence of restenosis has been markedly reduced by drug-eluting stents and studies evaluating stress testing after the use of these stents have not yet been performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress testing is warranted in patients with late recurrent angina and those with suggestive but atypical symptoms. It has also been suggested that routine testing may be of value for risk stratification in asymptomatic patients when performed more than three to six months after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/24,28-30,42\">",
"     24,28-30,42",
"    </a>",
"    ]. This approach is based upon the premise that a positive test identifies asymptomatic patients who have a worse prognosis and might benefit from intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The published data with stenting largely support this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], although a report of PTCA in the BARI trial failed to demonstrate benefit from routine exercise testing in stable patients for three years after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive test was associated with an increase in risk in a study of 356 consecutive patients who underwent successful PCI with stenting and then stress radionuclide myocardial perfusion imaging at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/28\">",
"       28",
"      </a>",
"      ]. Target vessel ischemia was present in 81 patients (23 percent) and was silent in 62 percent; 16 of these patients underwent early revascularization and were not included in the prognostic analysis. The rate of critical events (cardiac death, myocardial infarction, and late target vessel revascularization) was higher among the patients with silent ischemia compared to those without ischemia (32 versus 17 percent); the difference was entirely due to a higher rate of repeat revascularization. Patients with symptomatic ischemia tended to have more extensive and severe ischemia and a higher rate of events (52 percent).",
"     </li>",
"     <li>",
"      Similar findings were observed in a review of 370 patients who underwent dual-isotope exercise rMPI at least one month after PCI with bare metal stenting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/29\">",
"       29",
"      </a>",
"      ]. Evidence of ischemia was seen in 86 patients (23 percent) at a median of 3.9 months; the ischemia involved the target vessel in 65 (76 percent). The rate of death or MI at 30 months was significantly higher in the patients with ischemia (17 versus 9.1 percent, adjusted hazard ratio 2.08). The increase in risk was similar in patients with silent and symptomatic ischemia. There was also a significant increase in mortality (10.4 versus 4.6 percent).",
"     </li>",
"     <li>",
"      An increase in death or MI in patients with reversible defects was also noted in another report (",
"      <a class=\"graphic graphic_figure graphicRef79631 \" href=\"UTD.htm?31/57/32669\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, some cardiologists recommend routine stress imaging in asymptomatic patients at six to nine months after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with a high risk scan would be referred for angiography and, if appropriate, revascularization, while patients with a normal, low, or intermediate risk study would be followed medically with repeat testing every one to three years or when symptoms occur. However, the applicability of this approach to current practice, in which drug-eluting stents are primarily used, is uncertain because of the marked reduction in restenosis compared to bare metal stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue for which data are more limited is the value of stress testing in patients with multivessel coronary disease who have undergone incomplete revascularization with stenting limited to the culprit lesion. This problem was addressed in a prospective single center review of 322 consecutive patients who underwent exercise rMPI four to six months after incomplete revascularization; 23 percent had angina during the exercise test [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/44\">",
"     44",
"    </a>",
"    ]. At a median follow-up of 33 months, the yearly rate of cardiac events ranged for 1.5 to 5.1 to 8.5 percent in patients with normal, mildly abnormal, and severely abnormal findings on exercise rMPI. In this setting, rMPI added incremental prognostic value to the clinical and angiographic findings and to the Duke treadmill score, particularly in patients with an intermediate or high score.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recommendations after PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although stress testing in patients with chest pain is appropriate, multiple major society guidelines argue against routine testing of asymptomatic patients after PCI. These include the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline for exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"     1",
"    </a>",
"    ], the 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/American",
"    </span>",
"    Society of Echocardiography (ASE) guideline on the clinical use of echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/45\">",
"     45",
"    </a>",
"    ], the 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/American",
"    </span>",
"    Society of Nuclear Cardiology (ASNC) guideline for the clinical use of radionuclide imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/46\">",
"     46",
"    </a>",
"    ], and the 2005 American College of Cardiology Foundation and American Society of Nuclear Cardiology",
"    <span class=\"nowrap\">",
"     (ACCF/ASNC)",
"    </span>",
"    appropriateness criteria for the use of SPECT rMPI during stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    exercise testing guidelines recommended exercise testing after discharge for activity counseling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise training as part of a cardiac rehabilitation program and for patients with recurrent ischemic symptoms (",
"    <a class=\"graphic graphic_table graphicRef53059 \" href=\"UTD.htm?16/40/17036\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"     1",
"    </a>",
"    ]. The evidence was considered less well established for routine testing within the first 12 months and periodically thereafter in selected, high-risk, asymptomatic patients in an attempt to detect restenosis (now much less of a problem), incomplete revascularization, or progression of native disease.",
"   </p>",
"   <p>",
"    Among patients referred for testing who can exercise, either exercise rMPI or exercise echocardiography was recommended; among patients who cannot exercise, pharmacologic stress with imaging should be used. Exercise ECG testing alone was not recommended because of the decrease in sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/13,18-23\">",
"     13,18-23",
"    </a>",
"    ] and its inability to localize the site of disease.",
"   </p>",
"   <p>",
"    Similar conclusions were reached by the 2005",
"    <span class=\"nowrap\">",
"     ACCF/ASNC",
"    </span>",
"    appropriateness criteria which concluded that, among asymptomatic patients, the value of risk assessment with SPECT rMPI during stress testing was uncertain in patients two or more years post-PCI or less than one year post-PCI who had been asymptomatic prior to the previous revascularization. SPECT rMPI was inappropriate less than one year post-PCI in patients who had been symptomatic prior to the previous revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend the following approach, using stress radionuclide myocardial perfusion imaging for patients with left bundle branch block, non-sinus rhythm or prior infarction with resting wall motion abnormalities, and stress echocardiography for those with left ventricular hypertrophy and normal resting systolic function (",
"    <a class=\"graphic graphic_algorithm graphicRef51749 \" href=\"UTD.htm?37/35/38462\">",
"     algorithm 1",
"    </a>",
"    ). For other patients, the choice of stress radionuclide myocardial perfusion imaging or stress echocardiography is based upon local availability and expertise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who can attain an adequate level of exercise (defined as &ge;85 of their predicted maximal heart rate), symptom-limited treadmill or bicycle exercise is the preferred form of stress because it provides the most information concerning patient symptoms, exercise capacity, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"       1",
"      </a>",
"      ]. The inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD, a finding that has been noted in patients with known or suspected CHD and specifically in those who have undergone revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with an uncomplicated, angiographically successful PCI who remain asymptomatic probably do",
"      <strong>",
"       not",
"      </strong>",
"      need routine stress imaging unless they are at high risk after PCI. High risk features include decreased left ventricular function, multivessel disease, proximal left anterior descending disease, previous sudden cardiac death, diabetes mellitus, hazardous occupations, and suboptimal PCI results [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1,46\">",
"       1,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some recommend routine stress imaging at six to nine months after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the main benefit of such an approach appears to be a reduced incidence of late target vessel revascularization at the cost of unnecessary revascularization in most patients and no evidence of a survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/28\">",
"     28",
"    </a>",
"    ]. Furthermore, it is not known if the data in support of routine testing are as applicable to patients receiving drug-eluting stents, which markedly reduce the incidence of restenosis (",
"    <a class=\"graphic graphic_figure graphicRef53472 \" href=\"UTD.htm?35/25/36254\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], and aggressive risk factor reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients presenting with symptoms typical of myocardial ischemia less than six months after PCI (especially patients with symptoms similar to those found on testing prior to PCI) should undergo coronary angiography as a first step, unless contraindicated. If angina occurs later, stress imaging can be used to assess the degree and area of ischemia, since progression of native coronary disease rather than in-stent restenosis becomes progressively more likely. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"       \"Drug-eluting intracoronary stents: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stress imaging is recommended at any time in patients who develop atypical symptoms after PCI to assess whether these symptoms represent ischemia.",
"     </li>",
"     <li>",
"      In patients with a negative or low-risk stress imaging study after PCI (a study that does not lead to or is not deemed to require intervention), we recommend that stress imaging be repeated every two years or for the subsequent development of symptoms. A shorter interval should be considered for diabetic patients, who have more rapid progression of disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, all patients should be treated with aggressive risk factor reduction (eg, aggressive antihypertensive and lipid lowering therapy and smoking cessation), which should slow the rate of progression and may even promote regression of native vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION OF PATIENTS AFTER CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress testing after CABG can identify graft disease or occlusion as well as progression of native disease in lesions that have not been bypassed. While internal mammary artery grafts have a high patency rate (88 percent and 83 percent after 5 and 10 years respectively), saphenous venous graft occlusion occurs in approximately 10 percent of patients during the first year with subsequent 5 and 10 year patency rates of 74 percent and 41 percent respectively (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"UTD.htm?23/28/24013\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This section will review the role of stress testing in the detection of graft disease or progressive native disease sufficient to produce ischemia after CABG. A second issue, the use of stress radionuclide myocardial perfusion imaging or echocardiography prior to CABG to detect hibernating myocardium (ie, dysfunctional but viable myocardium), is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnostic accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress testing can accurately detect graft stenosis, even in patients with atypical symptoms, and can effectively localize the stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Comparison to exercise ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress imaging is superior to exercise ECG testing alone for the detection of graft stenosis or progression of native disease after CABG as it is for the evaluation of patients who have undergone PCI (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The magnitude of this difference was illustrated in a meta-analysis of studies that evaluated the performance of exercise ECG testing, stress radionuclide myocardial perfusion imaging, and stress echocardiography after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/52\">",
"     52",
"    </a>",
"    ]. The sensitivity of the exercise ECG was 45 percent compared to 68 and 86 percent with stress radionuclide myocardial perfusion imaging and stress echocardiography, respectively. The specificities of the three tests were comparable (82, 84, and 90 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Stress radionuclide myocardial perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress radionuclide myocardial perfusion imaging can accurately detect graft stenosis, even in patients with atypical symptoms, and can effectively localize the stenosis, particularly if gated SPECT (single photon emission computed tomography) imaging is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/53,54,56,57\">",
"     53,54,56,57",
"    </a>",
"    ]. In one study, for example, thallium-201 SPECT imaging and coronary angiography were performed in 50 patients at 51 months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/53\">",
"     53",
"    </a>",
"    ]. All patients had chest pain, although the symptoms were atypical in 40 percent. The sensitivity and specificity of the imaging study were 80 and 87 percent.",
"   </p>",
"   <p>",
"    Similar values (80 and 88 percent) were noted in a previous report evaluating serial planar radionuclide myocardial perfusion imaging in 55 consecutive patients with 154 grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/56\">",
"     56",
"    </a>",
"    ]. Typical anginal pain occurred only in patients with new perfusion defects, while patients without new perfusion defects had no or only atypical chest pain. One report suggests that the specificity of radionuclide myocardial perfusion imaging may be less if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    rather than exercise stress is used, most likely due to attenuation artifact from pharmacologic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity for individual diseased vascular territories appears to be substantially higher with gated SPECT stress rMPI: 82 percent for the left anterior descending artery territory, 92 percent for the right coronary artery territory, and 75 percent for the left circumflex artery territory [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/53\">",
"     53",
"    </a>",
"    ]. In contrast, localization of the occluded graft was correct in only 61 percent of patients with planar imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In conclusion, the main indication for stress rMPI after CABG is to identify areas of ischemic myocardium caused mainly by saphenous venous graft occlusion. Gated SPECT imaging adds incrementally to the diagnostic accuracy of rMPI, and assists in the localization of the stenotic lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic accuracy of stress echocardiography has been evaluated in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/52,55,58,59\">",
"     52,55,58,59",
"    </a>",
"    ]. In a meta-analysis cited above, the sensitivity and specificity for stress echocardiography after CABG were 86 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/52\">",
"     52",
"    </a>",
"    ]. There was an almost significant trend toward greater sensitivity than seen with stress radionuclide myocardial perfusion imaging (86 versus 68 percent), while specificity was similar (84 versus 90 percent).",
"   </p>",
"   <p>",
"    The efficacy of exercise echocardiography was evaluated in a series of 213 patients who were studied two weeks to 21 years after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/55\">",
"     55",
"    </a>",
"    ]. The sensitivity and specificity were 79 and 82 percent overall and 85 and 81 percent if inconclusive tests (poor image quality or a submaximal test) were excluded. The sensitivity of detecting any coronary stenosis was higher for vascular compromise in two or three regions compared to one region (96 versus 77 percent). However, among patients with multivessel disease on angiography, only 69 percent had abnormalities in multiple regions on echocardiography. Most false negative tests were associated with vascular compromise limited to the posterolateral region on angiography.",
"   </p>",
"   <p>",
"    A second report evaluated 50 patients who were unable to exercise and underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    -atropine stress echocardiography at a mean of five years after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/59\">",
"     59",
"    </a>",
"    ]. The overall sensitivity and specificity were 78 and 89 percent, respectively. However, echocardiography was less successful in identifying significant stenosis in individual vascular territories. The sensitivity was 45 percent in the right coronary artery, 50 percent in the left circumflex artery, and 64 percent in the left anterior descending artery.",
"   </p>",
"   <p>",
"    There was also a relatively low sensitivity (57 percent) for identifying multivessel disease on the basis of inducible abnormalities in more than one region. Limiting factors for identifying multivessel disease included vascular overlap and the differences in the threshold for ischemia such that an end point might be reached in one territory that was not sufficient to induce ischemia in another territory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Time after CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of stress imaging for the evaluation of post-CABG patients depends upon the presence or absence of symptoms and the time from the surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Within two years",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant reversible perfusion defects suggestive of ischemia occur in about one-quarter of patients by one year after CABG; not all of these patients have angina. These observations are illustrated by two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 411 patients (34 percent asymptomatic, 66 percent with chest pain or dyspnea, 79 percent with an internal mammary graft) underwent exercise thallium-201 rMPI within two years after CABG (mean 11 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/60\">",
"       60",
"      </a>",
"      ]. More than 50 percent of patients had reversible defects on rMPI, but only 26 percent had more than three segments of myocardium involved, and only 12 percent had evidence of redistribution proximal to a graft insertion site.",
"      <br/>",
"      <br/>",
"      At five years, the survival rate free of cardiac death or myocardial infarction was 87 percent overall; for patients with 0, 1 to 3, 4 to 6, and &ge;7 ischemic segments on rMPI, the rates were 92, 89, 85, and 72 percent, respectively (",
"      <a class=\"graphic graphic_figure graphicRef71789 \" href=\"UTD.htm?27/26/28078\">",
"       figure 5",
"      </a>",
"      ). The findings were not stratified according to whether or not the patients had symptoms prior to the imaging study; this is a major limitation since all symptomatic patients should be tested.",
"     </li>",
"     <li>",
"      In an analysis from the EAST trial, 336 patients who had been randomly assigned to either PCI or CABG (90 percent with internal mammary graft) underwent thallium-201 SPECT rMPI with exercise one year after their revascularization procedure, regardless of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/61\">",
"       61",
"      </a>",
"      ]. Among those who underwent CABG, 19 (11 percent) reported angina at the time of testing; however, 47 (27 percent) had a large or moderate-sized reversible defect on rMPI. At two years, survival free of cardiac death or MI in patients with large or moderate-sized defects was significantly lower than in those without such findings (88 versus 96 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these observations, the value of early routine stress testing was limited in a much larger review of 1678 patients from the BARI trial in which exercise testing was scheduled at one, three, and five years after PCI or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients who took the test at each interval, regardless of the test result, had a low two-year mortality of 1.9 to 3.5 percent that was much less than the 9.4 to 12.6 percent mortality in those who did not take the test. Exercise parameters did not improve prediction of mortality in the two years after the one and three year tests. In comparison, at the five-year test, both a Duke treadmill score &gt;-6 (low to moderate risk) and exercising to Bruce stage 3 (",
"    <a class=\"graphic graphic_table graphicRef70044 \" href=\"UTD.htm?12/51/13118\">",
"     table 6",
"    </a>",
"    ) were independently predictive of subsequent two-year survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Five years",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, saphenous vein graft patency begins to decline rapidly after five years, while patency rates for arterial grafts remain high (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"UTD.htm?23/28/24013\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In patients with saphenous vein grafts who are more than five years post-CABG, irrespective of symptoms, stress SPECT rMPI has been an effective method for risk stratification, prognosis, and determination of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/62-66\">",
"     62-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report evaluated 294 patients at least five years post-CABG, 85 percent of whom received a saphenous vein graft [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/62\">",
"     62",
"    </a>",
"    ]. During the 31-month follow up, the event rate (death or nonfatal myocardial infarction) was 14 percent. Two exercise scintigraphic variables, the 201-Tl reversibility score, which was a global measure of the ischemic index, and the presence of increased lung thallium uptake, which is a measure of exercise-induced left ventricular dysfunction, added significant prognostic information over clinical and exercise data. When these variables were present, the odds of a cardiac event increased by 80 and 10 percent, respectively.",
"   </p>",
"   <p>",
"    A later and larger study included 1765 patients who underwent dual-isotope SPECT rMPI at 7.1 &plusmn; 5.0 years post-CABG; 1544 were followed for at least one year after testing (mean two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/65\">",
"     65",
"    </a>",
"    ]. Data were not available concerning the type of graft used. A total of 53 cardiac deaths occurred. There was a significant increase in annual death rates as a function of summed stress score for ischemia, which was equal to the total of all segmental scores added together at stress.",
"   </p>",
"   <p>",
"    Stress rMPI provided important prognostic information in patients more than five years post-CABG, irrespective of symptoms, and in symptomatic patients who were &le;5 years post-CABG. In both groups, a moderate or severely abnormal summed stress score predicted a significantly higher annual cardiac death rate (2.1 and 3.1 percent, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef67966 \" href=\"UTD.htm?17/0/17422\">",
"     figure 6",
"    </a>",
"    ). Cardiac mortality was very low in patients with a normal rMPI (0 and 0.7 percent per year) at &le;5 and more than five years post-CABG, respectively. Asymptomatic patients who were &le;5 years post-CABG also had a lower cardiac death rate (1.3 percent per year) and did not benefit from stress rMPI.",
"   </p>",
"   <p>",
"    A third series included 873 asymptomatic patients who had undergone CABG a mean of seven years previously [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/66\">",
"     66",
"    </a>",
"    ]. An internal mammary artery graft was utilized in almost 80 percent and complete revascularization was achieved in 84 percent. At three year follow-up, two major factors had independent prognostic value:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reversible radionuclide perfusion defects were predictive of all-cause mortality (12 versus 5 percent) and death or myocardial infarction (13 versus 7 percent). Perfusion defects were present in 81 percent of patients who died.",
"     </li>",
"     <li>",
"      Impaired exercise capacity (&le;6 METs) was also predictive of all-cause mortality (18 versus 4 percent) and death or myocardial infarction (19 versus 5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are more limited on the value of stress echocardiography at five years after CABG, but the test appears to be as useful as stress rMPI. The potential efficacy was illustrated in a report of 718 patients who underwent exercise echocardiography a mean of 5.7 years after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/67\">",
"     67",
"    </a>",
"    ]. Cardiac death or myocardial infarction occurred in 11 percent of patients at 2.9 year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/67\">",
"     67",
"    </a>",
"    ]. Echocardiographic evidence of extensive exercise-induced left ventricular dysfunction provided incremental prognostic information to clinical, rest echocardiographic, and exercise electrocardiographic variables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Recommendations after CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although stress testing in patients with chest pain is appropriate, multiple major society guidelines have argued",
"    <strong>",
"     against",
"    </strong>",
"    routine testing of all asymptomatic patients after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1,45,46\">",
"     1,45,46",
"    </a>",
"    ]. These include the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline for exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"     1",
"    </a>",
"    ], the 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/American",
"    </span>",
"    Society of Echocardiography (ASE) guideline on the clinical use of echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/45\">",
"     45",
"    </a>",
"    ], the 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/American",
"    </span>",
"    Society of Nuclear Cardiology (ASNC) guideline for the clinical use of radionuclide imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/46\">",
"     46",
"    </a>",
"    ], and the 2005 American College of Cardiology Foundation and American Society of Nuclear Cardiology",
"    <span class=\"nowrap\">",
"     (ACCF/ASNC)",
"    </span>",
"    appropriateness criteria for the use of SPECT rMPI during stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there have been differences among the guidelines in the selection of asymptomatic patients in whom stress testing may be appropriate, with increasing support for wider use of testing over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2002",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      exercise testing guideline concluded that the evidence was less well established for the testing of selected, high-risk, patients (eg, graft occlusion, incomplete coronary revascularization, or disease progression) who were asymptomatic (",
"      <a class=\"graphic graphic_table graphicRef53059 \" href=\"UTD.htm?16/40/17036\">",
"       table 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"       1",
"      </a>",
"      ]. Among patients who can exercise, either exercise rMPI or exercise echocardiography was recommended; among patients who cannot exercise, pharmacologic stress should be used (",
"      <a class=\"graphic graphic_table graphicRef52995 \" href=\"UTD.htm?17/42/18093\">",
"       table 2",
"      </a>",
"      ). Exercise ECG testing alone was not recommended because of the decrease in sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/52-55\">",
"       52-55",
"      </a>",
"      ], the need to identify the site of ischemia, and the frequent presence of baseline ECG abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2003",
"      <span class=\"nowrap\">",
"       ACC/AHA/ASNC",
"      </span>",
"      radionuclide imaging guideline concluded that the weight of evidence supported routine stress testing in selected high-risk, asymptomatic patients and recommended that stress SPECT rMPI be performed at three to five years after revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/46\">",
"       46",
"      </a>",
"      ]. Exercise was the preferred stress, while adenosine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      stress was recommended in patients who are unable to exercise.",
"     </li>",
"     <li>",
"      The 2005",
"      <span class=\"nowrap\">",
"       ACCF/ASNC",
"      </span>",
"      appropriateness criteria concluded that stress testing in asymptomatic patients was appropriate in all patients &ge;5 years after CABG, and that efficacy was uncertain in patients fewer than five years after CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We feel that there is substantial evidence, as noted above, that stress rMPI is an effective means of risk stratification and provides guidance to appropriate therapy in patients more than five years post-CABG with or without ischemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/62,65-67\">",
"     62,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend the following approach, using stress radionuclide myocardial perfusion imaging for patients with left bundle branch block, non-sinus rhythm or prior infarction with resting wall motion abnormalities and stress echocardiography for those with left ventricular hypertrophy and normal resting systolic function (",
"    <a class=\"graphic graphic_algorithm graphicRef74777 \" href=\"UTD.htm?41/43/42685\">",
"     algorithm 2",
"    </a>",
"    ). For other patients, the choice of stress radionuclide myocardial perfusion imaging or stress echocardiography is based upon local availability and expertise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before five years, stress testing is warranted only in symptomatic patients.",
"     </li>",
"     <li>",
"      After five years, periodic testing of asymptomatic patients is recommended. Patients with a moderate to severe perfusion defect and reversibility on stress radionuclide myocardial perfusion imaging or inducible wall motion abnormalities in multiple segments on stress echocardiography should be considered for coronary angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients who can attain an adequate level of exercise (85 to 90 percent of the predicted maximal heart rate), treadmill or bicycle exercise is the preferred form of stress because it provides the most information concerning patient symptoms, exercise capacity, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"       1",
"      </a>",
"      ]. The inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD, a finding that has been noted in patients with known or suspected CHD and specifically in those who have undergone CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?19/42/20138/abstract/43,66\">",
"       43,66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, all patients should be treated with aggressive risk factor reduction (eg, aggressive antihypertensive and lipid lowering therapy and smoking cessation), which should slow the rate of progression and may even promote regression of native vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/1\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/3\">",
"      Fraker TD Jr, Fihn SD, 2002 Chronic Stable Angina Writing Committee, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/4\">",
"      Roger VL, Pellikka PA, Oh JK, et al. Stress echocardiography. Part I. Exercise echocardiography: techniques, implementation, clinical applications, and correlations. Mayo Clin Proc 1995; 70:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/5\">",
"      Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999; 130:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/6\">",
"      Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis. Am Heart J 2001; 142:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/7\">",
"      Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/8\">",
"      Marwick T, D'Hondt AM, Baudhuin T, et al. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? J Am Coll Cardiol 1993; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/9\">",
"      Nishioka T, Mitani H, Uehata A, et al. Utility and limitation of treadmill exercise echocardiography for detecting significant coronary stenosis in infarct-related arteries in patients with healed myocardial infarction. Am J Cardiol 2002; 89:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/10\">",
"      Geleijnse ML, Vigna C, Kasprzak JD, et al. Usefulness and limitations of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in patients with left bundle branch block. A multicentre study. Eur Heart J 2000; 21:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/11\">",
"      O'Keefe JH Jr, Barnhart CS, Bateman TM. Comparison of stress echocardiography and stress myocardial perfusion scintigraphy for diagnosing coronary artery disease and assessing its severity. Am J Cardiol 1995; 75:25D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/12\">",
"      Verani MS. Myocardial perfusion imaging versus two-dimensional echocardiography: comparative value in the diagnosis of coronary artery disease. J Nucl Cardiol 1994; 1:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/13\">",
"      Dori G, Denekamp Y, Fishman S, Bitterman H. Exercise stress testing, myocardial perfusion imaging and stress echocardiography for detecting restenosis after successful percutaneous transluminal coronary angioplasty: a review of performance. J Intern Med 2003; 253:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/14\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/15\">",
"      Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/16\">",
"      Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/17\">",
"      Cannan CR, Yeh W, Kelsey SF, et al. Incidence and predictors of target vessel revascularization following percutaneous transluminal coronary angioplasty: a report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Am J Cardiol 1999; 84:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/18\">",
"      Hecht HS, Shaw RE, Chin HL, et al. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. J Am Coll Cardiol 1991; 17:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/19\">",
"      Hecht HS, Shaw RE, Bruce TR, et al. Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 66:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/20\">",
"      Hirzel HO, Nuesch K, Gruentzig AR, Luetolf UM. Short- and long-term changes in myocardial perfusion after percutaneous transluminal coronary angioplasty assessed by thallium-201 exercise scintigraphy. Circulation 1981; 63:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/21\">",
"      Beygui F, Le Feuvre C, Maunoury C, et al. Detection of coronary restenosis by exercise electrocardiography thallium-201 perfusion imaging and coronary angiography in asymptomatic patients after percutaneous transluminal coronary angioplasty. Am J Cardiol 2000; 86:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/22\">",
"      Hecht HS, DeBord L, Shaw R, et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993; 71:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/23\">",
"      Crouse LJ, Vacek JL, Beauchamp GD, Kramer PH. Use of exercise echocardiography to evaluate patients after coronary angioplasty. Am J Cardiol 1996; 78:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/24\">",
"      Giedd KN, Bergmann SR. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. J Am Coll Cardiol 2004; 43:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/25\">",
"      Takeuchi M, Miura Y, Toyokawa T, et al. The comparative diagnostic value of dobutamine stress echocardiography and thallium stress tomography for detecting restenosis after coronary angioplasty. J Am Soc Echocardiogr 1995; 8:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/26\">",
"      K&oacute;sa I, Blasini R, Schneider-Eicke J, et al. Myocardial perfusion scintigraphy to evaluate patients after coronary stent implantation. J Nucl Med 1998; 39:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/27\">",
"      Milavetz JJ, Miller TD, Hodge DO, et al. Accuracy of single-photon emission computed tomography myocardial perfusion imaging in patients with stents in native coronary arteries. Am J Cardiol 1998; 82:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/28\">",
"      Zellweger MJ, Weinbacher M, Zutter AW, et al. Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. J Am Coll Cardiol 2003; 42:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/29\">",
"      Rajagopal V, Gurm HS, Brunken RC, et al. Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting. Am Heart J 2005; 149:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/30\">",
"      Cottin Y, Rezaizadeh K, Touzery C, et al. Long-term prognostic value of 201Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting. Am Heart J 2001; 141:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/31\">",
"      Mertes H, Erbel R, Nixdorff U, et al. Exercise echocardiography for the evaluation of patients after nonsurgical coronary artery revascularization. J Am Coll Cardiol 1993; 21:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/32\">",
"      Wijns W, Serruys PW, Reiber JH, et al. Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy. Am J Cardiol 1985; 55:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/33\">",
"      Jain A, Mahmarian JJ, Borges-Neto S, et al. Clinical significance of perfusion defects by thallium-201 single photon emission tomography following oral dipyridamole early after coronary angioplasty. J Am Coll Cardiol 1988; 11:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/34\">",
"      Hardoff R, Shefer A, Gips S, et al. Predicting late restenosis after coronary angioplasty by very early (12 to 24 h) thallium-201 scintigraphy: implications with regard to mechanisms of late coronary restenosis. J Am Coll Cardiol 1990; 15:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/35\">",
"      Iskandrian AS, Lemlek J, Ogilby JD, et al. Early thallium imaging after percutaneous transluminal coronary angioplasty: tomographic evaluation during adenosine-induced coronary hyperemia. J Nucl Med 1992; 33:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/36\">",
"      Manyari DE, Knudtson M, Kloiber R, Roth D. Sequential thallium-201 myocardial perfusion studies after successful percutaneous transluminal coronary artery angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. Circulation 1988; 77:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/37\">",
"      Bachmann R, Sechtem U, Voth E, et al. Dipyridamole scintigraphy and intravascular ultrasound after successful coronary intervention. J Nucl Med 1997; 38:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/38\">",
"      Rod&eacute;s-Cabau J, Candell-Riera J, Domingo E, et al. Frequency and clinical significance of myocardial ischemia detected early after coronary stent implantation. J Nucl Med 2001; 42:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/39\">",
"      Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/40\">",
"      Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996; 27:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/41\">",
"      Sch&uuml;hlen H, Kastrati A, Pache J, et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001; 37:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/42\">",
"      Ho KT, Miller TD, Holmes DR, et al. Long-term prognostic value of Duke treadmill score and exercise thallium-201 imaging performed one to three years after percutaneous transluminal coronary angioplasty. Am J Cardiol 1999; 84:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/43\">",
"      Krone RJ, Hardison RM, Chaitman BR, et al. Risk stratification after successful coronary revascularization: the lack of a role for routine exercise testing. J Am Coll Cardiol 2001; 38:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/44\">",
"      Galassi AR, Grasso C, Azzarelli S, et al. Usefulness of exercise myocardial scintigraphy in multivessel coronary disease after incomplete revascularization with coronary stenting. Am J Cardiol 2006; 97:207.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/46\">",
"      Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/47\">",
"      Brindis RG, Douglas PS, Hendel RC, et al. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. J Am Coll Cardiol 2005; 46:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/48\">",
"      Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/49\">",
"      Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/50\">",
"      Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/51\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/52\">",
"      Chin AS, Goldman LE, Eisenberg MJ. Functional testing after coronary artery bypass graft surgery: a meta-analysis. Can J Cardiol 2003; 19:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/53\">",
"      Lakkis NM, Mahmarian JJ, Verani MS. Exercise thallium-201 single photon emission computed tomography for evaluation of coronary artery bypass graft patency. Am J Cardiol 1995; 76:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/54\">",
"      Greenberg BH, Hart R, Botvinick EH, et al. Thallium-201 myocardial perfusion scintigraphy to evaluate patients after coronary bypass surgery. Am J Cardiol 1978; 42:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/55\">",
"      Kafka H, Leach AJ, Fitzgibbon GM. Exercise echocardiography after coronary artery bypass surgery: correlation with coronary angiography. J Am Coll Cardiol 1995; 25:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/56\">",
"      Pfisterer M, Emmenegger H, Schmitt HE, et al. Accuracy of serial myocardial perfusion scintigraphy with thallium-201 for prediction of graft patency early and late after coronary artery bypass surgery. A controlled prospective study. Circulation 1982; 66:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/57\">",
"      Deluca AJ, Cusack E, Aronow WS, Monsen CE. Sensitivity, specificity, positive predictive value, and negative predictive value of the dipyridamole sestamibi stress test in predicting graft occlusion or &gt; or = 50% new native coronary artery disease in men versus women and in patients aged &gt; or = 65 years versus &lt; 65 years who had prior coronary artery bypass grafting. Am J Cardiol 2004; 94:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/58\">",
"      Crouse LJ, Vacek JL, Beauchamp GD, et al. Exercise echocardiography after coronary artery bypass grafting. Am J Cardiol 1992; 70:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/59\">",
"      Elhendy A, Geleijnse ML, Roelandt JR, et al. Assessment of patients after coronary artery bypass grafting by dobutamine stress echocardiography. Am J Cardiol 1996; 77:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/60\">",
"      Miller TD, Christian TF, Hodge DO, et al. Prognostic value of exercise thallium-201 imaging performed within 2 years of coronary artery bypass graft surgery. J Am Coll Cardiol 1998; 31:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/61\">",
"      Alazraki NP, Krawczynska EG, Kosinski AS, et al. Prognostic value of thallium-201 single-photon emission computed tomography for patients with multivessel coronary artery disease after revascularization (the Emory Angioplasty versus Surgery Trial [EAST]). Am J Cardiol 1999; 84:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/62\">",
"      Palmas W, Bingham S, Diamond GA, et al. Incremental prognostic value of exercise thallium-201 myocardial single-photon emission computed tomography late after coronary artery bypass surgery. J Am Coll Cardiol 1995; 25:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/63\">",
"      Khoury AF, Rivera JM, Mahmarian JJ, Verani MS. Adenosine thallium-201 tomography in evaluation of graft patency late after coronary artery bypass graft surgery. J Am Coll Cardiol 1997; 29:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/64\">",
"      Nallamothu N, Johnson JH, Bagheri B, et al. Utility of stress single-photon emission computed tomography (SPECT) perfusion imaging in predicting outcome after coronary artery bypass grafting. Am J Cardiol 1997; 80:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/65\">",
"      Zellweger MJ, Lewin HC, Lai S, et al. When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. J Am Coll Cardiol 2001; 37:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/66\">",
"      Lauer MS, Lytle B, Pashkow F, et al. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting. Lancet 1998; 351:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/42/20138/abstract/67\">",
"      Arruda AM, McCully RB, Oh JK, et al. Prognostic value of exercise echocardiography in patients after coronary artery bypass surgery. Am J Cardiol 2001; 87:1069.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1566 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20138=[""].join("\n");
var outline_f19_42_20138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES OF STRESS TEST PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radionuclide myocardial perfusion imaging versus echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - General use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - After revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      APPLICABILITY TO CURRENT PRACTICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION OF PATIENTS AFTER PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnostic accuracy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Comparison to exercise ECG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stress radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Time after PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Within one month",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - More than three months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recommendations after PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION OF PATIENTS AFTER CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnostic accuracy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Comparison to exercise ECG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Stress radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Time after CABG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Within two years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Five years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Recommendations after CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1566|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?37/35/38462\" title=\"algorithm 1\">",
"      MPI algorithm post PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/43/42685\" title=\"algorithm 2\">",
"      MPI algorithm post CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1566|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/16/24845\" title=\"figure 1\">",
"      Stenting versus PTCA in CAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/25/36254\" title=\"figure 2\">",
"      Lack of restenosis with sirolimus stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24013\" title=\"figure 3\">",
"      IMA versus vein graft patency after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/57/32669\" title=\"figure 4\">",
"      Stress MPI after stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/26/28078\" title=\"figure 5\">",
"      Prognosis MPI post CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/0/17422\" title=\"figure 6\">",
"      Stress MPI after CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/59/24508\" title=\"table 1\">",
"      ACC AHA ETT diagnosis CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/42/18093\" title=\"table 2\">",
"      ACC AHA choice imaging CHD diagnosis able to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33516\" title=\"table 3\">",
"      ACC AHA choice imaging risk I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/3/27707\" title=\"table 4\">",
"      Performance pharm stress tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/40/17036\" title=\"table 5\">",
"      ACC AHA ETT post revasculariz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/51/13118\" title=\"table 6\">",
"      Exercise testing protocols",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_42_20139="Bronchocentric granulomatosis";
var content_f19_42_20139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bronchocentric granulomatosis: Causes and associated conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Causes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergic",
"       </td>",
"       <td>",
"        Allergic bronchopulmonary aspergillosis (ABPA)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Infectious",
"       </td>",
"       <td>",
"        Tuberculosis, atypical mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal: histoplasmosis, blastomycosis, coccidioidomycosis, mucormycosis, aspergillosis (nonallergic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary echinococcosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza A",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Other",
"       </td>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchogenic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other: glomerulonephritis, red cell aplasia, diabetes insipidus, and scleritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20139=[""].join("\n");
var outline_f19_42_20139=null;
var title_f19_42_20140="Trials cervical cerclage";
var content_f19_42_20140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of randomized trials on cervical cerclage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Delivery before 33 completed weeks",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Significance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"1\">",
"        n",
"       </td>",
"       <td class=\"subtitle2\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        MRC/RCOG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerclage (n=647)",
"       </td>",
"       <td colspan=\"1\">",
"        83",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        p &le;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No cerclage (n=645)",
"       </td>",
"       <td colspan=\"1\">",
"        110",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Rush et al, (1984)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerclage (n=96)",
"       </td>",
"       <td colspan=\"1\">",
"        12",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No cerclage (n=98)",
"       </td>",
"       <td colspan=\"1\">",
"        10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Lazar et al, (1984)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerclage (n=268)",
"       </td>",
"       <td colspan=\"1\">",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No cerclage (n=238)",
"       </td>",
"       <td colspan=\"1\">",
"        1",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Dor et al, (1982)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerclage (n=25)",
"       </td>",
"       <td colspan=\"1\">",
"        6",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No cerclage (n=25)",
"       </td>",
"       <td colspan=\"1\">",
"        5",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRC/RCOG: Medical Research Council/Royal College of Obstetricians and Gynecologists; NS: no significant difference between cerclage and no cerclage.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in MRC/RCOG, Br J Obstet Gynecol 1993; 100:516.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20140=[""].join("\n");
var outline_f19_42_20140=null;
var title_f19_42_20141="Features of tickborne infx";
var content_f19_42_20141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected features of Rocky Mountain spotted fever,* human monocytotropic ehrlichiosis, human granulocytotropic anaplasmosis,&bull; and Ehrlichia ewingii infection - United States&Delta;",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent (disease)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary vector(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approx- imate dist- ribution&loz;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incu- bation period (days)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common initial signs and symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common laboratory abnormalities",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rash",
"       </td>",
"       <td class=\"subtitle1\">",
"        Case- fatality rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsia rickettsii (Rocky Mountain spotted fever)",
"       </td>",
"       <td>",
"        Dermacentor variabilis (American dog tick), Derma- centor andersoni",
"(Rocky Mountain wood tick), and Rhipicephalus sanguineus (brown dog",
"tick) in AZ&sect;",
"       </td>",
"       <td>",
"        Widespread in the United States, especially South Atlantic and South Central states",
"       </td>",
"       <td>",
"        2-14",
"       </td>",
"       <td>",
"        Fever, nausea, vomiting, myalgia, anorexia, and headache",
"       </td>",
"       <td>",
"        Thrombo- cytopenia, mild hyponatremia, and mildly elevated hepatic transaminase levels",
"       </td>",
"       <td>",
"        Maculopapular rash approx -imately 2-4 days after fever onset in",
"50-80 percent of adults (&gt;90 percent in children); might involve",
"palms and soles",
"       </td>",
"       <td>",
"        5-10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichia chaffeensis (human monocyto- tropic ehrlichiosis)",
"       </td>",
"       <td>",
"        Amblyomma americanum (lone star tick)",
"       </td>",
"       <td>",
"        South and Mid-Atlantic, North/South Central United States, and isolated areas of New England",
"       </td>",
"       <td>",
"        5-14",
"       </td>",
"       <td>",
"        Fever, headache, malaise, and myalgia",
"       </td>",
"       <td>",
"        Leukopenia, thromobo- cytopenia, and elevated serum transaminase levels",
"       </td>",
"       <td>",
"        Rash in &lt;30 percent of adults and approximately 60 percent of children",
"       </td>",
"       <td>",
"        2-3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaplasma phagocyto- philum (human granulo- cytotropic anaplasmosis)",
"       </td>",
"       <td>",
"        Ixodes scapularis and Ixodes pacificus (blacklegged tick) in the United States",
"       </td>",
"       <td>",
"        New England, North Central and Pacific states",
"       </td>",
"       <td>",
"        5-21",
"       </td>",
"       <td>",
"        Fever, headache, malaise, myalgia, and vomiting",
"       </td>",
"       <td>",
"        Leukopenia, thrombo- cytopenia, elevated serum transaminase levels",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        &lt;1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichia ewingii infection",
"       </td>",
"       <td>",
"        Amblyomma americanum (lone star tick)",
"       </td>",
"       <td>",
"        South Atlantic and South Central United States to isolated areas of New England",
"       </td>",
"       <td>",
"        5-14",
"       </td>",
"       <td>",
"        Fever, headache, myalgia, nausea, and vomiting",
"       </td>",
"       <td>",
"        Leukopenia, thrombo- cytopenia, and elevated serum transaminase levels",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        No docu- mented fatalities",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * SOURCE: Walker DH, Raoult D. Rickettsia rickettsii and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:2287-95.",
"     <br>",
"      &bull; SOURCE: Walker DH, Dumler JS. Ehrlichia chaffeensis (human monocytotropic ehrlichiosis), Anaplasma phagocytophilum (human granulocytotropic anaplasmosis) and other ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:2310-8.",
"      <br>",
"       &Delta; Treatment for each of these diseases is the same: adults, doxycycline 100 mg orally (PO) or intravenously (IV) twice daily; and children, doxycycline 2.2 mg/kg administered PO or IV twice daily.",
"       <br>",
"        &loz; Mountain: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada. East South Central: Kentucky, Tennessee, Alabama, Mississippi. East North Central: Ohio, Indiana, Illinois, Michigan, Wisconsin. West South Central: Arkansas, Louisiana, Oklahoma, Texas. West North Central: Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, Kansas. Pacific: Washington, Oregon, California. New England: Massachusetts, Connecticut, Rhode Island, New Hampshire. South Atlantic: Delaware, Maryland, Virginia, District of Columbia, West Virginia, North Carolina, South Carolina, Georgia, Florida. Mid-Atlantic: New York, New Jersey, Pennsylvania.",
"        <br>",
"         &sect; SOURCE: Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005;353:587-94.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Champman, AS, Bakken, JS, Folk, SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis -- United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20141=[""].join("\n");
var outline_f19_42_20141=null;
var title_f19_42_20142="Causes ischemic stroke children and young adults";
var content_f19_42_20142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of ischemic stroke in children and young adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Patent foramen ovale",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial septal aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial myxoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial fibrillation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other arrhythmia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiomyopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac surgery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac catheterization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Extracorporeal membrane oxygenation (ECMO)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatic heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prosthetic valve",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sickle cell disease and iron deficiency anemias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Inherited prothrombotic states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Protein C deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Protein S deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antithrombin III deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Factor V Leiden gene mutation (associated with activated protein C resistance)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Prothrombin gene mutation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Elevated homocysteine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Elevated lipoprotein(a)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Polycythemia vera",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Acquired prothrombotic states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiphospholipid antibody syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            L-asparaginase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Protein-losing enteropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Disseminated intravascular coagulation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Leukemia and other malignancies",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Noninflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Arterial dissection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Spontaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Traumatic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Secondary to connective tissue disease (Ehlers-Danlos, Marfan)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fibromuscular dysplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Transient cerebral arteriopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Radiation vasculopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Moyamoya",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Primary moyamoya disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Secondary moyamoya syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Sickle cell disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Neurofibromatosis type 1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Down syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Williams syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Cranial radiation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Fibromuscular dysplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Young women who smoke and use oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Vasculitis and postinfectious vasculopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Viral or bacterial infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Congenital heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vasospasm following subarachnoid hemorrhage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Congenital vessel hypoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Migraine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Takayasu arteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Giant cell arteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Kawasaki disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Polyarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vasculitis associated with rheumatologic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Primary central nervous system angiitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Infectious/postinfectious vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Human Immunodeficiency Virus (HIV)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Varicella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Bacterial meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fabry disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Homocystinuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Menkes' disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Ingestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cocaine, methamphetamine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20142=[""].join("\n");
var outline_f19_42_20142=null;
var title_f19_42_20143="IVUS diffuse coronary disease";
var content_f19_42_20143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronary artery disease is a diffuse process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 153px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With contrast angiography a stenosis, assumed to be the result of plaque, is seen relative to the normal looking reference segment. Although the rest of the vessel appears to be normal, intracoronary ultrasound demonstrates the presence of a moderate amount of plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_42_20143=[""].join("\n");
var outline_f19_42_20143=null;
